Curriculum Vitae and Bibliography Rafael Fonseca, MD

RE-AIMS 2/8/2021 1:52:28 PM

Curriculum Vitae and Bibliography

Rafael Fonseca, MD

Personal Information Place of Birth: Mexico City, Mexico Citizenship: United States of America Work Address: Mayo Clinic Scottsdale

13400 E Shea Blvd Scottsdale, AZ 85259-5499

Email Address: [email protected]

Present Academic Rank and Position

Consultant - Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona

12/2003 - Present

Consultant (Joint Appointment) - Basic Sciences, Research Laboratories, Mayo Clinic, Scottsdale, Arizona

12/2003 - Present

Professor of Medicine - Mayo Clinic College of Medicine and Science 12/2006 - Present

Getz Family Professor of Cancer - Mayo Clinic College of Medicine and Science, Department of Education Administration

11/2009 - Present

Distinguished Mayo Investigator - Mayo Clinic 11/2010 - Present

Education Universidad Anahuac - MD, Medical School Education 1985 - 1991

University of Miami - Resident, Internal Medicine 1991 - 1994

Mayo Graduate School of Medicine, Mayo Clinic College of Medicine - Fellow, Clinical Hematology and Medical Oncology

1994 - 1998

Certification Board Certifications

American Board of Internal Medicine (ABIM) Internal Medicine 1994 - 2004

Medical Oncology 1997 - 2007

Hematology 1998 - Present

Consejo Mexicano de Medicina Interna Internal Medicine 1997 - Present

Mayo Clinic Quality Academy Mayo Clinic Quality Fellow: Bronze Level Certification 2011

Licensure Mexico 1653403 (expired) (Medical)

Minnesota 37350 (expired) (Medical)

Arizona 32565 (Medical)

Honors and Awards Honorific Mention for having obtained the highest final GPA of the Medical School Class - Universidad Anahuac

06/1989

Berlex Oncology Foundation Award: Epidemiology and Clinical Trial Design - Berlex Oncology Foundation

08/1996

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Berlex Oncology Foundation Award: Genetics in Oncology - Berlex Oncology Foundation

03/1997

Berlex Oncology Foundation Award: Pharmacology of Anticancer Drugs - Berlex Oncology Foundation

10/1997

Outstanding Achievement Award as Clinical Fellow in Hematology - Mayo Clinic

1998

Young Investigator Award - Eastern Cooperative Oncology Group 06/2001 Young Investigator Award - ECOG Aventis 11/2001 New Investigator Award, Department of Internal Medicine - Awarding Organization

01/2002

Young Investigator Award in Hematology - Celgene, Achievement Awards for Clinical Research in Hematology

12/2002

Getz Family Professor of Cancer, Named Professorship Award - Mayo Clinic College of Medicine and Science

11/2009

Distinguished Mayo Clinic Investigator - Mayo Clinic 11/2010 Academic Excellence Award in the Faculty of Health Sciences - Mexico Norte, Vince in Bono Malum, Universidad Anahuac

09/2012

Previous Professional Positions and Major Appointments Instructor of Medicine - Mayo Clinic College of Medicine and Science 04/1997 - 07/1999

Senior Associate Consultant - Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota

1998 - 2001

Assistant Professor of Medicine - Mayo Clinic College of Medicine and Science 07/1999 - 04/2002

Consultant - Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota

2001 - 12/2003

Associate Professor of Medicine - Mayo Clinic College of Medicine and Science

04/2002 - 11/2006

Chair - Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona 02/2012 - 06/2020

Professional Memberships and Societies

Professional Memberships and Services

American Association for Cancer Research Member 2010 - Present Special Conference

Myeloma Biology, Clinical Implications of Genomics Session Chair 02/2005

American Association of Cancer Research Minorities in Cancer Research

Member 2010 - Present American College of Physicians

Member 07/2016 - 06/2017 American Society of Clinical Oncology

Member 01/2017 - 12/2017 Multiple Myeloma

TRM Oncology Expert Round Table EPIC (Emerging Paradigms in Care) Congress Coverage

Program Chair 06/2016

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

American Society of Hematology Member 01/2017 - 12/2017 ASH 2015 Multiple Myeloma Highlights Meeting

EPIC (Emerging Paradigms in Care) Congress Coverage Program Chair 12/2015

Faculty Meeting Scientific Committee on Plasma Cell Neoplasia

Vice Chair 02/2016 Scientific Committee

Chairs Meeting Vice Chair 02/2016

Scientific Subcommittee on Plasma Cell Neoplasms Member 01/2014 - 12/2015 Vice Chair 01/2016 - 12/2016 Chair 01/2017 - 12/2017

Association of American Physicians and Surgeons Member 01/2017 - 12/2017

Eastern Cooperative Oncology Group Member

Endeavor - Proteasome Inhibition Global Advisory Board Advisory Board Member 04/2015

European Hematology Association 11the Congress

The Role of Molecular Diagnostics for Patient Management in Multiple Myeloma and Leukemia

Chair 06/2006 Goldwater Institute

Visiting Healthcare Fellow 2017 - Present International Myeloma Society

Member 01/2017 - 12/2017 International Prognostic Index in Myeloma Working Group

Committee Member 01/2001 International Society of Hematology

Fellow Mexican Society of Internal Medicine

Member Multiple Myeloma Research Consortium

Genomics Core Chair 2003 - 2010

Leadership Team Member

Tissue Banking Core Member

Multiple Myeloma Research Foundation Molecular Genetics of Multiple Myeloma

Round Table Chair 02/2003

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

National Institutes of Health National Cancer Institute

NCI SPORE Grant Review Reviewer

NCI Study Sections Developmental Therapeutics Study Section

Ad Hoc Reviewer North Central Cancer Treatment Group

Member

Study Sections

NIH NCI Cancer Genetics Study Section

Ad Hoc Reviewer 02/2015

Journal Responsibilities

Journal Editorial Responsibilities

Genes, Chromosomes and Cancer Editorial Board Member 11/2016 - Present

Journal of Clinical Oncology Editorial Board Member

Leukemia Editorial Board Member

LIVESTRONG Quarterly Editorial Advisory Board

Molecular Cancer Therapeutics Editorial Board Member

Journal Other Responsibilities

American Journal of Hematology Reviewer

American Journal of Medicine Reviewer

Amyloid Reviewer

Blood Reviewer

British Journal of Cancer Reviewer

British Journal of Haematology Reviewer

Circulation Reviewer

Haematologica Reviewer

International Journal of Cancer Reviewer

Journal of Clinical Apheresis Reviewer

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Journal of Clinical Oncology Reviewer

Leukemia Reviewer

Nature Cancer Reviews Reviewer

Nature Medicine Reviewer

New England Journal of Medicine Reviewer Manuscript Review CME Program

Reviewer 01/2012 - 06/2012 Oncogene

Reviewer The American Journal of the Medical Sciences

Reviewer

Education Interests and Accomplishments

Teaching Physical Examination Sophomore Medical Student Class Course Preceptor University of Miami, Jackson Memorial Hospital

08/1993 - 04/1994

Medical Physiology and Pathophysiology Preceptor American Institute of Medicine

10/1993 - 06/1994

Hematology Course Mayo Medical School Rochester, Minnesota

01/1995 - 02/1998

Testicular Lymphoma: High Incidence of Extranodal Relapse Poster Presentation Mayo Clinic Internal Medicine Research Forum Rochester, Minnesota

12/1995

Multiple Myeloma and the Translocation t(11;14)(q13;q32) Poster Presentation Mayo Clinic Internal Medicine Research Forum Rochester, Minnesota

1997

Cytogenetic Abnormalities in Systemic Amyloidosis: A Comparison of Conventional Cytogenetic Analysis to Fluorescent in-situ Hybridization with Simultaneous Cytoplasmic Immunoglobulin Staining Mayo Clinic Internal Medicine Research Forum Rochester, Minnesota

1998

Cytogenetic Abnormalities in Multiple Myeloma and Related Plasma Cell Disorders: A Comparison of Conventional cytogenetic Analysis to Fluorescent in-situ Hybridization with Simultaneous Cytoplasmic I Mayo Clinic Internal Medicine Research Forum Rochester, Minnesota

1998

A Descriptive Study of Chromosomal Abnormalities in Systemic Amyloidosis and Correlation with Biologic/Prognostic Variables Mayo Clinic Internal Medicine Research Forum Rochester, Minnesota

1998

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Mentorship Aguayo, Patricia (Masters Student) Description: Study of the monoclonal gammopathies of undetermined significance. She worked under the guidance of Dr. Fonseca to search for IgH translocations in the clonal plasma cell of patients with MGUS. Current Status: Staff Psychiatrist at Salt Lake City Outcome: Multiple research projects and some publications

10/1998 - 05/1999

Hayman, Suzanne (Faculty) Description: Current Status: Mayo Clinic Staff Outcome: The mentoring resulting in publications in prestigious biomedical journals (Blood) and presentations at National and International meetings.

06/2000 - 07/2001

Schop, Roelandt (Research Trainee) Description: The work focused on Waldenstroms macroglobulinemia and on the genetic and cytogenetic changes observed in the clonal cell of patients with macroglobulinemia. The work has resulted in one manuscript being accepted and three more currently being submitted. Current Status: Staff Physician, Leiden University, The Netherlands Hematology Research Trainee Outcome: Multiple research projects and some publications.

06/2000 - 12/2001

Abraham, Roshini (Postdoctoral Fellow) Description: Work focused on the light chain associated amyloidosis. Current Status: Consultant, Mayo Staff Outcome: Multiple research projects and some publications.

06/2000 - 07/2002

Bailey, Richard (Doctoral Student) Description: Mentor for Ph.D. work done by Mr. Bailey who is enrolled on a doctoral program imparted by Warnborough University Current Status: Laboratory Scientist in New Zealand Outcome:

11/2000 - 05/2002

Winkler, Jerry (Research Trainee) Description: First trainee on Hematology Training Grant. Dr. Winkler had to select from several institutional laboratories for his research experience and chose to work under the supervision of Dr. Fonseca. Current Status: Community oncologist Outcome:

06/2001

Debes, Carina (Research Trainee) Description: Hematology Research Trainee. Dr. Debes has worked under the supervision of Dr. Fonseca to elucidate the clinical significance of chromosome 13 in myeloma. She has worked also in a clustering analysis project elucidating the complex interactions of chromosomal abnormalities in myeloma. Current Status: Staff Scientist, Cross Cancer Center, Alberta, Canada Outcome:

06/2001 - 12/2001

Picken, Elisa (Medical Student) Description: Mayo Medical School student working in our laboratory during her research trimester. She focused on elucidating the molecular mechanisms for IL-1beta upregulation in the clonal plasma cells of myeloma. Current Status: Physician Outcome:

07/2001 - 10/2001

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Ghobrial, Irene (Fellow) Description: Hematology/Oncology Fellow at Mayo Clinic Rochester working in the clinical program as well as continuing research projects related to the biology of Waldenström macroglobulinemia. Current Status: Principal investigator of several research grants including multiple R01 and the Stand Up to Cancer (SU2C) program project like grant. She is a recognized International expert in the areas of multiple myeloma and and MGUS. Outcome: Multiple joint projects and publications including ongoing collaborative work.

07/2001 - 08/2004

Gonzalez Paz, Natalia (Research Trainee) Description: Dr. Gonzalez acquired research experience with the use of interphase fluorescent in-situ hybridization. She has also worked with immunofluorescence techniques in the characterization of novel translocations in myeloma. Current Status: Hematology Research Trainee Outcome: Multiple research projects and some publications.

08/2001 - 01/2007

Al-Masri, Azzah (Postgraduate Student) Description: Studied the effect of ras in myeloma cell growth and studies of microRNAs in multiple myeloma Current Status: Scientist at OSHU Outcome: Multiple research projects and some publications.

07/2004 - 03/2006

Chng, Wee Joo (Visiting Research Fellow) Description: Studies of hyperdiploid myeloma Current Status: He currently serves as a Cancer Center Director of the National University of Singapore. Outcome: Multiple research projects and some publications.

10/2004 - 10/2007

Schop, Roelandt (Special Project Associate) Description: Work focused on Waldenström macroglobulinemia and the genetic and cytogenetic changes observed in the clonal cell of patients with macroglobulinemia. Current Status: Staff hematologist Outcome: The work resulted in several publications and submissions.

05/2005 - 04/2006

Henry, Travis (Postdoctoral Fellow) Description: Research focused on the impact of deletion of chromosome 13 as it relates to myeloma disease pathogenesis. Current Status: Staff scientist at the FDS (last known). Outcome:

03/2006 - 06/2011

Braggio, Estaban (Postdoctoral Fellow) Description: Studied the field of multiple myeloma genetics with an emphasis on gene inactivation by methylation, gene expression pathways of drug mechanisms and copy number change in other B cell neoplasias. Current Status: Outcome: Associate Consultant, Mayo Clinic

11/2006 - 01/2011

Jimenez-Zepeda, Victor Hugo (Postdoctoral Fellow) Description: Research focused on the genetic events related to the origin and progression of multiple myeloma Current Status: Clinical Investigator, Calgary, Canada Outcome:

03/2007 - 08/2009

Molnar, Soledad (Trainee) Description: American Society of Hematology Visiting Trainee. Research focused on the study of genetics and genomics of the plasma cell neoplasms. Current Status: Physician in Argentina. Outcome:

05/2008 - 07/2008

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Segges, Priscilla (Research Trainee) Description: Research focused on the field of multiple myeloma with an emphasis on copy number abnormalities of negative regulators of NF-kB signaling pathway by fluorescence in situ hybridization. Current Status: Scientist in Brazil. Outcome:

08/2009 - 09/2009

Issa, Samar (Postdoctoral Fellow) Description: Research focused on multiple myeloma genetics. Current Status: Scientist in France. Outcome:

12/2009 - 11/2010

Albarracin, Flavio (Visiting Scientist) Description: Research focused on understanding the principles and practices surrounding myeloma translational and clinical research, specifically the molecular cytogenetics of myeloma. Sponsored by Argentinean Hematological Society. Current Status: Physician in Argentina. Outcome:

01/2010 - 02/2010

Smetana, Jan (Research Trainee) Description: Engaged in projects related to array-CGH and specific validation of identified novel genetic targets. Sponsored by Czech Myeloma Foundation. Current Status: Unknown Outcome:

02/2010 - 10/2010

McGhan, Lee (General Surgery Resident) Description: Work focused on breast cancer translational and genomics research with an interest in clinical outcomes and biomarkers related to underlying biology. Current Status: Surgeon in the UK Outcome:

07/2010 - 06/2011

Chirackal, Sintobastian (Sinto) (Postdoctoral Fellow) Description: Research focused on improving treatment of high risk multiple myeloma. Current Status: Postdoctoral fellow in my laboratory. Outcome:

05/2011 - Present

Panchabhai, Sonali (Postdoctoral Fellow) Description: Multiple research projects and some publications, including work on CD47 and Tummor associated macrophages (TAMs). Current Status: Scientist at AbbVie Outcome: Multiple research projects and some publications.

07/2012 - 12/2015

Monge, Jorge (Postdoctoral Fellow) Description: Multiple research projects and some publications, including working on Calcium isotopes. Current Status: Hematology and Oncology fellow at N. Columbia Outcome:

03/2013 - 03/2014

Schlam, Ilana (Research Trainee) Description: Multiple research projects and some publications. Current Status: Hematology and Oncology Fellow Outcome:

09/2014 - 04/2015

Institutional/Departmental Administrative Responsibilities, Committee Memberships and Other Activities

Mayo Clinic

Hematologic Malignancies Program Leader 2007 - 2011 Program Leader 2007 - 2011

Mayo Clinic Cancer Center

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Deputy Director 2007 - 02/29/2012 Mayo Clinic Cancer Center Committees

Mayo Clinic Cancer Center Scientific Advisory Council Member 2010 - 2012

Mayo Clinic Task Forces/Work Groups ECOG Myeloma Committee

Laboratory Chair 2001 - 2008 Mayo Clinic in Rochester

Department of Internal Medicine Division of Hematology

Hematology Research Committee Member 1999 - 2004

Translational Research Committee Chair 2000 - 2004

Mayo Clinic in Arizona

Department of Internal Medicine Chair 02/2012 - Present Division of Hematology/Oncology

Hematological Malignancies Site Director 2004 - 2008

Research Vice Chair

Mayo Clinic Arizona Committees Executive Operations Team

Member 02/2012 - Present Executive Operations Team - Arizona

Cancer Center Committee Member 2007 - 2012

Presentations Extramural National or International

Invited

Leukoencephalopathy in Patients Treated for Small Cell Lung Cancer with Combination Chemotherapy plus Radiation Therapy to the Chest, and Prophylactic Cranial Irradiation American Radium Society San Francisco, California

03/1996

Long Term Use of Anagrelide in Young Patients with Essential Thrombocythemia American Society of Hematology 41st Annual Meeting New Orleans, Louisiana

12/1998

Clinical Implications of Chromosome Abnormalities in Myeloma National Cancer Institute Bethesda, Maryland

02/1999

Translocations at 14q32 are Common in Patients with the Monoclonal Gammopathy of Undetermined Significance (MGUS) International Myeloma Workshop Stockholm, Sweden

09/1999

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

NCCTG Phase II Trial of 2-Chlorodeoxyadenosine (2-CDA) as Initial Therapy for Mantle Cell Lymphoma: A Well-tolerated Treatment with Promising Activity American Society of Hematology 41st Annual Meeting; North Central Cancer Treatment Group and Mayo Clinic New Orleans, Louisiana

12/1999

Translocations at 14q32 are Common in Patients with the Monoclonal Gammopathy of Undetermined Significance (MGUS) American Society of Hematology 41st Annual Meeting New Orleans, Louisiana

12/1999

Waldenstrom Macroglobulinemia and Light Chain Amyloidosis Chilean Society of Hematology Workshop Santiago de Chile, Chile

07/2000

Workshop on Lymphoproliferative Disorders Chilean Society of Hematology Santiago, Chile

07/2000

The t(11;14) and Cyclin D1 Deregulation in Myeloma Leukemia and Lymphoma Society of America, Translational Research Symposium Washington, District of Columbia

09/2000

Genetics of Waldenström Macroglobulinemia Patient Education Forum International Waldenstrom Macroglobulinemia Foundation Miami, Florida

03/2001

Chromosomal Abnormalities in Myeloma NIH M. Potter Research Meeting Bethesda, Maryland

04/2001

Prognostic Implications of Chromosomal Abnormalities as Detected by FISH VIII International Myeloma Workshop Banff, Alberta, Canada

05/2001

Secondary Translocations Involving c-myc and Other Oncogenes: Translocations During Tumor Progression Complement Primary Translocations VIII International Myeloma Workshop Banff, Alberta, Canada

05/2001

Genetics of Myeloma Aventis Pharmaceuticals Bridgewater, New Jersey

03/2002

Taller sobre el Myeloma Multiple Chilean Society of Hematology, Hospital Clinico de la Universidad de Chile Santiago, Chile

07/2002

Molecular Genetics of Waldenstrom Macroglobulinemia Second International Waldenstrom Macroglobulinemia Workshop Athens, Greece

09/2002

Molecular Genetics of Myeloma Lymphoma and Myeloma Conference, Cornell University New York, New York

10/2002

Novel Therapeutic Agents Roundtable Multiple Myeloma Research Foundation New York, New York

10/2002

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Genetics of Myeloma Seminar Series University of Minnesota Cancer Center St. Paul, Minnesota

11/2002

Novel Therapeutic Approaches in the Treatment of Multiple Myeloma Multiple Myeloma Research Foundation Institutional Insights Johns Hopkins University School of Medicine Baltimore, Maryland

11/2002

Molecular Genetics of Multiple Myeloma Roundtable Multiple Myeloma Research Foundation Paris, France

02/2003

Genetics of Myeloma Cancer Center Seminar Mayo Clinic Arizona Scottsdale, Arizona

03/2003

FISH Use in Hematological Malignancies Ms. Sinai Hospital Symposium New York, New York

04/2003

Genetics of Myeloma TGen/Mexican Institute of Genomic Collaboration Translational Genomics Research Institute Phoenix, Arizona

04/2003

Genetic Testing in Hematologic Neoplasms Vysis, Inc. Chicago, Illinois

05/2003

Genetics of Multiple Myeloma International Myeloma Workshop Salamanca, Spain

05/2003

Genetics of Myeloma Moffitt Cancer Center Multiple Myeloma Research Retreat Tampa, Florida

09/2003

Bone Disease in Myeloma III Congress of the Inter-American Division of the International Society of Hematology Santiago, Chile

10/2003

Genetics of Smoldering Myeloma Fund to Cure Myeloma Investigators Meeting New York, New York

10/2003

Mieloma Multiple Argentinean Society of Hematology, Enfermedad de Waldenstrom and Amyloidosis de Cadena Ligera Mar del Plata, Argentina

10/2003

Prognostic Implication of Genetic Abnormalities in Myeloma Multiple Myeloma Research Foundation, Institutional Insights, Princess Margaret Hospital Toronto, Ontario, Canada

10/2003

Genetics of Waldenström Macroglobulinemia Second International Patient and Physician Summit on Waldenstrom Macroglobulinemia Los Angeles, California

11/2003

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Multiple Myeloma: Clinical Implications of Genetic Abnormalities American Association for Cancer Research Annual Meeting Orlando, Florida

03/2004

Genomics of Myeloma Focus on Myeloma and Plasma Cell Disorders Conference Los Angeles, California

04/2004

Genomics of Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia Clinical Trials Collaborative Group (WMCTG) First Annual Meeting Cambridge, Massachusetts

04/2004

Microarray Analysis of Waldenstrom Macroglobulinemia Third Annual International Waldenstrom Macroglobulinemia Foundation Educational Forum Chicago, Illinois

05/2004

Scientific Advisors Retreat International Myeloma Foundation Hamilton, Bermuda

05/2004

Proteasome Inhibition: A Novel Approach to the Treatment of Multiple Myeloma Paradise Valley, Arizona

07/2004

Controversies and Practical Issues in Hematological Malignancies Las Vegas, Nevada

09/2004

Angiogenesis Symposium Mayo Clinic Rochester, Minnesota

10/2004

Genomics of Waldenstrom Macroglobulinemia Third International Workshop on Waldenstrom Macroglobulinemia Paris, France

10/2004

Presentation Hispanic Network, Scientific Symposium (Pfizer) New London, Connecticut

10/2004

Presentation Lymphoma & Myeloma 2004 Conference New York, New York

10/2004

Proteasome Inhibition: A Novel Option to the Treatment of Multiple Myeloma New Orleans, Louisiana

10/2004

International Myeloma Foundation Patient Seminar San Diego, California

11/2004

Mieloma and Waldenstrom Macroglobulinemia Mexican Society of Internal Medicine Veracruz, Mexico

11/2004

Presentation MMRF Institutional Insights Program Phoenix, Arizona

11/2004

Presentation Postgraduate Institute of Medicine Yuma, Arizona

11/2004

Presentation MMRF Scientific Advisors Summit Chicago, Illinois

01/2005

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Myeloma Biology, Clinical Implications of Genomics Speaker American Association for Cancer Research Special Conference San Diego, California

02/2005

What is New in Multiple Myeloma IWMF Support Group Phoenix, Arizona

02/2005

What is New in Multiple Myeloma Leukemia & Lymphoma Society Phoenix, Arizona

03/2005

Genomics: Unlocking the Mysteries of Myeloma Multiple Myeloma Satellite Symposium Sydney, Australia

04/2005

Integration of Genetics in a Comprehensive Pathogenesis Model for Myeloma 10th International Myeloma Workshop

04/2005

Chromosome 13 and Bortezomid: Clinical Implications American Society of Clinical Oncology (ASCO) Annual Meeting Orlando, Florida

05/2005

FISH en el Diagnostico de Mieloma 22nd Congress of the Spanish Society of Anatomic Pathology Palma de Mellocra, Spain

05/2005

Is Myeloma Becoming a Chronic Disease? Evaluating Results of Revlimd™ Studies American Society of Clinical Oncology (ASCO) Annual Meeting Orlando, Florida

05/2005

Waldenstrom Macroglobulinemia; Genetics and Cytogenetics IWMF Support Group Tampa, Florida

05/2005

Genetics of Myeloma and Amyloidosis 15th Annual Hematology Oncology Reviews Amelia Island, Florida

07/2005

Relapse Treatment and Novel Therapies International Myeloma Foundation Patient and Family Seminar Baltimore, Maryland

08/2005

Cytogenetic Abnormalities in Multiple Myeloma Japanese Society of Multiple Myeloma Tokyo, Japan

11/2005

Myeloma Genetics Kyoto Prefectural University of Medicine Kyoto, Japan

11/2005

Myeloma Genetics, Clinical and Prognostic Implication Invited Disease State Expert Faculty Presenter Comprehensive Cancer Center Palm Springs, California

11/2005

Cytogenetics, Molecular Genetics, and Prognostic Factors in Myeloma Millennium Pharmaceuticals: The Promise of Proteasome Inhibition: Future Directions in Multiple Myeloma and Lymphoma Atlanta, Georgia

12/2005

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Myeloma Genetics, Clinical & Prognostic Implication LAC/USC Medical Center Educational Conference Los Angeles, California

12/2005

Myeloma: Diagnosis, Classification, Prognosis, Staging 3rd Mayo Clinic State of the Art Symposium on Hematologic Malignancies Scottsdale, Arizona

01/2006

Myeloma Genetics, Clinical and Prognostic Implication Blood SPORE Winter Conference, City of Hope Duarte, California

02/2006

Application of Cytogenetics in Treatment of Multiple Myeloma Symposium: The Promise of Proteasome Inhibition: Future Directions in Multiple Myeloma and Non-Hodgkin's Lymphoma Montreal, Quebec, Canada

04/2006

Genomics of Myeloma New Concepts in Organ-site Research Session American Association for Cancer Research 97th Annual Meeting Washington, District of Columbia

04/2006

Highlights of the Day - Multiple Myeloma American Society of Clinical Oncology (ASCO) Annual Meeting Atlanta, Georgia

06/2006

Integration of Novel Therapies in Current Treatment of Myeloma: An Evolving Paradigm. Diagnosis, Prognosis and Staging American Society of Clinical Oncology (ASCO) Annual Meeting Atlanta, Georgia

06/2006

Myeloma Genetics, Clinical and Prognostic Implication 2nd Genetics Pathogenesis Roundtable Spiazzo, Italy

06/2006

Cytogenetics and Molecular Cytogenetics in Myeloma: The Path to Discovery and the Need in the Clinic 50 years of 46 Chromosomes: Progress in Cytogenetics National Cancer Institute Chromosome Workshop Bethesda, Maryland

07/2006

The Place of Bone Marrow Transplantation in the Bortezomib Era Brazilian Bone Marrow Transplantation Congress Satellite Symposium Curitiba, Brazil

08/2006

New Development in Hematological Malignancies Multiple Myeloma Update Detroit, Michigan

10/2006

The Biology of Myeloma: Cytogenetics, FISH and Beyond Lymphoma and Myeloma Conference New York, New York

10/2006

Top Therapeutic Targets for Multiple Myeloma Multiple Myeloma Research Consortium New York, New York

10/2006

Immunomodulation: Assessing the Science of Hematologic Malignancies American Society of Hematology Annual Meeting Orlando, Florida

12/2006

Roundtable MMRF Scientific Agenda New York, New York

03/2007

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Plasma Cell Disorders Eleventh International Invitational Workshop Kos Island, Greece

06/2007

Great Debates in Hematology The American School of Hematology Chicago, Illinois

09/2007

Symposium International Myeloma Foundation Honolulu, Hawaii

09/2007

Malignant Hematology Conference Washington University St. Louis, Missouri

10/2007

Multiple Myeloma Research Foundation Institutional Insights Stanford University Palo Alto, California

11/2007

Presentation Kettering Health Network Tumor Board Kettering, Ohio

11/2007

Presentation American Society of Hematology Annual Meeting Atlanta, Georgia

12/2007

Co-Director Mayo Clinic State of the Art Symposium - Hematologic Malignancies Scottsdale, Arizona

01/2008

Hematology Highlights The American School of Oncology 49th Annual Hematology Meeting Los Angeles, California

02/2008

Presentation Best of ASH Seattle, Washington

02/2008

Symposium International Hematology Symposium San Jose, Costa Rica

02/2008

Presentation American Society of Clinical Oncology Chicago, Illinois

05/2008

Presentation Oncology Nursing Society Congress CME Philadelphia, Pennsylvania

05/2008

Presentation 10th International Conference on Malignant Lymphoma Lugano, Switzerland

06/2008

Presentation Nevada Cancer Center Las Vegas, Nevada

06/2008

Presentation Mayo Alumni Meeting Puebla, Mexico

09/2008

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Erming Tian PhD Thesis Defense Trondheim, Norway

11/2008

The Richard Lent Memorial Multiple Myeloma Lecture Series Weill Cornell Medical College, Center of Excellence for Myeloma and Lymphoma New York, New York

12/2008

Presentation International Myeloma Workshop Washington, District of Columbia

02/2009

Great Debates and Updates in Hematology Boca Raton, Florida

04/2009

Presentation American Society of Clinical Oncology Orlando, Florida

05/2009

Presentation International Society for Laboratory Hematology, XXIInd International Symposium on Technological Innovations in Laboratory Hematology Las Vegas, Nevada

05/2009

2009 Oncology Highlights, News 45th ASCO Annual Meeting Santa Monica, California

08/2009

Presentation Society for Hematopathology Workshop Cleveland, Ohio

09/2009

Upcoming Trends in the Treatment of Hematological Malignancies First Annual Oncology Conference, Hackensack University Medical Center Hackensack, New Jersey

09/2009

Presentation 51st ASH Annual Meeting New Orleans, Louisiana

12/2009

Presentation 60th Congress - Clinica Ruiz Puebla, Mexico

01/2010

Presentation Hematology 2010: Advances in Science, Emerging Data and Novel Therapeutics San Francisco, California

01/2010

Presentation International Waldenstrom's Macroglobulinemia Foundation - Patient Education Forum Las Vegas, Nevada

04/2010

Presentation Mayo Clinic in Arizona International Patient/Referring Physician Event Hermosillo, Mexico

04/2010

Presentation Mexican Congress of Hematology Puebla, Mexico

04/2010

Presentation 2010 Pharmaceutical Alliance for CME Summit Philadelphia, Pennsylvania

05/2010

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Presentation National University Cancer Institute Singapore

07/2010

Presentation Hematology/Oncology Associations of Guatemala and Panama Guatemala

08/2010

Presentation World Health Communications 4th International Workshop on Myeloma Cape Cod, Massachusetts

09/2010

Presentation XVth Meeting of the European Association for Haematopathology Uppsala, Sweden

09/2010

Presentation Congreso de la Associacion Espanola de Hematologica Spain

10/2010

Presentation Lymphoma Research Foundation Workshop Scottsdale, Arizona

03/2011

Multiple Myeloma Imedex NOCR Las Vegas, Nevada

02/2012

Newly Diagnosed MM: Doublet vs. Triplet as First Line Therapy Bridging the Gap: 2012 3rd Annual Hematologic Malignancy Conference Hong Kong, China

02/2012

New Pharmacovigilance Data Discussion Advisory Board Amgen Advisory Board Dallas, Texas

03/2012

Presentation International Society of Hematology World Congress Cancun, Mexico

04/2012

State of the Art Care for Myeloma 2011 XXXIV World Congress International Society of Hematology Cancun, Mexico

04/2012

Cancer Genomics Connection to a Healthier Future Indian Wells, California

05/2012

Challenging Cases in Multiple Myeloma Research to Practice New Orleans, Louisiana

05/2012

Presentation PRISM NTP Advisory Committee Baveno, Italy

05/2012

Presentation American Society of Clinical Oncology Chicago, Illinois

05/31/2012 - 06/05/2012

Presentation 2012 Oncology Highlights: News from the Annual Oncology Meeting Houston, Texas

07/2012

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Presentation 2012 Oncology Highlights: News from the Annual Oncology Meeting San Francisco, California

07/2012

Physician Conference 7th International Workshop on Waldenstrom's Macroglobulinemia & Symposium on Multiple Myeloma Bing Center for Waldenstrom's Macroglobulinemia and IWWM7 Consortium 2012 Newport, Rhode Island

08/2012

Presentation Hematology Conference Cancun, Mexico

08/2012

7th International Workshop on Waldenstrom's Macroglobulinemia & Symposium on Multiple Myeloma Physician Conference Bing Center for Waldenstrom's Macroglobulinemia and IWWM7 Consortium 2012-Newport RI Newport, Rhode Island

08/22/2012 - 08/26/2012

Multiple Myeloma Research Practice Los Angeles, California

09/2012

Transform 2012 Mayo Clinic Center for Innovation Rochester, Minnesota

09/2012

Year in Review Multitumor CME Symposium Los Angeles, California

09/2012

Presentation 10th International Workshop on Myeloma Pharmacogenomics and Novel Therapeutics Scottsdale, Arizona

10/2012

Presentation Lymphoma and Myeloma 2012 New York, New York

10/2012

The New Frontiers in Extending Survival for Patients with Relapsed/Refractory Multiple Myeloma Symposium Waldorf Astoria New York, New York

10/25/2012

Panel Member Onyx Investigator Forum New York, New York

11/2012

Panel Member Proteasome Inhibitor Global Franchise Advisory Panel Washington, District of Columbia

11/2012

Presentation Onyx-Global Franchise Advisory Panel Washington, District of Columbia

11/2012

Presentation American Society of Hematology Atlanta, Georgia

12/2012

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Presentation American Society of Hematology Atlanta, Georgia

12/2012

Progress in Second Line/Relapsed WM Therapies International Waldenstrom's Macroglobulinemia Foundation Educational Forum San Diego, California

05/2013

Presentation Best of ASCO Hematology Oncology Conference Cancun, Mexico

06/2013

Presentation European Hematology Association Sweden

06/2013

Overcoming Challenges in the Treatment of Relapsed/Refractory Multiple Myeloma CME Workshop Houston, Texas

07/2013

Meeting Clinical Challenges in Myeloma: A Roadmap to Improved Patient Care PeerView CME Penn State College of Medicine University Park, Pennsylvania

08/2013

OMICS 101 Pre-Mayo Clinic Individualizing Medicine Conference Course American Society of Hematology Rochester, Minnesota

09/2013

Oncology Exchange: Emerging Strategies in the Management of Multiple Myeloma CME Certified Symposium Park City, Utah

09/2013

Year in Review: Research to Practice Multi Tumor CME Symposium Orlando, Florida

10/2013

OMICS 101 Pre-Mayo Clinic Individualizing Medicine Conference Course American Society of Hematology New Orleans, Louisiana

12/2013

Debate: Of the following frontline options for transplant-ineligible multiple myeloma, which would you recommend?Lenalidomide + low-dose dexamethasone in 4-week cycles until progressionBegin treatment with lenalidomide-dexamethasone Plasma Cell Disorders Debate Imedex Great Debates & Updates in Hematologic Malignancies New York, New York

04/2014

Debate: What is the optimal therapeutic approach for myeloma patients with bortezomib-lenalidomide relapsed/refractory disease? Novel doublets ± corticosteroid Plasma Cell Disorders Debate Imedex Great Debates and Updates in Hematologic Malignancies New York, New York

04/2014

Presentation Best of ASCO Cancun, Mexico

09/2014

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Multiple Myeloma Competitive Landscape Near and Long Term Guest Speaker Opinion Presentation to Celgene Sales Representatives POA Meeting Scottsdale, Arizona

10/2014

Risk Stratification: Is FISH Past Its Prime? Speaker Lymphoma & Myeloma 2014 International Congress New York, New York

10/2014

Scientific Talk/Symposium NIH Advisory Board Bethesda, Maryland

10/2014

Beyond the Guidelines: Module 2: Maintenance/Consolidation Therapy Research to Practice Satellite Symposium ASH Conference San Francisco, California

12/2014

Myeloma: Initial Therapy in Older Patients Clinical and Multidisciplinary Hematology and Oncology 2015: The 12th Annual Review Scottsdale, Arizona

01/2015

Faculty Member 2nd Annual Summit on Practical and Emerging Trends in Lymphoid Malignancies and Multiple Myeloma Whistler, British Columbia, Canada

03/2015

Keynote Speaker 9th Annual Living with Myeloma Conference/Roundtable Scottsdale, Arizona

03/2015

Therapies in R/R Multiple Myeloma and Depth of Response in Relapse Onyx Pharmaceuticals and L & M Healthcare Communications Cancun, Mexico

03/2015

Faculty Member Oncologist and Nurse Investigators Consult on Actual Patients from the Practices of the Invited FacultyPart 2: Multiple Myeloma Oncology Nursing Society (ONS) Congress - Oncology Tumor Panel Series Orlando, Florida

04/2015

Which Technology Makes Most Sense MRD Workshop: Myeloma 2015 Boston, Massachusetts

04/2015

Panel Discussion Accelerating Innovation: Living Longer and Stronger Chicago, Illinois

05/2015

Consultation Onyx ASPIRe Launch Los Angeles, California

06/2015

Presentation EPIC Congress Coverage ASCO 2015 Multiple Myeloma Highlights Chicago, Illinois

06/2015

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Educational Activity: Multiple Myeloma Guest Speaker Best of ASCO Miami, Florida

07/2015

Comprehensive Board Review in Hematology and Medical Oncology Faculty Comprehensive Board Review in Hematology and Medical Oncology Houston, Texas

09/2015

Diagnostic and Response Criteria: Risk Assessment and Stratification Speaker 15th International Myeloma Workshop Rome, Italy

09/2015

Speaker 2015 Canadian Hematology Conference Toronto, Ontario, Canada

10/2015

Faculty Panel Research to Practice CME Year in Review Symposia New York, New York

10/2015

Presentation International Myeloma Workshop Wuerzburg, Germany

03/2016

Presentation International Myeloma Workshop Frankfurt, Germany

03/2016

Kyprolis Speaker Program Initiative Faculty Amgen, Inc. Buenos Aires, Argentina

03/2016

Smoldering Myeloma: To Treat or Not to Treat Training Presentation New York, New York

03/2016

Speaker Emirates Haematology Conference (EHC) Dubai, United Arab Emirates

03/2016

Guest Speaker Emirates Hematology Conference 2016 Dubai, United Arab Emirates

04/2016

The Biology of Multiple Myeloma. Towards the Discovery of New Drugs Mexican Hematology Society Meeting Merida Yucatan, Mexico

04/2016

Myeloma Crowd Round Table Faculty Salt Lake City, Utah

05/2016

Speaker Panel NB Hematology Day 2016 Moncton, New Brunswick, Canada

05/2016

Advances in Minimal Residual Disease Testing in Myeloma Moderator 2016 MRD Roundtable New York, New York

06/2016

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Future Treatment Considerations in Multiple Myeloma Consultant Janssen/Bendcare Advisory Board Meeting Scottsdale, Arizona

08/2016

Multiple Myeloma in 2016 and Beyond: An Expert Panel Discussion Chair Epic Multiple Myeloma in 2016 and Beyond Scottsdale, Arizona

08/2016

Hemato Oncology Conference Cancun 2016 Consultant Cancun, Mexico

09/2016

Evolving Therapeutic Approaches and Shifting Paradigms in the Treatment of Multiple Myeloma Consultant Plexus: Multiple Myeloma CME Meeting Las Vegas, Nevada

09/2016

Expert Perspectives in Advancing Treatment Paradigms for Multiple Myeloma: Practical Issues and Considerations for Nurses Consultant Plexus: Multiple Myeloma CME Meeting Los Angeles, California

09/2016

Year In Review: A Multi-tumor Regional Symposia Series Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers Faculty Panel Research to Practice 5th Year in Review Boston, Massachusetts

09/2016

Examining the Role of Medical Innovation in the Cost of Cancer Care The Economist War on Cancer Boston, Massachusetts

09/2016

Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach Lymphoma & Myeloma 2016 New York, New York

10/2016

Multiple Myeloma: A Success Story Medica Sur Cancer Center Inauguration Medical Sur Mexico

01/18/2017 - 01/20/2017

Relapsed Therapy for Myeloma Clinical and Multidisciplinary Hematology and Oncology 2017 CME Scottsdale, Arizona

01/27/2017

Emerging Updates in Personalized Treatment of Multiple Myeloma Faculty/Speaker Annual Practical Recommendations in Immuno and Molecular Oncology Meeting Maui, Hawaii

02/11/2017

Treatment of Multiple Myeloma PEMEX Conference Mexico

02/22/2017 - 02/25/2017

Speaker Myeloma Crowd Meeting San Diego, California

03/2017

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Speaker 11th Annual Living with Myeloma Conference Scottsdale, Arizona

03/18/2017

How do I Treat ND Disease 2017 Multiple Myeloma Academy Madrid, Spain

05/05/2017

How do I Treat Relapsed Refractory MM: Relapsed Patient After a Long Initial Remission 2017 Multiple Myeloma Academy Madrid, Spain

05/05/2017

MRD: The Evidence, Data, and its Limitations 2017 Multiple Myeloma Academy Madrid, Spain

05/05/2017

NGS Technology for the Assessment of MRD in MM 2017 Multiple Myeloma Academy Madrid, Spain

05/05/2017

Speaker Celgene Latin American Multiple Myeloma Event Madrid, Spain

06/24/2017

FLC as an Excellent Indicator of Biochemical Relapse Amgen Mexico S.A. de C.V. 2107 / Tour of MM R/R Mexico City, Mexico

07/20/2017 - 07/21/2017

Positioning Second Generation IP in the First Relapse Amgen Mexico S.A. de C.V. 2107 / Tour of MM R/R Mexico City, Mexico

07/20/2017 - 07/21/2017

Segmentation of Patients and Choice of Therapies Based on IP Amgen Mexico S.A. de C.V. 2107 / Tour of MM R/R Mexico City, Mexico

07/20/2017 - 07/21/2017

Genetics in MM Patients International Myeloma Society Santiago, Chile

08/09/2017 - 08/12/2017

Speaker Myeloma Crowd Roundtable Phoenix, Arizona

10/14/2017

Monoclonal Antibodies for the Treatment of MM 59th National Congress of the Spanish Hematology and Hemotherapy Society; and 33rd National Congress of the Spanish Society of Thrombosis and Hemostasi Malaga, Spain

10/26/2017 - 10/28/2017

Speaker Multiple Myeloma Symposium Buenos Aires, Argentina

11/16/2017

Regional

Invited

Presentation Leukemia Society of America: Minnesota Chapter Minneapolis, Minnesota

06/2000

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

The t(14;16)(q32;q23) in Myeloma Cell Lines is Associated with c-maf Overexpression Despite Breakpoints at 16q23 Being Located as Far as 1 Mb Away From c-maf Fragile Sites, Gene Amplification and Cancer Meeting Rochester, Minnesota

08/2000

Oncogenesis of Myeloma Mayo Clinic Cytogenetics Department Rochester, Minnesota

10/2002

Genetics of Multiple Myeloma Medical Grand Rounds Moffitt Cancer Center Tampa, Florida

01/2003

Amyloidosis and Genomic Tools for the 21st Century Plenary sessions Jornadas Medicas del Hospital Espanol Mexico City, Mexico

02/2005

Myeloma Biology, Clinical Implications of Genomics Medical Grand Rounds University of New Mexico

02/2005

Genetics and Genomics of Myeloma Hematology Grand Rounds USC Keck School of Medicine Los Angeles, California

04/2005

Multiple Myeloma Grand Rounds St. Vincent Hospital Santa Fe, New Mexico

11/2005

Newer Approaches in the Treatment of Multiple Myeloma: Do Emerging Therapies Offer an Advantage? Grand Rounds Chandler Regional Hospital Chandler, Arizona

12/2005

Grand Rounds University of Arizona College of Medicine Tucson, Arizona

02/2006

Grand Rounds Memorial Sloan-Kettering Cancer Center New York, New York

10/2007

Hematology and Medical Oncology Grand Rounds St. Louis University St. Louis, Missouri

10/2007

Hematology Oncology Division Grand Rounds University of Miami Sylvester Cancer Center Miami, Florida

04/2008

Grand Rounds University of Southern California Los Angeles, California

05/2008

Presentation Annual Meeting of Society of Utah Medical Oncologists Park City, Utah

10/2008

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Grand Rounds University of Pittsburgh Medical Center Pittsburgh, Pennsylvania

04/2009

Presentation Rush University Multiple Myeloma Fellows Meeting Chicago, Illinois

02/2010

Presentation Great Debates & Updates in Hematology 2010 New York, New York

04/2010

Clinical Debates in Multiple Myeloma: The Evolving Role of Transplant Regional CME Meeting, St. Michael's Medical Center Newark, New Jersey

05/2010

A New Generation of Therapy for Multiple Myeloma: The Clinical Role of Novel Treatment CME Online Penn State College

04/2012

Rounds with the Investigators Program Research to Practice Miami, Florida

04/2012

Multiple Myeloma Quintiles - CME Series Natrona Heights, Pennsylvania

06/2012

Multiple Myeloma Quintiles - CME Series Highland Park, Illinois

08/2012

Clinical Perspectives: Analysis of Evolving Strategies to Manage Relapsed and Refractory Multiple Myeloma Molina Healthcare of New Mexico Albuquerque, New Mexico

09/2012

Presentation Multiple Myeloma and Beyond 2012 Scottsdale, Arizona

09/2012

Hematology Lecture MD Anderson

10/2012

2013 Living with Cancer Break Out Sessions Phoenix, Arizona

01/2013

Prostate Cancer CME Program Plexus Communications Corpus Christi, Texas

01/2013

Grand Rounds Research to Practice Hollywood, Florida

02/2013

Grand Rounds City of Hope Visitor Center Duarte, California

05/2013

Multiple Myeloma Presentation Winship Cancer Institute, Emory University Atlanta, Georgia

07/2013

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Presentation EPIC Multiple Myeloma Program Scottsdale, Arizona

08/2013

Evolving Therapeutic Approaches and Shifting Paradigms in the Treatment of Multiple Myeloma Multiple Myeloma CME Presentation Plexus Scottsdale, Arizona

01/17/2017

Multiple Myeloma 11th Annual Mid-America Cancer Symposium Wichita, Kansas

08/26/2017

Visiting Professorship Visiting Professorships Visiting Scientist National Institutes of Health, National Cancer Institute Bethesda, Maryland

01/1999

Hematology Grand Rounds Victoria General Hospital Halifax, Nova Scotia, Canada

05/2016

Clinical Practice, Interests, and Accomplishments Member of the Dysproteinemia Clinical Group. Dr. Fonseca has developed an expertise in the management of the plasma cell disorders. His clinical practice is primarily composed of patients with multiple myeloma, primary amyloidosis, monoclonal gammopathy of undetermined significance and Waldenstrom's macroglobulinemia.

Research Interests and Accomplishments A. My laboratory is focused on the study of the genetics of multiple myeloma and related disorders. We were first to describe the clinical implications of the most common genetic abnormalities for the disease. Based on the knowledge that was generated by Dr. Bergsagel we also identified two major subtypes of the disease; hyperdiploid and non-hyperdiploid multiple myeloma. We also described similar genetic abnormalities in the early stages of the disease, as well as other specific abnormalities in Waldenström macroglobulinemia. We have participated in the efforts that have described other key pathways for the genetics of the disease including Nf-KB and C-MYC. We were granted a patent for the clinical testing of myeloma bone marrow samples derived from all of this information. We describe the presence and clinical implications of subclones in myeloma cells. B. Our laboratory is intimately involved in further understanding the mechanism of action of some of the common drugs used for the treatment of myeloma. We are particularly interested in the mechanism of action of lenalidomide. We have recently discovered that accumulation of hydrogen peroxide in the intracellular environment is one of the main mechanisms leading to cytotoxicity and highly dependent on the presence of monoclonal proteins in the intracellular environment. C. My lab has also been intimately involved with the development of biomarkers and other genetic prognostic analysis associated with clinical trials for multiple myeloma. We have been very actively engaged in various clinical trials for patients with amyloidosis. D. We have been developing calcium isotopes as biomarkers for bone disease for multiple myeloma. We hope to be able to develop this as it only real-time marker of bone information for bone destruction. With our collaborators we can measure calcium isotope fractionation it’s a way to determine whether there’s influx or influx of calcium to the bone matrix. E. I have been very actively engaged in developing best practices for biobanking for myeloma samples, both for research purposes as well as associated with clinical trials for correlative studies. We have been able to develop the best practices for biobanking for patient support organizations such as the Multiple Myeloma Research Consortium (MMRC) and industry funded clinical trials.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Patent - Application of Ca Isotope Analysis to the Early Detection of Metastatic Cancer. App. 14/207,160. Date Filed: 03/12/2014. USA 112624.00458. Inventors: Rafael Fonseca M.D.; Ariel Anbar; Joseph Skulan; Gwyneth Gordon Patent - Application of Ca Isotope Analysis to the Early Detection of Metastatic Cancer. App. 61/784,033. Date Filed: 03/14/2013. USA 11264.00370. Inventors: Rafael Fonseca M.D.; Ariel Anbar; Joseph Skulan; Gwyneth Gordon Patent - Methods and Materials for Assessing Hydrogen Peroxide Accumulation in Cells. App. 15/737.219. Date Filed 12/15/2017. USA. 07039-1464US1. Inventors: Rafael Fonseca, MD, Sinto Sebastian Chirackal, Ph.D. Patent - Methods and Materials for Assessing Hydrogen Peroxide Accumulation in Cells. App. 62/180,327. Date Filed: 06/16/2015. USA 07039-1464P01. Inventors: Sinto Sebastian Chirackal Ph.D.; Rafael Fonseca M.D. Patent - Methods and Materials for Assessing Hydrogen Peroxide Accumulation in Cells. App. PCT/US2016/037899. Date filed: 06/16/2016. USA 07039-1464W01. Inventors: Rafael Fonseca M.D.; Sinto Sebastian Chirackal Ph.D. Patent - Methods and Materials for Assessing Responsiveness to Lenalidomide, Thalidomide, and/or Other Thalidomide Analogs. App 12757445.7 Date Filed: 03/08/2012. Europe-EPO 07039-1056EP1. Inventors: Esteban Braggio Ph.D.; Rafael Fonseca M.D.; Alexander (Keith) K. Stewart M.B.Ch.B.; Peter (Leif) L. Bergsagel M.D. Patent - Methods and Materials for Assessing Responsiveness to Lenalidomide, Thalidomide, and/or Other Thalidomide Analogs. App. 61/452,027. Date filed: 03/11/2011. USA 07039-1056P01. Inventors: Peter (Leif) L. Bergsagel M.D.; Alexander (Keith) K. Stewart M.B.Ch.B.; Rafael Fonseca M.D.; Esteban Braggio Ph.D Patent - Methods and Materials for Assessing Responsiveness to Lenalidomide, Thalidomide, and/or Other Thalidomide Analogs. App. PCT/US2012/028285. Date filed 03/08/2012. USA 07039-1056W01. Inventors: Alexander (Keith) K. Stewart M.B.Ch.B.; Peter (Leif) L. Bergsagel M.D.; Rafael Fonseca M.D.; Esteban Braggio Ph.D. Patent - Methods for Assessing Responsiveness of Cancer Cells to Lenalidomide, Thalidomide, and/or Other Thalidomide Analogs. App. 17168706.4. Date Filed: 03/08/2012. Europe-EPO. 07039-1056EP2. Inventors: Esteban Braggio Ph.D.; Rafael Fonseca M.D.; Alexander (Keith) K. Stewart M.B.Ch.B.; Peter (Leif) L. Bergsagel M.D. Patient- Physical Obstruction of Scalp Arterial Circulation to Prevent Chemotherapy Associated Alopecia. App. 62/733.300. Filed 9/19/2018. USA. 07039-1830P01. Inventor: Rafael Fonseca, MD.

Research Grants Awarded

Active Grants

Federal Program Director / Principal Investigator

Mayo Comprehensive Cancer Center Grant. Funded by National Cancer Institute. (P30 CA 15083)

06/2019 - 02/2024

Co-Investigator Mayo Clinic Multiple Myeloma SPORE. Funded by National Cancer Institute. (P50 CA186781-01A1)

09/2015 - 08/2021

Federal sub award Co-Investigator Comprehensive Cancer Center Grant. Funded by National Cancer

Institute. (CA015083 ) 06/2019 - 02/2024

Foundation Program Director / Principal Investigator

MMRC Tissue Bank - 2. Funded by Multiple Myeloma Research Consortium. (FONSECA #2)

01/2006 - 12/2021

Program Director /

MMRC - Funding for Multiple Myeloma Program Coordinator (MMPC). Funded by Multiple Myeloma Research Consortium

01/2011 - 12/2020

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Principal Investigator Program Director / Principal Investigator

A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship between Patient Outcomes, Treatment Regimens and Molecular Profiles. Funded by Multiple Myeloma Research Foundation. (CoMMpass)

02/2014 - 12/2021

Industry Program Director / Principal Investigator

MCO48E Phase II Trial of RAD001 in Relapsed/Refractory Multiple Myeloma. Funded by Novartis

05/2005 - 04/2009

Program Director / Principal Investigator

(A4021001) Open label Phase 1 Study of CP-751,871 in Patients with Multiple Myeloma. Funded by Pfizer Inc.

07/2005 - 06/2007


Cylene Proposal CX-4945, CX-5461, CX-3543 Investigation. Funded by Cylene Pharmaceuticals, Inc.

08/2008 - 08/2009


MCA 1316-10: PX-171-009 Lab: A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma. Funded by Onyx Pharmaceuticals Corporation. (PX-171-009)

09/2010 - 09/2012


SOW Amendment 1, TCD14079: Exploratory Biomarker Work. Funded by Sanofi Aventis. (TD14079)

11/2014 - 10/2017


TED10893 Phase 2/Contract Amendment 2. Funded by Sanofi Aventis 08/2016 - 08/2018


SOW Amend 1, Protocol V3 / ECTx: GO39775: AN OPEN-LABEL, MULTICENTER, PHASE I TRIAL OF THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF BFCR4350A IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA.. Funded by Genentech Incorporated. (GO39775)

02/2018 - 02/2021

Co-Program Director / Principal Investigator

PX-171-003: An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma . Funded by Proteolix, Inc.

08/2007 - 08/2009

Co-Investigator 10-002922/TED10893: A Phase 1 Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hematological Malignancies. Funded by Sanofi Aventis. (TED10893)

11/2010 - 11/2012

Mayo Clinic Co-Investigator MCA Site/RECOVER: Phase 2 Randomized, Double-Blind Trial

TREating hospitalized patients with COVID-19 with Camostat MesilatE, a TMPRSS2 Inhibitor. Funded by Development - Gifts from benefactors

06/2020 - 05/2021

Completed Grants

Federal

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Principal Investigator

Chromosomal Abnormalities in Myeloma as Detected by FISH. Funded by National Cancer Institute. (R01 CA 83724)

04/2000 - 03/2004


Chromosomal Abnormalities in Myeloma as Detected by FISH. Funded by National Cancer Institute

01/2004 - 02/2004


Chromosomal Abnormalities in Myeloma as Detected by FISH. Funded by National Cancer Institute

03/2004 - 11/2008


ECOG Core Lab B. Funded by National Cancer Institute. (U10 CA021115)

05/2004 - 04/2010


Genetic Epidemiology of CLL. Funded by National Cancer Institute. (U01 CA118444)

08/2006 - 08/2007


Program Leadership - Mayo Comprehensive Cancer Center. Funded by National Cancer Institute. (P30 CA015083-33 PL)

03/2007 - 06/2007


Mayo Comprehensive Cancer Center. Funded by National Cancer Institute. (P30 CA015083-33 CRO FONS)

07/2007 - 02/2009



07/2007 - 02/2009


Chromosomal Abnormalities in Myeloma as Detected by FISH. Funded by National Cancer Institute. (R01 R01 CA083724)

03/2009 - 07/2014



04/2009 - 02/2014

Co-Investigator Studies of Monoclonal Gammopathies. Funded by National Cancer Institute. (P01 CA 62242)

04/2005 - 01/2011

Co-Director Mayo Clinic Multiple Myeloma SPORE. Funded by National Cancer Institute. (P50 P50 CA186781)

07/2014 - 06/2019

Federal sub award Program Director / Principal Investigator

SPORE in Myeloma DFHCC Project 5. Funded by National Cancer Institute. (CA100707)

09/2003 - 06/2008


Project 3 for CA 62242 - IgH Translocation as a Seminal Event in MGUS & Myeloma. Funded by National Cancer Institute. (CA062242-10A1)

04/2005 - 01/2010


Mayo Comprehensive Cancer Center - CRO. Funded by National Cancer Institute. (CA015083-33)

07/2007 - 02/2009

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM


Comprehensive Cancer Center Grant - Admin. Funded by National Cancer Institute. (CA015083-34 ADMIN)

03/2008 - 02/2009


Mayo Clinic Cancer Center - Biostatistics. Funded by National Cancer Institute. (CA015083-34 BIOSTATS)

03/2008 - 02/2009


Mayo Comprehensive Cancer Center - PHARM. Funded by National Cancer Institute. (CA015083-34 PHARM)

03/2008 - 02/2009


SPORE in Myeloma DFHCC Project 5. Funded by National Cancer Institute. (CA100707)

09/2008 - 08/2013


SPORE in Myeloma Tissue Core (Core 2). Funded by National Cancer Institute. (CA100707)

09/2008 - 08/2013


Mayo Comprehensive Cancer Center - PHARMACY. Funded by National Cancer Institute. (CA015083 PHARMACY)

03/2009 - 02/2014


Mayo Comprehensive Cancer Center - Protocol Specific Research Support. Funded by National Cancer Institute. (CA015083 PSRS)

04/2009 - 02/2010


Comprehensive Cancer Center Grant - Admin . Funded by National Cancer Institute. (CA015083 ADMINISTRATION)

04/2009 - 02/2014


Mayo Clinic Cancer Center - Biostatistics. Funded by National Cancer Institute. (CA015083 BIOSTATISTICS)

04/2009 - 02/2014


Mayo Comprehensive Cancer Center - Senior Leadership. Funded by National Cancer Institute. (CA015083 SR LEADERSHIP)

04/2009 - 02/2014


ECOG Core Lab B. Funded by National Cancer Institute. (U10 CA021115)

05/2010 - 02/2015


Calcium Isotopes: Inorganic Biosignatures of Multiple Myeloma Progression. Funded by Mayo - ASU Seed Grant

01/2012 - 12/2012


Screening and Interception of Precursor Myeloma. Funded by American Association for Cancer Research. (DFCI 6323401 AACR-DT28-18)

09/2018 - 12/2019

Co-Investigator Eastern Cooperative Oncology Group - Operations Office. Funded by National Cancer Institute. (CA 21115)

05/2004 - 04/2010

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Co-Investigator Improving the clinical utility of Ca isotope analysis by assessing population-level variation in the Ca isotope composition of blood. Funded by Flinn Foundation. (Subagreement 14-397)

07/2013 - 06/2016

Foundation Principal Investigator

Detection of the Translocation T(11;14)(Q13;q32) in Myeloma Patients Using Fiber-Fluorescent In-situ Hybridization. Funded by Leukemia Society of America, Inc.. (Leukemia #5)

09/1998 - 08/2001


Fellow Award. Funded by Kathy Giusti Multiple Myeloma Research Foundation

11/1998 - 11/1999


Identification and Characterization of 14q32 Translocations in Patients with MGUS. Funded by Giusti Myeloma Res Fdn

01/1999 - 12/1999


Chromosomal Abnormalities in Waldenstrom's Macroglobulinemia. Funded by International Waldenstrom's Macroglobulinemia Foundation

12/1999 - 11/2000


Macroglobulinemia and FISH. Funded by International Waldenstrom's Macroglobulinemia Foundation. (IWMF #1)

01/2000 - 10/2003


Genomic instability in plasma cell dyscrasias. Funded by Cancer Research Fund of the Damon Runyon-Walter Winchell Foundation. (DAMON #2)

07/2000 - 06/2004


LeBow - Fund to Cure Myelome. Funded by Bennett S. LeBow Foundation. (LEBOW #1)

05/2002 - 04/2004


Waldestrom Foundation. Funded by International Waldenstrom's Macroglobulinemia Foundation

07/2003 - 06/2004


Cancer Research Fund of the Damon Runyon-Walter Winchell Foundation. Funded by Foundation. (FNDT DAMON #2 MCA)

01/2004 - 06/2005


Nereus - Sample Processing Services Agreement. Funded by Multiple Myeloma Research Consortium

01/2007 - 12/2008


aCGH and GEP Validation Using cig-FISH. Funded by Multiple Myeloma Research Consortium

01/2009 - 12/2009


Interrogation of CpG Island in Multiple Myeloma. Funded by Multiple Myeloma Research Consortium

01/2009 - 12/2010


Interrogation of CpG Island Methylation in Multiple Myeloma. Funded by Multiple Myeloma Research Consortium. (TUS 010)

01/2010 - 12/2010


A Comparison of Frequencies of Somatic Alterations Associated with Poor Prognosis in Multiple Myeloma Among Tumors from African-American and European American Patients. Funded by Multiple Myeloma Research Consortium. (None)

03/2010 - 02/2011

Industry Program Director / Principal Investigator

An Exploratory Phase II Study of PHA-739358 in Patients with Multiple Myeloma Harbouring the t (4;14) translocation with or without FGFR3 Expression. Funded by Nerviano Medical Sciences

05/2008 - 04/2010


Correlative: FISH studies for Celgene . Funded by Celgene 07/2010 - 02/2011

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM


MCA 1522-11: Analysis of Pim function in multiple myeloma and therapy . Funded by Amgen. (MCA 1522-11)

11/2011 - 11/2012


MCA 1636-12: 12011-001: : Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of ONX 0912 in Patients with Hematological Malignancies. Funded by Onyx Pharmaceuticals Corporation. (12011-001 (0912))

04/2012 - 04/2014


MCA 1636-12: 12011-001:REPLACEMENT BUDGET-REVISED EXHIBIT A for Phase 2 Services: Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of ONX 0912 in Patients with Hematological Malignancies. Funded by Onyx Pharmaceuticals Corporation. (12011-001 (0912))

04/2012 - 04/2016


MCA 1651-12: Onyx 2011-003: : A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients with Relapsed Multiple Myeloma. Funded by Onyx Pharmaceuticals Corporation

05/2012 - 05/2014


11-007291: AX-MM-PI-0010: Phase II trial of nab-paclitaxel (Abraxane) in Multiple Myeloma. Funded by Celgene. (AX-MM-PI-0010)

08/2012 - 08/2015


Protocol OPOZ007: Phase Ib, Multicenter Study of Oprozomib, Pomalidomide, and Dexamethasone in Primary Refractory or Relapsed and Refractory Multiple Myeloma. Funded by Onyx Pharmaceuticals Corporation. (OPZ007)

11/2013 - 11/2014


Protocol OPOZ007: Phase Ib/3, Multicenter Study of Oprozomib, Pomalidomide, and Dexamethasone in Primary Refractory or Relapsed and Refractory Multiple Myeloma. Funded by Onyx Pharmaceuticals Corporation. (OPZ007)

11/2013 - 11/2014


Fonseca Lab/Onyx/ Sample Assays from previous study. Funded by Onyx Pharmaceuticals Corporation

01/2014 - 12/2014


Exploratory biomarker work for Phase 2. Funded by Sanofi Aventis 07/2014 - 06/2016


SOW Amend#1 :TED10893 Exploratory biomarker work for Phase 2. Funded by Sanofi Aventis

07/2014 - 06/2016


TCD11863 Exploratory Biomarker Work. Funded by Sanofi Aventis. (TCD11863)

11/2014 - 10/2015


Contract Amendment / Multiple Myeloma CD138 enrichment proposal #3. Funded by Karyopharm Therapeutics Inc

03/2015 - 03/2017


TED14154 with Sanofi. Funded by Sanofi Aventis 08/2016 - 12/2017

Co-Investigator A9001086 - A Methods Study to Determine the Performance Specifications of a Flow Cytometry Assay to Quantify the Expression of

10/2002 - 09/2004

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

the IGF1 Receptor in Patients with Multiple Myeloma Relapsed or Refractory to Conventional Therapy.. Funded by Pfizer Inc.. (PFIZER #99; 1A4637)

Co-Program Director / Principal Investigator

PX-171-004 Amendment 1 & 2: An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients with Relapsed Multiple Myeloma . Funded by Proteolix, Inc.. (PX-171-004)

10/2007 - 10/2009

Co-Investigator A Phase Ib Study of SGN-40 (anti-huCD40 mAb) plus Rituximab and Gemcitabine in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL). Funded by Seattle Genetics, Inc.

01/2008 - 01/2011

Co-Investigator 08-001485: MC0882: A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) for Untreated Low Grade Non-Hodgkin Lymphoma Requiring Treatment. Funded by Celgene

05/2008 - 05/2013

Co-Investigator CA180180: A Phase I Single Arm Dose Escalation Study of the Combination of Dasatinib (Sprycel®) with Lenalidomide (Revlimid®) and Dexamethasone in Subjects with Relapsed and/ or Refractory Multiple Myeloma. Funded by Bristol-Myers Squibb Pharmaceutical

06/2008 - 06/2011

Co-Investigator MC0883: A Phase 2 Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib (VELCADE®), and Dexamethasone (R-CyBor-D) in Relapsed Low Grade and Mantle Cell Lymphoma. Funded by Millennium

10/2008 - 10/2013

Co-Investigator A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies. Funded by Millennium: The Takeda Oncology Company

12/2008 - 12/2010

Co-Investigator A Phase Ib multicenter dose-determination study, with an adaptive, randomized, placebo-controlled, double-blind phase II, using various repeated IV doses of BHQ880 in combination with zoledronic acid in relapsed or refractory myeloma patients. Funded by Novartis. (CBHQ880A2102)

04/2009 - 04/2011

Co-Investigator CC-4047-MM-002: A Phase 1/2 Multi-center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of CC-4047 Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refracotory . Funded by Celgene. (CC-4047-MM-002)

11/2009 - 11/2014

Co-Investigator Phase I/II Study of combination of Aurora Kinase Inhibitor MLN8237 and Bortezomib in Relapsed or Refractory Multiple Myeloma. Funded by Millennium Pharmaceuticals, Inc.. (MC088A)

12/2009 - 12/2012

Co-Investigator A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera- Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofi. Funded by Incyte. (INCB 18424-351)

02/2010 - 02/2014

Co-Investigator CTK1258A2204: A phase II, multi-center, non-randomized, open-label study of TK1258 in patients with relapsed or refractory multiple myeloma, who are with or without (t(4;14) translocation. Funded by Novartis. (CTK1258A 2204)

02/2010 - 02/2012

Co-Investigator C16004: An Open-Label, Dose-Escalation, Phase 1 Study Evaluating the Safety and Tolerability of Weekly Dosing of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Relapsed and Refractory Multiple Myeloma. Funded by Millennium Pharmaceuticals, Inc.

09/2010 - 09/2012

Co-Investigator 10-002630/ PX-171-009 (CTA Amend 1): A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and

11/2010 - 11/2013

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multipl. Funded by Onyx Pharmaceuticals Corporation. (PX-171-009)

Co-Investigator 10-002630/ PX-171-009: A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multipl. Funded by Onyx Pharmaceuticals Corporation. (PX-171-009)

11/2010 - 11/2013

Co-Investigator MC0986/ A Phase II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Patients with Relapsed non-Hodgkin Lymphoma. Funded by Novartis. (MC0986)

01/2011 - 01/2014

Mayo Clinic Principal Investigator

Discretionary Funds. Funded by Mayo Clinic 06/1997 - 07/1998


Translocations in MGUS. Funded by Mayo Clinic B-cell Neoplasia Proposal

09/1999 - 08/2001


A Software Environment to Integrate Multiple Data Type for the analysis of Genomic Data for Multiple Myeloma. Funded by asu-mayo seed agreement. (FONSECA -KIM)

01/2006 - 12/2006


Novel Cellular Model To Study Chromosome Abnormality. Funded by ASU/Mayo Seed Grant

01/2008 - 12/2008


Drug Resistance in Myeloma. Funded by Development - Gifts from benefactors

01/2019 - 01/2020

Inventions, Commercialization and Offering

A. Patent Patent Number Country Date Filed Date Issued Cytogenetically Determined Prognosis of Myeloma Rafael Fonseca, Philip R Greipp

7662579 US 11/2003 02/2010

Cytogenetically Determined Prognosis of Myeloma Rafael Fonseca M.D.; Philip R. Greipp M.D.

70705134 US 11/2002 02/2010

Cytogenetically Determined Prognosis of Myeloma Rafael Fonseca M.D., Philip R. Greipp M.D.

7662579 USA 11/2003 02/2010

Methods and Materials for Assessing Responsiveness to Lenalidomide, Thalidomide, and/or Other Thalidomide Analogs Alexander (Keith) K. Stewart M.B.Ch.B.; Peter (Leif) L. Bergsagel M.D.; Rafael Fonseca M.D.; Esteban Braggio Ph.D.

2012229333 AU 10/2013 04/2017

Methods and Materials for Assessing Responsiveness to Lenalidomide, Thalidomide, and/or Other Thalidomide Analogs

2683412 DE 03/2012 05/2017

Methods and Materials for Assessing Responsiveness to Lenalidomide, Thalidomide, and/or Other Thalidomide Analogs Peter (Leif) L. Bergsagel M.D., Esteban Braggio Ph.D., Rafael Fonseca M.D., Alexander (Keith) K. Stewart M.B.Ch.B.

2683412 EP 03/2012 05/2017


2683412 FR 03/2012 05/2017

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM


2683412 GB 03/2012 05/2017


2683412 IT 03/2012 05/2017

Methods and Materials for Assessing Responsiveness to Lenalidomide, Thalidomide, and/or Other Thalidomide Analogs Alexander (Keith) K. Stewart M.B.Ch.B.; Peter (Leif) L. Bergsagel M.D.; Rafael Fonseca M.D.; Esteban Braggio Ph.D.

14003622 US 11/2013 05/2017

Methods and Materials for Assessing Responsiveness to Lenalidomide, Thalidomide, and/or Other Thalidomide Analogs Alexander (Keith) K. Stewart M.B.Ch.B., Peter (Leif) L. Bergsagel M.D., Esteban Braggio Ph.D., Rafael Fonseca M.D.

9662319 USA 11/2013 05/2017

Methods for Assessing Responsiveness of Cancer Cells to Lenalidomide, Thalidomide, and/or Other Thalidomide Analogs Peter (Leif) L. Bergsagel M.D., Esteban Braggio Ph.D., Rafael Fonseca M.D., Alexander (Keith) K. Stewart M.B.Ch.B.

3266452 EP 03/2012 07/2019


3266452 DE 03/2012 07/2019


3266452 FR 03/2012 07/2019


3266452 GB 03/2012 07/2019

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

Bibliography

Peer-reviewed Articles 1. Fonseca R, Tefferi A. Practical aspects in the diagnosis and management of aplastic anemia. Am J Med

Sci. 1997 Mar; 313 (3):159-69 PMID: 9075433 DOI: 10.1097/00000441-199703000-00007 2. Fonseca R, Frytak S, Mokri B. The case of the phantom bladder. J Urol. 1997 Apr; 157(4):1354. PMID:

9120942 3. Fonseca R, Tefferi A, Strickler JG. Follicular dendritic cell sarcoma mimicking diffuse large cell lymphoma:

a case report. Am J Hematol. 1997 Jul; 55 (3):148-55 PMID: 9256295 DOI: 10.1002/(sici)1096-8652(199707)55:3<148::aid-ajh6>3.0.co;2-s

4. Fonseca R, Hartmann LC, Petersen IA, Donohue JH, Crotty TB, Gisvold JJ. Ductal carcinoma in situ of the breast. Ann Intern Med. 1997 Dec 1; 127 (11):1013-22 PMID: 9412283 DOI: 10.7326/0003-4819-127-11-199712010-00013

5. Fonseca R, Witzig TE, Gertz MA, Kyle RA, Hoyer JD, Jalal SM, Greipp PR. Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases. Br J Haematol. 1998 May; 101 (2):296-301 PMID: 9609525 DOI: 10.1046/j.1365-2141.1998.00700.x

6. Fonseca R, Witzig TE, Olson LJ, Edwards BS, Khoor A, Walker RC. Disseminated Kaposi's sarcoma after heart transplantation: association with Kaposi's sarcoma-associated herpesvirus. J Heart Lung Transplant. 1998 Jul; 17 (7):732-6 PMID: 9703241

7. Loprinzi CL, Pisansky TM, Fonseca R, Sloan JA, Zahasky KM, Quella SK, Novotny PJ, Rummans TA, Dumesic DA, Perez EA. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol. 1998 Jul; 16: (7)2377-81. PMID: 9667254 DOI: 10.1200/JCO.1998.16.7.2377

8. Fonseca R, Yamakawa M, Nakamura S, van Heerde P, Miettinen M, Shek TW, Myhre Jensen O, Rousselet MC, Tefferi A. Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: a review. Am J Hematol. 1998 Oct; 59 (2):161-7 PMID: 9766802 DOI: 10.1002/(sici)1096-8652(199810)59:2<161::aid-ajh10>3.0.co;2-c

9. Fonseca R, Rajkumar SV, White WL, Tefferi A, Hoagland HC. Anemia after orchiectomy. Am J Hematol. 1998 Nov; 59 (3):230-3 PMID: 9798661 DOI: 10.1002/(sici)1096-8652(199811)59:3<230::aid-ajh8>3.0.co;2-2

10. Fonseca R, Ahmann GJ, Jalal SM, Dewald GW, Larson DR, Therneau TM, Gertz MA, Kyle RA, Greipp PR. Chromosomal abnormalities in systemic amyloidosis. Br J Haematol. 1998 Dec; 103 (3):704-10 PMID: 9858220 DOI: 10.1046/j.1365-2141.1998.01034.x

11. Rajkumar SV, Fonseca R, Witzig TE, Gertz MA, Greipp PR. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia. 1999 Mar; 13 (3):469-72 PMID: 10086738 DOI: 10.1038/sj.leu.2401336

12. Fonseca R, O'Neill BP, Foote RL, Grill JP, Sloan JA, Frytak S. Cerebral toxicity in patients treated for small cell carcinoma of the lung. Mayo Clin Proc. 1999 May; 74(5):461-5. PMID: 10319075 DOI: 10.4065/74.5.461

13. Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Therneau TM, Kyle RA, Litzow MR, Gertz MA, Greipp PR. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. J Clin Oncol. 1999 May; 17: (5)1551-7. PMID: 10334543 DOI: 10.1200/JCO.1999.17.5.1551

14. Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, Therneau TM, Kyle RA, Litzow MR, Gertz MA. Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant. 1999 Jun; 23(12):1267-72. PMID: 10414914 DOI: 10.1038/sj.bmt.1701805

15. Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, Therneau TM, Kyle RA, Litzow MR, Gertz MA. Beta(2)-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma. Bone Marrow Transplant. 1999 Jun; 23(12):1261-1266. PMID: 10414913

16. Rajkumar SV, Fonseca R, Dewald GW, Therneau TM, Lacy MQ, Kyle RA, Greipp PR, Gertz MA. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet. 1999 Aug; 113 (1):73-7 PMID: 10459351 DOI: 10.1016/s0165-4608(99)00009-6

17. Rajkumar S, Fonseca R, Lacy M, Witzig T, Lust J, Greipp P, Therneau T, Kyle R, Litzow M, Gertz M. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Bone Marrow Transplant. 1999 Sep; 24(5):497-503. PMID: 10482933 DOI: 10.1038/sj.bmt.1701943

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

18. Fonseca R, Hoyer JD, Aguayo P, Jalal SM, Ahmann GJ, Rajkumar SV, Witzig TE, Lacy MQ, Dispenzieri A, Gertz MA, Kyle RA, Greipp PR. Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma. Leuk Lymphoma. 1999 Nov; 35 (5-6):599-605 PMID: 10609798 DOI: 10.1080/10428199909169625

19. Fonseca R, Coignet LJ, Dewald GW. Cytogenetic abnormalities in multiple myeloma. Hematol Oncol Clin North Am. 1999 Dec; 13 (6):1169-80, viii PMID: 10626143 DOI: 10.1016/s0889-8588(05)70119-2

20. Fonseca R, Greipp PR. Multiple myeloma. Conn's Current Therapy. 2000; 466-9. PMID: 0

21. Fonseca R, Habermann TM, Colgan JP, O'Neill BP, White WL, Witzig TE, Egan KS, Martenson JA, Burgart LJ, Inwards DJ. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer. 2000 Jan 1; 88 (1):154-61 PMID: 10618618 DOI: 10.1002/(sici)1097-0142(20000101)88:1<154::aid-cncr21>3.0.co;2-t

22. Gertz MA, Fonseca R, Rajkumar SV. Waldenstrom's macroglobulinemia. Oncologist. 2000; 5 (1):63-7 PMID: 10706651 DOI: 10.1634/theoncologist.5-1-63

23. Shoho AR, Porrata LF, Fonseca R. 76-year-old man with retroperitoneal bleeding after prostatectomy. Mayo Clin Proc. 2000 Mar; 75(3):299-302. PMID: 10725960 DOI: 10.4065/75.3.299

24. Fonseca R, Trendle MC, Leong T, Kyle RA, Oken MM, Kay NE, Van Ness B, Greipp PR. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol. 2000 Apr; 109(1):24-9. PMID: 10848778

25. Hoyer JD, Hanson CA, Fonseca R, Greipp PR, Dewald GW, Kurtin PJ. The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Am J Clin Pathol. 2000 Jun; 113(6):831-7. PMID: 10874884 DOI: 10.1309/4W8E-8F4K-BHUP-UBE7

26. Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Kyle RA, Gertz MA, Greipp PR. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res. 2000 Aug; 6 (8):3111-6 PMID: 10955791

27. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Kyle RA, Gertz MA, Greipp PR. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc. 2000 Sep; 75(9):897-901. PMID: 10994824 DOI: 10.4065/75.9.897

28. Fonseca R, Rajkumar SV, Ahmann GJ, Jalal SM, Hoyer JD, Gertz MA, Kyle RA, Greipp PR, Dewald GW. Fish demonstrates treatment-related chromosome damage in myeloid but not plasma cells in primary systemic amyloidosis. Leuk Lymphoma. 2000 Oct; 39 (3-4):391-5 PMID: 11342320 DOI: 10.3109/10428190009065839

29. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Witzig TE, Lust JA, Larson D, Therneau TM, Kyle RA, Litzow MR, Greipp PR, Gertz MA. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant. 2000 Nov; 26(9):979-83. PMID: 11100277 DOI: 10.1038/sj.bmt.1702640

30. Tefferi A, Fonseca R, Pereira DL, Hoagland HC. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc. 2001 Jan; 76(1):22-8. PMID: 11155408 DOI: 10.4065/76.1.22

31. Jalal SM, Law ME, Stamberg J, Fonseca R, Seely JR, Myers WH, Hanson CA. Detection of diagnostically critical, often hidden, anomalies in complex karyotypes of haematological disorders using multicolour fluorescence in situ hybridization. Br J Haematol. 2001 Mar; 112 (4):975-80 PMID: 11298595 DOI: 10.1046/j.1365-2141.2001.02630.x

32. Teh SH, Farley DR, Gharib H, Fonseca R, Goellner JR, van Heerden JA. Primary thyroid amyloidosis and thyroid lymphoma. Contemp Surg. 2001 Mar; 57(3):137-9.

33. Fonseca R, Oken MM, Harrington D, Bailey RJ, Van Wier SA, Henderson KJ, Kay NE, Van Ness B, Greipp PR, Dewald GW. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia. 2001 Jun; 15 (6):981-6 PMID: 11417487 DOI: 10.1038/sj.leu.2402125

34. Fonseca R, Conte G, Greipp PR. Laboratory correlates in multiple myeloma: how useful for prognosis? Blood Rev. 2001 Jun; 15(2):97-102. PMID: 11409909 DOI: 10.1054/blre.2001.0154

35. Hayman SR, Fonseca R. Plasma cell leukemia. Curr Treat Options Oncol. 2001 Jun; 2 (3):205-16 PMID: 12057120 DOI: 10.1007/s11864-001-0034-4

36. Dispenzieri A, Lacy MQ, Kyle RA, Therneau TM, Larson DR, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Gertz MA. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol. 2001 Jul 15; 19: (14)3350-6. PMID: 11454882 DOI: 10.1200/JCO.2001.19.14.3350

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

37. Rajkumar SV, Dispenzieri A, Fonseca R, Lacy MQ, Geyer S, Geyer S, Lust JA, Kyle RA, Greipp PR, Gertz MA, Witzig TE. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia. 2001 Aug; 15 (8):1274-6 PMID: 11480571 DOI: 10.1038/sj.leu.2402183

38. Hayman SR, Bailey RJ, Jalal SM, Ahmann GJ, Dispenzieri A, Gertz MA, Greipp PR, Kyle RA, Lacy MQ, Rajkumar SV, Witzig TE, Lust JA, Fonseca R. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood. 2001 Oct 1; 98 (7):2266-8 PMID: 11568015 DOI: 10.1182/blood.v98.7.2266

39. Rajkumar SV, Fonseca R, Witzig TE. Complete resolution of reflex sympathetic dystrophy with thalidomide treatment. Arch Intern Med. 2001 Nov 12; 161(20):2502-3. PMID: 11700165

40. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Therneau TM, Kyle RA, Greipp PR, Gertz MA. Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. Am J Hematol. 2001 Dec; 68 (4):269-75 PMID: 11754416 DOI: 10.1002/ajh.10003

41. Schop RF, Jalal SM, Van Wier SA, Ahmann GJ, Bailey RJ, Kyle RA, Greipp PR, Rajkumar SV, Gertz MA, Lust JA, Lacy MQ, Dispenzieri A, Witzig TE, Fonseca R. Deletions of 17p13.1 and 13q14 are uncommon in Waldenstrom macroglobulinemia clonal cells and mostly seen at the time of disease progression. Cancer Genet Cytogenet. 2002 Jan 1; 132 (1):55-60 PMID: 11801310 DOI: 10.1016/s0165-4608(01)00526-x

42. Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Blood EA, Rajkumar SV, Kay NE, Van Ness B, Greipp PR. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. Cancer Res. 2002 Feb 1; 62(3):715-20. PMID: 11830525

43. Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Hoyer JD, Harrington D, Kay NE, Van Ness B, Greipp PR. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood. 2002 May 15; 99 (10):3735-41 PMID: 11986230 DOI: 10.1182/blood.v99.10.3735

44. Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Russell SJ, Greipp PR. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res. 2002 Jul; 8(7):2210-6. PMID: 12114422

45. Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA, Kyle RA, Gertz MA, Greipp PR, Dewald GW. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002 Aug 15; 100(4):1417-24. PMID: 12149226

46. Schop RF, Kuehl WM, Van Wier SA, Ahmann GJ, Price-Troska T, Bailey RJ, Jalal SM, Qi Y, Kyle RA, Greipp PR, Fonseca R. Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood. 2002 Oct 15; 100 (8):2996-3001 PMID: 12351413 DOI: 10.1182/blood.V100.8.2996

47. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle RA, Witzig TE. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002 Nov 1; 20: (21)4319-23. PMID: 12409330

48. Kumar S, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Bone marrow angiogenesis in multiple myeloma: effect of therapy. Br J Haematol. 2002 Dec; 119 (3):665-71 PMID: 12437642 DOI: 10.1046/j.1365-2141.2002.03871.x

49. Fonseca R, Ahmann GJ. Assays for neoplastic cell enrichment in bone marrow samples. Methods Mol Med. 2003; 85:333-42. PMID: 12710218 DOI: 10.1385/1-59259-380-1:333

50. Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL, Fonseca R, Hayman SR, Lust JA, Kyle RA, Greipp PR, Witzig TE, Rajkumar SV. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc. 2003 Jan; 78(1):34-9. PMID: 12528875 DOI: 10.4065/78.1.34

51. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003 Jan; 78(1):21-33. PMID: 12528874 DOI: 10.4065/78.1.21

52. Debes-Marun CS, Dewald GW, Bryant S, Picken E, Santana-Davila R, Gonzalez-Paz N, Winkler JM, Kyle RA, Gertz MA, Witzig TE, Dispenzieri A, Lacy MQ, Rajkumar SV, Lust JA, Greipp PR, Fonseca R. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia. 2003 Feb; 17(2):427-36. PMID: 12592343 DOI: 10.1038/sj.leu.2402797

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

53. Pardanani A, Witzig TE, Schroeder G, McElroy EA, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Kyle RA, Greipp PR, Gertz MA, Rajkumar SV. Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood. 2003 Feb 1; 101 (3):827-30 Epub 2002 Sept 05 PMID: 12393530 DOI: 10.1182/blood-2002-06-1698

54. Kumar S, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Wellik L, Witzig TE, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood. 2003 Mar 1; 101 (5):1715-7 Epub 2002 Oct 17 PMID: 12393501 DOI: 10.1182/blood-2002-08-2441

55. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, Morra E, Pangalis GA, Miguel JFS, Branagan AR, Dimopoulos MA. Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):110-5. PMID: 12720118

56. Schop RFJ, Fonseca R. Genetics and cytogenetics of Waidenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):142-5. PMID: 12720124

57. Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Therneau TM, Larson DR, Greipp PR, Witzig TE, Basu R, Suarez GA, Fonseca R, Lust JA, Gertz MA. POEMS syndrome: definitions and long-term outcome. Blood. 2003 Apr 1; 101 (7):2496-506 Epub 2002 Nov 27 PMID: 12456500 DOI: 10.1182/blood-2002-07-2299

58. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM, Iturria N, Kumar S, Lust JA, Kyle RA, Greipp PR, Witzig TE. Thalidomide as initial therapy for early-stage myeloma. Leukemia. 2003 Apr; 17(4):775-9. PMID: 12682636 DOI: 10.1038/sj.leu.2402866

59. Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA, Fonseca R. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood. 2003 May 15; 101 (10):3801-8 Epub 2002 Dec 19 PMID: 12515719 DOI: 10.1182/blood-2002-09-2707

60. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, Dewald GW, Van Ness B, Van Wier SA, Henderson KJ, Bailey RJ, Greipp PR. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003 Jun 1; 101(11):4569-75. PMID: 12576322

61. Kyle RA, Child JA, Anderson K, Barlogie B, Bataille R, Bensinger W, Blade J, Boccadoro M, Dalton W, Dimopoulos M, Djulbegovic B, Drayson M, Durie B, Facon T, Fonseca R, Gahrton G, Greipp P, Harousseau JL, Harrington D, Hussein M, Joshua D, Ludwig H, Morgan G, Oken M, Powles R, et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003 Jun; 121(5):749-57. PMID: 12780789

62. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, Greipp PR, Rajkumar SV. Expression of VEGF and its receptors by myeloma cells. Leukemia. 2003 Oct; 17(10):2025-31. PMID: 14513053 DOI: 10.1038/sj.leu.2403084

63. Thompson MA, Witzig TE, Kumar S, Timm MM, Haug J, Fonseca R, Greipp PR, Lust JA, Rajkumar SV. Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. Br J Haematol. 2003 Oct; 123 (2):305-8 PMID: 14531913 DOI: 10.1046/j.1365-2141.2003.04605.x

64. Fonseca R, Debes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM, Blood E, Oken MM, Santana-Davila R, Gonzalez-Paz N, Kyle RA, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003 Oct 1; 102 (7):2562-7 Epub 2003 June 12 PMID: 12805059 DOI: 10.1182/blood-2003-02-0493

65. Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macroglobulinaemia. Lancet Oncol. 2003 Nov; 4 (11):679-85 PMID: 14602248 DOI: 10.1016/s1470-2045(03)01246-4

66. Dispenzieri A, Lacy MQ, Rajkumar SV, Geyer SM, Witzig TE, Fonseca R, Lust JA, Greipp PR, Kyle RA, Gertz MA. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid. 2003 Dec; 10(4):257-61. PMID: 14986485 DOI: 10.3109/13506120309041743

67. Ghobrial IM, Wolf RC, Pereira DL, Fonseca R, White WL, Colgan JP, Habermann TM, Inwards DJ, Markovic SN, Ansell SM, Micallef IN, Porrata LF, Witzig TE. Therapeutic options in patients with lymphoma and severe liver dysfunction. Mayo Clin Proc. 2004 Feb; 79(2):169-75. PMID: 14959910 DOI: 10.4065/79.2.169

68. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, Kuehl WM, Hernandez JM, Minvielle S, Pilarski LM, Shaughnessy JD Jr, Stewart AK, Avet-Loiseau H. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004 Feb 15; 64 (4):1546-58 PMID: 14989251 DOI: 10.1158/0008-5472.can-03-2876

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

69. Kumar S, Witzig TE, Dispenzieri A, Lacy MQ, Wellik LE, Fonseca R, Lust JA, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia. 2004 Mar; 18(3):624-7. PMID: 14749707 DOI: 10.1038/sj.leu.2403285

70. Munshi NC, Hideshima T, Carrasco D, Shammas M, Auclair D, Davies F, Mitsiades N, Mitsiades C, Kim RS, Li C, Rajkumar SV, Fonseca R, Bergsagel L, Chauhan D, Anderson KC. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood. 2004 Mar 1; 103(5):1799-806. PMID: 12969976

71. Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, Greipp PR, Dalton WS, Sebti SM. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 2004 May 1; 103(9):3271-7. Epub 2004 Jan 15. PMID: 14726402 DOI: 10.1182/blood-2003-08-2764

72. Dispenzieri A, Kyle RA, Lacy MQ, Therneau TM, Larson DR, Plevak MF, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Gertz MA. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. 2004 May 15; 103 (10):3960-3 Epub 2004 Jan 22 PMID: 14739213 DOI: 10.1182/blood-2003-12-4192

73. Ma CX, Lacy MQ, Rompala JF, Dispenzieri A, Rajkumar SV, Greipp PR, Fonseca R, Kyle RA, Gertz MA. Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood. 2004 Jul 1; 104 (1):40-2 Epub 2004 Mar 09 PMID: 15010372 DOI: 10.1182/blood-2003-10-3400

74. Abraham RS, Geyer SM, Ramirez-Alvarado M, Price-Troska TL, Gertz MA, Fonseca R. Analysis of somatic hypermutation and antigenic selection in the clonal B cell in immunoglobulin light chain amyloidosis (AL). J Clin Immunol. 2004 Jul; 24 (4):340-53 PMID: 15163890 DOI: 10.1023/B:JOCI.0000029113.68758.9f

75. Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Larson DR, Kyle RA, Greipp PR. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004 Jul; 79 (7):867-74 PMID: 15244382 DOI: 10.4065/79.7.867

76. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Allmer C, Witzig TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant. 2004 Jul; 34(2):161-7. PMID: 15133489

77. Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Wellik LA, Fonseca R, Lust JA, Witzig TE, Kyle RA, Greipp PR, Rajkumar SV. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant. 2004 Aug; 34(3):235-9. PMID: 15170170 DOI: 10.1038/sj.bmt.1704555

78. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Allmer C, Witzig TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant. 2004 Sep; 34(6):485-90. PMID: 15286691 DOI: 10.1038/sj.bmt.1704633

79. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, McConnell JP, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Hogan WJ, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, McGregor CG, Jaffe AS. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004 Sep 15; 104 (6):1881-7 Epub 2004 Mar 25 PMID: 15044258 DOI: 10.1182/blood-2004-01-0390

80. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004 Sep 15; 22(18):3751-7. PMID: 15365071 DOI: 10.1200/JCO.2004.03.029

81. Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, Vesole DH, Gertz MA, Eastern Cooperative Oncology Group. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer. 2004 Dec 1; 101(11):2593-8. PMID: 15493038 DOI: 10.1002/cncr.20658

82. Dispenzieri A, Wiseman GA, Lacy MQ, Litzow MR, Anderson PM, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata L, Elliott MA, Lust JA, Greipp PR, Rajkumar SV, Fonseca R, Witzig TE, Erlichman C, Sloan JA, Gertz MA. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia. 2005 Jan; 19: (1)118-25. PMID: 15526021 DOI: 10.1038/sj.leu.2403575

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

83. Fernandez-Zapico ME, Gonzalez-Paz NC, Weiss E, Savoy DN, Molina JR, Fonseca R, Smyrk TC, Chari ST, Urrutia R, Billadeau DD. Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell. 2005 Jan; 7 (1):39-49 PMID: 15652748 DOI: 10.1016/j.ccr.2004.11.024

84. Higgins MJ, Fonseca R. Genetics of multiple myeloma. Baillieres Best Pract Res Clin Haematol 2005; 18(4):525-36. PMID: 16026735

85. Abraham RS, Ballman KV, Dispenzieri A, Grill DE, Manske MK, Price-Troska TL, Paz NG, Gertz MA, Fonseca R. Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood. 2005 Jan 15; 105 (2):794-803 Epub 2004 Sept 23 PMID: 15388584 DOI: 10.1182/blood-2004-04-1424

86. Saccaro S, Fonseca R, Veillon DM, Cotelingam J, Nordberg ML, Bredeson C, Glass J, Munker R. Primary plasma cell leukemia: Report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol. 2005 Apr; 78(4):288-94. PMID: 15795922

87. Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, Ansell SM, Luyun R, Flynn PJ, Morton RF, Dakhil SR, Gross H, Kaufmann SH. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005 Aug 10; 23(23):5347-56. Epub 2005 Jun 27. PMID: 15983389 DOI: 10.1200/JCO.2005.13.466

88. Kumar S, Rajkumar SV, Kyle RA, Lacy MQ, Dispenzieri A, Fonseca R, Lust JA, Gertz MA, Greipp PR, Witzig TE. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. Journal of Clinical Oncology. 2005 Aug 20; 23(24):5668-74. PMID: 16110026

89. Chng WJ, Fonseca R. Genomics in multiple myeloma: biology and clinical implications. Pharmacogenomics. 2005 Sep; 6(6):563-73. PMID: 16142997

90. Stewart AK, Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol. 2005 Sep 10; 23(26):6339-44. PMID: 16155017

91. Chng WJ, Van Wier SA, Ahmann GJ, Winkler JM, Jalal SM, Bergsagel PL, Chesi M, Trendle MC, Oken MM, Blood E, Henderson K, Santana-Davila R, Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Fonseca R. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood. 2005 Sep 15; 106 (6):2156-61 Epub 2005 May 26 PMID: 15920009 PMCID: 1895145 DOI: 10.1182/blood-2005-02-0761

92. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ, Van Wier SA, Ahmann GJ, Fonseca R. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood. 2005 Oct 15; 106 (8):2837-40 Epub 2005 June 23 PMID: 15976175 PMCID: 1895302 DOI: 10.1182/blood-2005-04-1411

93. Chng WJ, Fonseca R. Risk stratification of patients with newly diagnosed multiple myeloma: optimizing treatment based on pretreatment characteristics. Clin Lymphoma Myeloma. 2005 Nov; 6 (3):200-7 PMID: 16354325 DOI: 10.3816/CLM.2005.n.047

94. Dewald GW, Therneau T, Larson D, Lee YK, Fink S, Smoley S, Paternoster S, Adeyinka A, Ketterling R, Van Dyke DL, Fonseca R, Kyle R. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood. 2005 Nov 15; 106 (10):3553-8 Epub 2005 July 19 PMID: 16030187 PMCID: 1895058 DOI: 10.1182/blood-2005-05-1981

95. Dingli D, Rajkumar SV, Nowakowski GS, Gertz MA, Dispenzieri A, Lacy MQ, Hayman S, Fonseca R, Lust JA, Kyle RA, Greipp PR, Witzig TE. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. Haematologica. 2005 Dec; 90: (12)1650-4. PMID: 16330438

96. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005 Dec 15; 106 (13):4050-3 Epub 2005 Aug 23 PMID: 16118317 PMCID: 1895238 DOI: 10.1182/blood-2005-07-2817

97. Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Greipp PR, Rajkumar SV, Kimlinger T, Lust JA, Fonseca R, Allred J, Witzig TE. A phase II trial of imatinib in patients with refractory/relapsed myeloma. Leuk Lymphoma. 2006 Jan; 47 (1):39-42 PMID: 16321825 DOI: 10.1080/10428190500271269

98. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR, Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006 Jan 20; 24(3):431-6. Epub 2005 Dec 19. PMID: 16365178 DOI: 10.1200/JCO.2005.03.0221

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

99. Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Fitch TR, Fenton RG, Fonseca R, Isham CR, Ziesmer SC, Erlichman C, Bible KC. Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points. Haematologica. 2006 Mar; 91(3):390-3. Epub 2006 Feb 17. PMID: 16503551

100. Halligan CS, Lacy MQ, Vincent Rajkumar S, Dispenzieri A, Witzig TE, Lust JA, Fonseca R, Gertz MA, Kyle RA, Pruthi RK. Natural history of thromboembolism in AL amyloidosis. Amyloid. 2006 Mar; 13(1):31-6. PMID: 16690498 DOI: 10.1080/13506120500537285

101. Chng WJ, Winkler JM, Greipp PR, Jalal SM, Bergsagel PL, Chesi M, Trendle MC, Ahmann GJ, Henderson K, Blood E, Oken MM, Hulbert A, Van Wier SA, Santana-Davila R, Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R. Ploidy status rarely changes in myeloma patients at disease progression. Leuk Res. 2006 Mar; 30(3):266-71. Epub 2005 Aug 18. PMID: 16111750 DOI: 10.1016/j.leukres.2005.07.004

102. Ghobrial IM, Fonseca R, Gertz MA, Plevak MF, Larson DR, Therneau TM, Wolf RC, Hoffmann RJ, Lust JA, Witzig TE, Lacy MQ, Dispenzieri A, Vincent Rajkumar S, Zeldenrust SR, Greipp PR, Kyle RA. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2006 Apr; 133 (2):158-64 PMID: 16611306 DOI: 10.1111/j.1365-2141.2006.06003.x

103. Chng WJ, Ahmann GJ, Henderson K, Santana-Davila R, Greipp PR, Gertz MA, Lacy MQ, Dispenzieri A, Kumar S, Rajkumar SV, Lust JA, Kyle RA, Zeldenrust SR, Hayman SR, Fonseca R. Clinical implication of centrosome amplification in plasma cell neoplasm. Blood. 2006 May 1; 107 (9):3669-75 Epub 2005 Dec 22 PMID: 16373658 PMCID: 1895774 DOI: 10.1182/blood-2005-09-3810

104. Chng WJ, Santana-Davila R, Van Wier SA, Ahmann GJ, Jalal SM, Bergsagel PL, Chesi M, Trendle MC, Jacobus S, Blood E, Oken MM, Henderson K, Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Fonseca R. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia. 2006 May; 20(5):807-13. PMID: 16511510 PMCID: 0 DOI: 10.1038/sj.leu.2404172

105. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006 Aug; 81 (8):1047-53 PMID: 16901028 DOI: 10.4065/81.8.1047

106. Schop RF, Van Wier SA, Xu R, Ghobrial I, Ahmann GJ, Greipp PR, Kyle RA, Dispenzieri A, Lacy MQ, Rajkumar SV, Gertz MA, Fonseca R. 6q deletion discriminates Waldenstrom macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genet Cytogenet. 2006 Sep; 169(2):150-3. PMID: 16938573 DOI: 10.1016/j.cancergencyto.2006.04.009

107. Chng WJ, Schop RF, Price-Troska T, Ghobrial I, Kay N, Jelinek DF, Gertz MA, Dispenzieri A, Lacy M, Kyle RA, Greipp PR, Tschumper RC, Fonseca R, Bergsagel PL. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood. 2006 Oct 15; 108 (8):2755-63 Epub 2006 June 27 PMID: 16804116 PMCID: 1895596 DOI: 10.1182/blood-2006-02-005488

108. Fonseca R, Van Wier SA, Chng WJ, Ketterling R, Lacy MQ, Dispenzieri A, Bergsagel PL, Rajkumar SV, Greipp PR, Litzow MR, Price-Troska T, Henderson KJ, Ahmann GJ, Gertz MA. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006 Nov; 20(11):2034-40. Epub 2006 Oct 05. PMID: 17024118 DOI: 10.1038/sj.leu.2404403

109. Chng WJ, Ketterling RP, Fonseca R. Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma. Genes Chromosomes Cancer. 2006 Dec; 45(12):1111-20. PMID: 16955468 DOI: 10.1002/gcc.20375

110. Ocio EM, Schop RF, Gonzalez B, Van Wier SA, Hernandez-Rivas JM, Gutierrez NC, Garcia-Sanz R, Moro MJ, Aguilera C, Hernandez J, Xu R, Greipp PR, Dispenzieri A, Jalal SM, Lacy MQ, Gonzalez-Paz N, Gertz MA, San Miguel JF, Fonseca R. 6q deletion in Waldenstrom macroglobulinemia is associated with features of adverse prognosis. Br J Haematol. 2007 Jan; 136(1):80-6. PMID: 17222197 DOI: 10.1111/j.1365-2141.2006.06389.x

111. Fonseca R. Strategies for risk-adapted therapy in myeloma. Hematology Am Soc Hematol Educ Program. 2007; 304-10. PMID: 18024644 DOI: 10.1182/asheducation-2007.1.304

112. Gonzalez-Paz N, Chng WJ, McClure RF, Blood E, Oken MM, Van Ness B, James CD, Kurtin PJ, Henderson K, Ahmann GJ, Gertz M, Lacy M, Dispenzieri A, Greipp PR, Fonseca R. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood. 2007 Feb 1; 109 (3):1228-32 Epub 2006 July 13 PMID: 16840723 DOI: 10.1182/blood-2006-05-024661

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

113. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, Kumar S, Lacy MQ, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Reeder CB, Roy V, Kyle RA, Rajkumar SV, Fonseca R. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007 Mar; 21(3):529-34. Epub 2007 Jan 18. PMID: 17230230 DOI: 10.1038/sj.leu.2404516

114. Fonseca R, Stewart AK. Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach. Mol Cancer Ther. 2007 Mar; 6 (3):802-10 PMID: 17363477 DOI: 10.1158/1535-7163.MCT-06-0620

115. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust JA, Russell SJ, Hayman SR, Roy V, Kumar S, Zeldenrust SR, Dalton RJ, Stewart AK. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007 Mar; 82: (3)323-41. PMID: 17352369 DOI: 10.4065/82.3.323

116. Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, Chung TH, Kim S, Mulligan G, Bryant B, Carpten J, Gertz M, Rajkumar SV, Lacy M, Dispenzieri A, Kyle R, Greipp P, Bergsagel PL, Fonseca R. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 2007 Apr 1; 67(7):2982-9. PMID: 17409404 DOI: 10.1158/0008-5472.CAN-06-4046

117. Hatjiharissi E, Ngo H, Leontovich AA, Leleu X, Timm M, Melhem M, George D, Lu G, Ghobrial J, Alsayed Y, Zeismer S, Cabanela M, Nehme A, Jia X, Moreau AS, Treon SP, Fonseca R, Gertz MA, Anderson KC, Witzig TE, Ghobrial IM. Proteomic analysis of waldenstrom macroglobulinemia. Cancer Res. 2007 Apr 15; 67 (8):3777-84 PMID: 17440091 DOI: 10.1158/0008-5472.CAN-06-3089

118. Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, Larson DR, Plevak MF, Jelinek DF, Fonseca R, Melton LJ 3rd, Rajkumar SV. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007 Jun 21; 356(25):2582-90. PMID: 17582068 DOI: 10.1056/NEJMoa070389

119. Henry T, Fonseca R. Genomics and proteomics in multiple myeloma and Waldenstrom macroglobulinemia. Curr Opin Hematol. 2007 Jul; 14(4):369-74. PMID: 17534163 DOI: 10.1097/MOH.0b013e3281ddb2b8

120. Stewart AK, Fonseca R. Review of molecular diagnostics in multiple myeloma. Expert Rev Mol Diagn. 2007 Jul; 7(4):453-9. PMID: 17620051 DOI: 10.1586/14737159.7.4.453

121. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, Braggio E, Henry T, Zhu YX, Fogle H, Price-Troska T, Ahmann G, Mancini C, Brents LA, Kumar S, Greipp P, Dispenzieri A, Bryant B, Mulligan G, Bruhn L, Barrett M, Valdez R, Trent J, Stewart AK, Carpten J, Bergsagel PL. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007 Aug; 12 (2):131-44 PMID: 17692805 PMCID: 2083698 DOI: 10.1016/j.ccr.2007.07.003

122. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, Litzow MR, Fonseca R, Roy V, Rajkumar SV, Gertz MA. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007 Sep; 21 (9):2035-42 Epub 2007 June 21 PMID: 17581613 DOI: 10.1038/sj.leu.2404801

123. Fonseca R, Hayman S. Waldenstrom macroglobulinaemia. Br J Haematol. 2007 Sep; 138(6):700-20. Epub 2007 Aug 02. PMID: 17672883 DOI: 10.1111/j.1365-2141.2007.06724.x

124. Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Geyer S, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Bergsagel PL, Stewart AK, Rajkumar SV. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc. 2007 Oct; 82 (10):1179-84 PMID: 17908524 DOI: 10.4065/82.10.1179

125. Curtis KK, Pruthi RK, Fonseca R, Gornet MK. Transfusion-dependent anemia after initiation of androgen deprivation therapy for metastatic prostate cancer. Urology. 2007 Oct; 70(4):811.e5-8. PMID: 17991572 DOI: 10.1016/j.urology.2007.07.030

126. Fonseca R, San Miguel J. Prognostic factors and staging in multiple myeloma. Hematol Oncol Clin North Am. 2007 Dec; 21 (6):1115-40, ix PMID: 17996591 DOI: 10.1016/j.hoc.2007.08.010

127. Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, Clark RJ, Melton LJ 3rd, Gertz MA, Kumar SK, Fonseca R, Jelinek DF, Rajkumar SV. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008 Jan 15; 111 (2):785-9 Epub 2007 Oct 17 PMID: 17942755 PMCID: 2200851 DOI: 10.1182/blood-2007-08-108357

128. Kelly SV, Burke RF, Lee KS, Torloni AS, Lee RW, Northfelt D, Fonseca R. Acute myocardial infarction: an unusual presentation of essential thrombocytosis in a 17-year-old man. Clin Adv Hematol Oncol. 2008 Feb; 6(2):133-6. PMID: 18347564

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

129. Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, Tiedemann R, Valdez R, Palmer SE, Haas SS, Stewart AK, Fonseca R, Kremer R, Cattoretti G, Bergsagel PL. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell. 2008 Feb; 13 (2):167-80 PMID: 18242516 PMCID: 2255064 DOI: 10.1016/j.ccr.2008.01.007

130. Chng WJ, Braggio E, Mulligan G, Bryant B, Remstein E, Valdez R, Dogan A, Fonseca R. The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood. 2008 Feb 1; 111 (3):1603-9 Epub 2007 Nov 15 PMID: 18006703 DOI: 10.1182/blood-2007-06-097774

131. Ahmann GJ, Chng WJ, Henderson KJ, Price-Troska TL, DeGoey RW, Timm MM, Dispenzieri A, Greipp PR, Sable-Hunt A, Bergsagel L, Fonseca R. Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility. Cancer Epidemiol Biomarkers Prev. 2008 Mar; 17(3):666-73. PMID: 18349285 DOI: 10.1158/1055-9965.EPI-07-2649

132. Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Blade J, Fonseca R, Dimopoulos M, Shimizu K, San Miguel J, Westin J, Harousseau JL, Beksac M, Boccadoro M, Palumbo A, Barlogie B, Shustik C, Cavo M, Greipp PR, Joshua D, Attal M, Sonneveld P, Crowley J. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood. 2008 Apr 15; 111(8):4039-47. Epub 2008 Feb 11 PMID: 18268097 PMCID: 4259800 DOI: 10.1182/blood-2007-03-081018

133. Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, Chng WJ, Ketterling RP, Gertz MA, Henderson K, Greipp PR, Dispenzieri A, Lacy MQ, Rajkumar SV, Bergsagel PL, Stewart AK, Fonseca R. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008 May; 22 (5):1044-52 Epub 2008 Jan 24 PMID: 18216867 PMCID: 3893817 DOI: 10.1038/leu.2008.4

134. Tiedemann RE, Mao X, Shi CX, Zhu YX, Palmer SE, Sebag M, Marler R, Chesi M, Fonseca R, Bergsagel PL, Schimmer AD, Stewart AK. Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. J Clin Invest. 2008 May; 118 (5):1750-64 PMID: 18431519 PMCID: 2323188 DOI: 10.1172/JCI34149

135. Inwards DJ, Fishkin PA, Hillman DW, Brown DW, Ansell SM, Kurtin PJ, Fonseca R, Morton RF, Veeder MH, Witzig TE. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer. 2008 Jul 1; 113 (1):108-16 PMID: 18470909 PMCID: 3465670 DOI: 10.1002/cncr.23537

136. Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, Sharma A, Enriquez Sarano, Pollak M, Jagannath S, Richardson P, Gualberto A. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol. 2008 Jul 1; 26(19):3196-203. Epub 2008 May 12. PMID: 18474873 DOI: 10.1200/JCO.2007.15.9319

137. Arendt BK, Ramirez-Alvarado M, Sikkink LA, Keats JJ, Ahmann GJ, Dispenzieri A, Fonseca R, Ketterling RP, Knudson RA, Mulvihill EM, Tschumper RC, Wu X, Zeldenrust SR, Jelinek DF. Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. Blood. 2008 Sep 1; 112 (5):1931-41 Epub 2008 June 20 PMID: 18567838 PMCID: 2518895 DOI: 10.1182/blood-2008-03-143040

138. Bashey A, Perez WS, Zhang MJ, Anderson KC, Ballen K, Berenson JR, To LB, Fonseca R, Freytes CO, Gale RP, Gibson J, Giralt SA, Kyle RA, Lazarus HM, Maharaj D, McCarthy PL, Milone GA, Nimer S, Pavlovsky S, Reece DE, Schiller G, Vesole DH, Hari P, Plasma Cell Disorders Working Committee. Comparison of twin and autologous transplants for multiple myeloma. Biol Blood Marrow Transplant. 2008 Oct; 14 (10):1118-1124 PMID: 18804041 PMCID: 2584240 DOI: 10.1016/j.bbmt.2008.07.007

139. Fonseca R, Rajkumar SV. Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial. Clin Lymphoma Myeloma. 2008 Oct; 8 (5):315-7 PMID: 18854289 DOI: 10.3816/CLM.2008.n.046

140. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Kumar S, Kyle RA, Fonseca R, Greipp PR, Lust JA, Rajkumar VS, Hayman SR, Buadi F, Russell SJ, Zeldenrust SR, Dispenzieri A. A novel report of cig-FISH and cytogenetics in POEMS syndrome. Am J Hematol. 2008 Nov; 83 (11):840-1 PMID: 18839437 PMCID: 3956589 DOI: 10.1002/ajh.21285

141. Chng WJ, Remstein ED, Fonseca R, Bergsagel PL, Vrana JA, Kurtin PJ, Dogan A. Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications. Blood. 2009 Jan 15; 113 (3):635-45 Epub 2008 Oct 30 PMID: 18974375 PMCID: 2628370 DOI: 10.1182/blood-2008-02-140996

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

142. Braggio E, Keats JJ, Leleu X, Wier SV, Jimenez-Zepeda VH, Schop RF, Chesi M, Barrett M, Stewart AK, Dogan A, Bergsagel PL, Ghobrial IM, Fonseca R. High-resolution genomic analysis in Waldenstrom's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas. Clin Lymphoma Myeloma. 2009 Mar; 9 (1):39-42 PMID: 19362969 PMCID: 3646570 DOI: 10.3816/CLM.2009.n.009

143. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S, Kumar S, Hayman S, Buadi F, Kyle RA, Greipp PR, Lust JA, Russell S, Rajkumar SV, Fonseca R, Dispenzieri A. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica. 2009 Mar; 94 (3):380-6 Epub 2009 Feb 11 PMID: 19211640 PMCID: 2649355 DOI: 10.3324/haematol.13369

144. Conte G, Braggio E, Figueroa G, Fonseca R. Genetic markers as prognostic factors in multiple myeloma [Spanish]. Rev Med Chil. 2009 Apr; 137(4):552-8. PMID: 0

145. Braggio E, Keats JJ, Leleu X, Van Wier S, Jimenez-Zepeda VH, Valdez R, Schop RF, Price-Troska T, Henderson K, Sacco A, Azab F, Greipp P, Gertz M, Hayman S, Rajkumar SV, Carpten J, Chesi M, Barrett M, Stewart AK, Dogan A, Bergsagel PL, Ghobrial IM, Fonseca R. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res. 2009 Apr 15; 69 (8):3579-88 Epub 2009 Apr 07 PMID: 19351844 PMCID: 2782932 DOI: 10.1158/0008-5472.CAN-08-3701

146. Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J, Noble B, Pirooz NA, Spong JE, Piza JG, Zepeda VH, Mikhael JR, Leis JF, Bergsagel PL, Fonseca R, Stewart AK. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009 Jul; 23 (7):1337-41 Epub 2009 Feb 19 PMID: 19225538 PMCID: 2711213 DOI: 10.1038/leu.2009.26

147. Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz MA, Dalton RJ, Mikhael JR, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Stewart AK, Kyle RA, Greipp PR, Rajkumar SV. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2009 Jul 16; 114 (3):518-21 Epub 2009 Mar 26 PMID: 19324902 PMCID: 2713462 DOI: 10.1182/blood-2009-01-202010

148. Ching WJ, Fonseca R. Centrosomes and myeloma; aneuploidy and proliferation. Environ Mol Mutagen. 2009 Oct; 50(8 Special Issue SI):697-707. PMID: 0

149. Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009 Oct 20; 27: (30)5008-14. PMID: 19720894 DOI: 10.1200/JCO.2009.23.6802

150. Reeder CB, Reece DE, Kukreti V, Mikhael JR, Chen C, Trudel S, Laumann K, Hentz J, Pirooz N, Piza J, Zepeda VJJ, Fonseca R, Bergsagel PL, Leis J, Tiedemann RE, Stewart AK. A phase II trial comparison of once versus twice weekly bortezomib in CYBORD chemotherapy for newly diagnosed myeloma: identical high response rates and less toxicity. Blood. 2009 Nov 20; 114(22):255.

151. Dispenzieri A, Gertz MA, Hayman SR, Buadi F, Kumar S, Reeder CB, Zeldenrust SR, Rajkumar SV, Detweiler-Short K, Lust JA, Witzig TE, Greipp PR, Russell SJ, Dingli D, Allred J, Laumann K, Thompson MA, Fonseca R, Stewart AK, Bergsagel PL, Mikhael JR, Roy V, Kyle R, Lacy MQ. A pilot study of pomalidomide and dexamethasone in previously treated light chain amyloidosis patients. Blood. 2009 Nov 20; 114(22):1482-3.

152. Gay F, Rajkumar SV, Jayabalan DS, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard JP, Lacy MQ, Chen-Kiang S, Roy V, Coleman M, Hayman SR, Buadi F, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Niesvizky R. Clarithromycin (biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (RD) as initial therapy for newly diagnosed multiple myeloma. Blood. 2009 Nov; 114(22):1119-20.

153. Fonseca R. Plasma cell leukemia. Blood. 2009 Nov 20; 114(22):1575-6. 154. Puig N, Trudel S, Keats JJ, Li ZH, Braggio E, Ahmann GJ, Zeng S, Fonseca R, Kukreti V. Spontaneous

remission in a patient with t(4;14) translocation multiple myeloma. J Clin Oncol. 2009 Nov 20; 27(33):e194-7. Epub 2009 Oct 05. PMID: 19805681 DOI: 10.1200/JCO.2009.22.0392

155. Gay F, Hayman S, Lacy MQ, Buadi F, Gertz MA, Kumar S, Dispenzieri A, Mikhael JR, Bergsagel L, Dingli D, Reeder CB, Lust JA, Russel S, Roj V, Zeldenrust SR, Witzig TE, Fonseca R, Kyle R, Greipp PR, Stewart AK, Rajkumar SV. Superiority of lenalidomide-dexamethasone versus thalidomide-dexamethasone as initial therapy for newly diagnosed multiple myeloma. Blood. 2009 Nov 20; 114(22):1494-5.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

156. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, Durie BG, Carrasco R, Sezer O, Reiman T, Pilarski L, Avet-Loiseau H, International Myeloma Working Group. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009 Dec; 23 (12):2210-21 Epub 2009 Oct 01 PMID: 19798094 PMCID: 2964268 DOI: 10.1038/leu.2009.174

157. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Greipp PR, Hayman SR, Kyle RA, Lacy MQ, Lust JA, Reeder CB, Roy V, Russell SJ, Short KE, Stewart AK, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Bergsagel PL. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009 Dec; 84 (12):1095-110 PMID: 19955246 PMCID: 2787395 DOI: 10.4065/mcp.2009.0603

158. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR, Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010 Jan; 11 (1):29-37 Epub 2009 Oct 21 PMID: 19853510 PMCID: 3042271 DOI: 10.1016/S1470-2045(09)70284-0

159. Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Kumar S, Dispenzieri A, Mikhael JR, Bergsagel PL, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Rajkumar SV. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood. 2010 Feb 18; 115 (7):1343-50 Epub 2009 Dec 11 PMID: 20008302 PMCID: 2826759 DOI: 10.1182/blood-2009-08-239046

160. Tiedemann RE, Zhu YX, Schmidt J, Yin H, Shi CX, Que Q, Basu G, Azorsa D, Perkins LM, Braggio E, Fonseca R, Bergsagel PL, Mousses S, Stewart AK. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood. 2010 Feb 25; 115 (8):1594-604 Epub 2009 Dec 07 PMID: 19996089 PMCID: 2830764 DOI: 10.1182/blood-2009-09-243980

161. Chng WJ, Gertz MA, Chung TH, Van Wier S, Keats JJ, Baker A, Bergsagel PL, Carpten J, Fonseca R. Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma. Leukemia. 2010 Apr; 24 (4):833-42 Epub 2010 Mar 11 PMID: 20220778 PMCID: 2977975 DOI: 10.1038/leu.2010.21

162. Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ 3rd, Colby CL, Therneau TM, Clark R, Kumar SK, Bradwell A, Fonseca R, Jelinek DF, Rajkumar SV. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet. 2010 May 15; 375 (9727):1721-8 PMID: 20472173 PMCID: 2904571 DOI: 10.1016/S0140-6736(10)60482-5

163. Kapoor P, Fonseca R, Rajkumar SV, Sinha S, Gertz MA, Stewart AK, Bergsagel PL, Lacy MQ, Dingli DD, Ketterling RP, Buadi F, Kyle RA, Witzig TE, Greipp PR, Dispenzieri A, Kumar S. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clin Proc. 2010 Jun; 85 (6):532-7 PMID: 20511484 PMCID: 2878257 DOI: 10.4065/mcp.2009.0677

164. Khan ML, Colby TV, Viggiano RW, Fonseca R. Treatment with bortezomib of a patient having hyper IgG4 disease. Clin Lymphoma Myeloma Leuk. 2010 Jun; 10(3):217-9. PMID: 20511168 DOI: 10.3816/CLML.2010.n.034

165. Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, Palumbo A, Roodman GD, San-Miguel JF, Singhal S, Weber DM, Zangari M, Wirtschafter E, Yellin O, Kyle RA. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol. 2010 Jul; 150(1):28-38. Epub 2010 May 09. PMID: 20507313 DOI: 10.1111/j.1365-2141.2010.08207.x

166. Dispenzieri A, Jacobus S, Vesole DH, Callandar N, Fonseca R, Greipp PR. Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. Leukemia. 2010 Aug; 24 (8):1406-11 Epub 2010 June 10 PMID: 20535147 PMCID: 2921007 DOI: 10.1038/leu.2010.129

167. Kumar S, Zhang L, Dispenzieri A, Van Wier S, Katzmann JA, Snyder M, Blood E, DeGoey R, Henderson K, Kyle RA, Bradwell AR, Greipp PR, Rajkumar SV, Fonseca R. Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. Leukemia. 2010 Aug; 24 (8):1498-505 Epub 2010 June 03 PMID: 20520636 PMCID: 3558529 DOI: 10.1038/leu.2010.128

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

168. Gay F, Rajkumar SV, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ, Chen-Kiang S, Roy V, Jayabalan DS, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Niesvizky R. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol. 2010 Sep; 85 (9):664-9 PMID: 20645430 PMCID: 3956597 DOI: 10.1002/ajh.21777

169. Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, Dispenzieri A, Greipp PR, Habermann TM, Hayman SR, Inwards DJ, Johnston PB, Kumar SK, Lacy MQ, Lust JA, Markovic SN, Micallef IN, Nowakowski GS, Porrata LF, Roy V, Russell SJ, Short KE, Stewart AK, Thompson CA, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Gertz MA. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc. 2010 Sep; 85 (9):824-33 Epub 2010 Aug 11 PMID: 20702770 PMCID: 2931618 DOI: 10.4065/mcp.2010.0304

170. Salhia B, Baker A, Ahmann G, Auclair D, Fonseca R, Carpten J. DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors. Cancer Res. 2010 Sep 1; 70(17):6934-44. Epub 2010 Aug 24. PMID: 20736376 DOI: 10.1158/0008-5472.CAN-10-0282

171. Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV, Buadi F. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010 Nov; 24 (11):1934-9 Epub 2010 Sept 09 PMID: 20827286 PMCID: 2978257 DOI: 10.1038/leu.2010.190

172. Ansell SM, Akasaka T, Manske M, Price-troska T, Ziesmer S, Braggio E, Fonseca R, Gupta M, Law ME, Witzig TE, Dyer MJS, Dogan A, Novak AJ. A newly identified translocation t(X;14)(p11;q32) In MALT lymphoma involving IGHS and GPR34 reveals a novel role for GPR34 in cell growth and tumor development. Blood. 2010 Nov 19; 116(21):833-4.

173. Dispenzieri A, Abraham M, Hayman SR, Buadi F, Kumar S, Reeder CB, Mikhael JR, Zeldenrust S, Rajkumar SV, Short KD, Greipp PR, Russell SJ, Dingli D, Allred J, Laumann K, Fonseca R, Bergsagel PL, Roy V, Stewart K, Lacy M. A phase-2 study of pomalidomide and dexamethasone in previously treated light chain (AL) amyloidosis. Blood. 2010 Nov 19; 116(21):434-5.

174. Braggio E, O'Neill BP, Macon W, Lopes MB, Schiff D, Fonseca R. Characterization of the Copy Number Changes In Primary CNS Lymphomas (PCNSL) by High Resolution Array Based Comparative Genomic Hybridization. Blood. 2010 Nov 19; 116(21):438-9.

175. Siegel DSD, Jacobus S, Rajkumar SV, Abonour R, Callander NS, Katz MS, Fonseca R, Vesole DH. Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in the ECOG E4A03 randomized clinical trial. Blood. 2010 Nov 19; 116(21):22-3.

176. Anderson KC, Cheson BD, Czuczman MS, Fonseca R, Gregory SA, Lonial S, Love N. Exploring the clinical decisions of US community-based oncologists and hematologists in the management of multiple myeloma and follicular lymphoma. Oncology. 2010 Dec; (Suppl 5):1-24.

177. Kay NE, Eckel-Passow JE, Braggio E, Vanwier S, Shanafelt TD, Van Dyke DL, Jelinek DF, Tschumper RC, Kipps T, Byrd JC, Fonseca R. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genet Cytogenet. 2010 Dec; 203 (2):161-8 PMID: 21156228 PMCID: 3026606 DOI: 10.1016/j.cancergencyto.2010.09.003

178. Lonial S, Anderson KC, Fonseca R, Love N. Up-front management of multiple myeloma. Oncology-new York. 2010 Dec; 24(5):8-14.

179. Poulain S, Braggio E, Roumier C, Aijjou R, Broucqsault N, Galiegue-Zouitina S, Manier S, Soenen V, Nibourel O, Duthilleul P, Fonseca R, Leleu X. High-throughput genomic analysis in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):106-8. PMID: 21454205 DOI: 10.3816/CLML.2011.n.021

180. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel DS, Sivachenko A, Stewart AK, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G, Golub TR. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011 Mar 24; 471(7339):467-72. PMID: 21430775 PMCID: 3560292 DOI: 10.1038/nature09837

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

181. Albarracin F, Fonseca R. Plasma cell leukemia. Blood Rev. 2011 May; 25(3):107-12. Epub 2011 Feb 03. PMID: 21295388 PMCID: 3907188 DOI: 10.1016/j.blre.2011.01.005

182. Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, Fonseca R, Stewart AK, Harousseau JL, Dimopoulos M, Jagannath S, Hajek R, Sezer O, Kyle R, Sonneveld P, Cavo M, Rajkumar SV, San Miguel, Crowley J, Avet-Loiseau H, International Myeloma. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011 May 5; 117(18):4696-700. Epub 2011 Feb 03. PMID: 21292777 PMCID: 3293763 DOI: 10.1182/blood-2010-10-300970

183. Hodge LS, Novak AJ, Grote DM, Braggio E, Ketterling RP, Manske MK, Price Troska TL, Ziesmer SC, Fonseca R, Witzig TE, Morice WG, Gertz MA, Ansell SM. Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1. Blood. 2011 May 12; 117 (19):e190-7 Epub 2011 Mar 17 PMID: 21415268 DOI: 10.1182/blood-2010-12-326868

184. Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T, Mulligan G, Chesi M, Bergsagel PL, Fonseca R. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia. 2011 Jun; 25 (6):1026-35 Epub 2011 Apr 05 PMID: 21468039 PMCID: 3432644 DOI: 10.1038/leu.2011.53

185. Hodge LS, Elsawa SF, Grote DM, Price-Troska TL, Asmann YW, Fonseca R, Gertz MA, Witzig TE, Novak AJ, Ansell SM. MicroRNA expression in tumor cells from Waldenstrom's macroglobulinemia reflects both their normal and malignant cell counterparts. Blood Cancer J. 2011 Jun; 1(6):e24. Epub 2011 Jun 17. PMID: 22829168 PMCID: 3255267 DOI: 10.1038/bcj.2011.25

186. Braggio E, McPhail ER, Macon W, Lopes MB, Schiff D, Law M, Fink S, Sprau D, Giannini C, Dogan A, Fonseca R, O'Neill BP. Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens. Clin Cancer Res. 2011 Jul 1; 17 (13):4245-53 Epub 2011 May 11 PMID: 21562036 PMCID: 3131452 DOI: 10.1158/1078-0432.CCR-11-0395

187. Kumar SK, Lacy MQ, Hayman SR, Stewart K, Buadi FK, Allred J, Laumann K, Greipp PR, Lust JA, Gertz MA, Zeldenrust SR, Bergsagel PL, Reeder CB, Witzig TE, Fonseca R, Russell SJ, Mikhael JR, Dingli D, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol. 2011 Aug; 86 (8):640-5 Epub 2011 May 31 PMID: 21630308 PMCID: 3901994 DOI: 10.1002/ajh.22053

188. Jimenez-Zepeda VH, Heilman RL, Engel RA, Carey EJ, Freeman C, Rakela J, Mulligan DC, Fonseca R, Stewart AK. Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants. Transplantation. 2011 Sep 15; 92(5):570-4. PMID: 21712755 DOI: 10.1097/TP.0b013e318225db2c

189. Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Laumann K, Mandrekar SJ, Reeder C, Rajkumar SV, Mikhael JR. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011 Sep 15; 118 (11):2970-5 Epub 2011 June 20 PMID: 21690557 PMCID: 3291492 DOI: 10.1182/blood-2011-04-348896

190. Kumar SK, Uno H, Jacobus SJ, Van Wier SA, Ahmann GJ, Henderson KJ, Callander NS, Haug JL, Siegel DS, Greipp PR, Fonseca R, Rajkumar SV. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2011 Oct 20; 118 (16):4359-62 Epub 2011 Aug 22 PMID: 21860025 PMCID: 3204907 DOI: 10.1182/blood-2011-03-342089

191. Jacobus SJ, Kumar S, Uno H, Van Wier, Ahmann GJ, Henderson KJ, Callander NS, Williams ME, Siegel DS, Greipp PR, Rajkumar SV, Fonseca R. Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03. Br J Haematol. 2011 Nov; 155(3):340-8. Epub 2011 Sep 09. PMID: 21902684 PMCID: 3192237 DOI: 10.1111/j.1365-2141.2011.08849.x

192. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL, Orlowski RZ, Stewart AK. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011 Nov 3; 118 (18):4771-9 Epub 2011 Aug 22 PMID: 21860026 PMCID: 3208291 DOI: 10.1182/blood-2011-05-356063

193. Braggio E, Kay N, Van Wier S, Tschumper RC, Smoley SA, Eckel-Passow JE, Sassoon T, Van Dyke DL, Byrd JC, Jelinek DF, Shanafelt TD, Fonseca R. Longitudinal genome wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. Blood. 2011 Nov 18; 118(21):1223-4.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

194. Pashos CL, Durie BGM, Rifkin R, Terebelo H, Gasparetto C, Mehta J, Toomey K, Abonour R, Fonseca R, Narang M, Shah JJ, Swem AS, Sullivan KA, Street TK, Khan ZM. Variation in health-related quality of life (HRQOL) among multiple myeloma patients by insurance coverage. Blood. 2011 Nov 18; 118(21):1361-2.

195. Watkins AJ, Hamoudi RA, Zeng N, Yan Q, Huang Y, Liu H, Zhang J, Braggio E, Fonseca R, de Leval, Isaacson PG, Wotherspoon A, McPhail ED, Dogan A, Du MQ. An integrated genomic and expression analysis of 7q deletion in splenic marginal zone lymphoma. PLoS One. 2012; 7(9):e44997. Epub 2012 Sep 13. PMID: 23028731 PMCID: 3441634 DOI: 10.1371/journal.pone.0044997

196. Weber MA, Black HR, Fonseca R, Garber J, Gonzalez-Campoy JM, Kimmelstiel C, Markowitz AB, Nakayama D, Stell LK, Stossel TP. Association of clinical researchers and educators a statement on relationships between physicians and industry. Endocr Pract. 2012; 18(6):1029-37. PMID: 22982801

197. Jung S, Kim S, Gale M, Cherni I, Fonseca R, Carpten J, Salhia B. DNA methylation in multiple myeloma is weakly associated with gene transcription. PLoS ONE. 2012; 7(12):e52626. PMID: 23285118 PMCID: 3527579

198. Liang WS, Craig DW, Carpten J, Borad MJ, Demeure MJ, Weiss GJ, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Barrett M, Phillips L, Benson H, Tembe W, Braggio E, Kiefer JA, Legendre C, Posner R, Hostetter GH, Baker A, Egan JB, Han H, Lake D, Stites EC, Ramanathan RK, Fonseca R, Stewart AK, Von Hoff D. Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One. 2012; 7 (10):e43192 Epub 2012 Oct 10 PMID: 23071490 PMCID: 3468610 DOI: 10.1371/journal.pone.0043192

199. Khan ML, Reeder CB, Kumar SK, Lacy MQ, Reece DE, Dispenzieri A, Gertz MA, Greipp P, Hayman S, Zeldenhurst S, Dingli D, Lust J, Russell S, Laumann KM, Mikhael JR, Leif Bergsagel P, Fonseca R, Vincent Rajkumar S, Keith Stewart A. A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. Br J Haematol. 2012 Feb; 156 (3):326-33 Epub 2011 Nov 23 PMID: 22107129 DOI: 10.1111/j.1365-2141.2011.08949.x

200. Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Hayman SR, Buadi FK, Dingli D, Knudson RA, Greenberg A, Russell SJ, Zeldenrust SR, Lust JA, Kyle RA, Bergsagel L, Rajkumar SV. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012 Mar 1; 119 (9):2100-5 Epub 2012 Jan 10 PMID: 22234687 PMCID: 3311247 DOI: 10.1182/blood-2011-11-390658

201. Fonseca R. Frontline treatment of multiple myeloma. Hematology. 2012 Apr; 17 Suppl 1:S101-4 PMID: 22507793 DOI: 10.1179/102453312X13336169156096

202. Cesarman-Maus G, Braggio E, Fonseca R. Thrombosis in multiple myeloma (MM). Hematology. 2012 Apr; 17 Suppl 1:S177-80. PMID: 22507814 PMCID: 3907192 DOI: 10.1179/102453312X13336169156933

203. Braggio E, Dogan A, Keats JJ, Chng WJ, Huang G, Matthews JM, Maurer MJ, Law ME, Bosler DS, Barrett M, Lossos IS, Witzig TE, Fonseca R. Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities. Mod Pathol. 2012 May; 25 (5):651-60 Epub 2012 Feb 03 PMID: 22301699 PMCID: 3341516 DOI: 10.1038/modpathol.2011.213

204. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, Stewart AK, Bergsagel PL, Fonseca R. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012 May 10; 119 (19):4391-4 Epub 2012 Feb 13 PMID: 22331188 PMCID: 3557400 DOI: 10.1182/blood-2011-11-390930

205. Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, Allred J, Laumann KM, Bergsagel LP, Dingli D, Mikhael JR, Reeder CB, Stewart AK, Zeldenrust SR, Greipp PR, Lust JA, Fonseca R, Russell SJ, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012 May 24; 119 (21):4860-7 Epub 2012 Apr 13 PMID: 22504925 PMCID: 3418771 DOI: 10.1182/blood-2012-01-407791

206. Colon-Otero G, Albertie M, Lesperance M, Weis JA, Coles A, Smith N, Mills L, Woodward T, Aspitia AM, Vishnu P, Willis F, Isley A, Fonseca R, Vachon C, Rajkumar SV. A pilot program in collaboration with African American churches successfully increases awareness of the importance of cancer research and participation in cancer translational research studies among African Americans. J Cancer Educ. 2012 Jun; 27 (2):294-8 PMID: 22072126 PMCID: 3736846 DOI: 10.1007/s13187-011-0288-x

207. Wagner LI, Robinson D, Weiss M, Katz M, Greipp P, Fonseca R, Cella D. Content development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction. J Pain Symptom Manage. 2012 Jun; 43(6):1094-104. Epub 2012 May 09. PMID: 22575718 PMCID: 3419469 DOI: 10.1016/j.jpainsymman.2011.06.019

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

208. Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, Kumar SK, Dingli D, Zeldenrust SR, Mikhael JR, Hall R, Rajkumar SV, Reeder C, Fonseca R, Bergsagel PL, Stewart AK, Roy V, Witzig TE, Lust JA, Russell SJ, Gertz MA, Lacy MQ. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 2012 Jun 7; 119 (23):5397-404 Epub 2012 Apr 04 PMID: 22493299 PMCID: 3369677 DOI: 10.1182/blood-2012-02-413161

209. Cesarman-Maus G, Braggio E, Maldonado H, Fonseca R. Absence of tissue factor expression by neoplastic plasma cells in multiple myeloma. Leukemia. 2012 Jul; 26(7):1671-4. Epub 2012 Feb 15. PMID: 22333877 DOI: 10.1038/leu.2012.43

210. Braggio E, Kay NE, VanWier S, Tschumper RC, Smoley S, Eckel-Passow JE, Sassoon T, Barrett M, Van Dyke DL, Byrd JC, Jelinek DF, Shanafelt TD, Fonseca R. Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. Leukemia 2012 Jul; 26 (7):1698-701 Epub 2012 Jan 20 PMID: 22261920 PMCID: 3893815 DOI: 10.1038/leu.2012.14

211. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, Kumar S, Rajkumar SV, Carpten JD, Barrett M, Fonseca R, Stewart AK, Bergsagel PL. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012 Aug 2; 120 (5):1067-76 Epub 2012 Apr 12 PMID: 22498740 PMCID: 3412330 DOI: 10.1182/blood-2012-01-405985

212. Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S, Middha S, Asmann Y, Schmidt J, Braggio E, Keats JJ, Fonseca R, Bergsagel PL, Craig DW, Carpten JD, Stewart AK. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012 Aug 2; 120 (5):1060-6 Epub 2012 Apr 23 PMID: 22529291 PMCID: 3412329 DOI: 10.1182/blood-2012-01-405977

213. Braggio E, Philipsborn C, Novak A, Hodge L, Ansell S, Fonseca R. Molecular pathogenesis of Waldenstrom's macroglobulinemia. Haematologica. 2012 Sep; 97 (9):1281-90 Epub 2012 July 06 PMID: 22773606 PMCID: 3436227 DOI: 10.3324/haematol.2012.068478

214. Vasmatzis G, Johnson SH, Knudson RA, Ketterling RP, Braggio E, Fonseca R, Viswanatha DS, Law ME, Kip NS, Ozsan N, Grebe SK, Frederick LA, Eckloff BW, Thompson EA, Kadin ME, Milosevic D, Porcher JC, Asmann YW, Smith DI, Kovtun IV, Ansell SM, Dogan A, Feldman AL. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood. 2012 Sep 13; 120 (11):2280-9 Epub 2012 Aug 01 PMID: 22855598 PMCID: 5070713 DOI: 10.1182/blood-2012-03-419937

215. Ansell SM, Akasaka T, McPhail E, Manske M, Braggio E, Price-Troska T, Ziesmer S, Secreto F, Fonseca R, Gupta M, Law M, Witzig TE, Dyer MJ, Dogan A, Cerhan JR, Novak AJ. t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth. Blood. 2012 Nov 8; 120 (19):3949-57 Epub 2012 Sept 10 PMID: 22966169 PMCID: 3496954 DOI: 10.1182/blood-2011-11-389908

216. Chung TH, Mulligan G, Fonseca R, Chng WJ. A novel measure of chromosome instability can account for prognostic difference in multiple myeloma. PLoS One. 2013; 8(6):e66361. Epub 2013 Jun 20. PMID: 23840451 PMCID: 3688789 DOI: 10.1371/journal.pone.0066361

217. Delgado M, Legeren M, Jurado JM, Zarcos I, Sanchez MJ, Fonseca R, Villaescusa A, Galvez F, Calvo A, Garcia-Puche JL. Advanced medullary thyroid cancer treated with Sorafenib: A case report. Journal of Solid Tumors. 2013; 3(1):34-37. DOI: http://dx.doi.org/10.5430/jst.v3

218. Braggio E, Fonseca R, Kay NE. CGH protocols: chronic lymphocytic leukemia. Methods Mol Biol. 2013; 973:87-98. PMID: 23412785 DOI: 10.1007/978-1-62703-281-0_6

219. Avet-Loiseau H, Durie BG, Cavo M, Attal M, Gutierrez N, Haessler J, Goldschmidt H, Hajek R, Lee JH, Sezer O, Barlogie B, Crowley J, Fonseca R, Testoni N, Ross F, Rajkumar SV, Sonneveld P, Lahuerta J, Moreau P, Morgan G, International Myeloma Working Group. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia. 2013 Mar; 27(3):711-7. Epub 2012 Oct 03. PMID: 23032723 PMCID: 3972006 DOI: 10.1038/leu.2012.282

220. Rio-Machin A, Ferreira BI, Henry T, Gomez-Lopez G, Agirre X, Alvarez S, Rodriguez-Perales S, Prosper F, Calasanz MJ, Martinez J, Fonseca R, Cigudosa JC. Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype. Leukemia. 2013 Apr; 27(4):925-31. Epub 2012 Oct 22. PMID: 23174883 DOI: 10.1038/leu.2012.302

221. Braggio E, Fonseca R. Genomic abnormalities of Waldenstrom macroglobulinemia and related low-grade B-cell lymphomas. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):198-201. Epub 2013 Mar 09. PMID: 23477936 DOI: 10.1016/j.clml.2013.02.015

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

222. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ, Mayo Clinic. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013 Apr; 88 (4):360-76 PMID: 23541011 DOI: 10.1016/j.mayocp.2013.01.019

223. Fernandez de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, LeLeu X, Dimopoulos MA, Chim CS, Schots R, Noeul A, Fantl D, Mellqvist UH, Landgren O, Chanan-Khan A, Moreau P, Fonseca R, Merlini G, Lahuerta JJ, Blade J, Orlowski RZ, Shah JJ, International Myeloma Working Group. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013 Apr; 27(4):780-91. Epub 2012 Nov 21 PMID: 23288300 PMCID: 4112539 DOI: 10.1038/leu.2012.336

224. Baker A, Braggio E, Jacobus S, Jung S, Larson D, Therneau T, Dispenzieri A, Van Wier SA, Ahmann G, Levy J, Perkins L, Kim S, Henderson K, Vesole D, Rajkumar SV, Jelinek DF, Carpten J, Fonseca R. Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood. 2013 Apr 18; 121(16):3147-52. Epub 2013 Feb 19. PMID: 23422747 PMCID: 3630830 DOI: 10.1182/blood-2012-07-443606

225. Braggio E, Egan JB, Fonseca R, Stewart AK. Lessons from next-generation sequencing analysis in hematological malignancies. Blood Cancer J. 2013 Jul 19; 3:e127 Epub 2013 July 19 PMID: 23872706 PMCID: 3730204 DOI: 10.1038/bcj.2013.26

226. Rajkumar SV, Gupta V, Fonseca R, Dispenzieri A, Gonsalves WI, Larson D, Ketterling RP, Lust JA, Kyle RA, Kumar SK. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia. 2013 Aug; 27 (8):1738-44 Epub 2013 Mar 21 PMID: 23515097 PMCID: 3773463 DOI: 10.1038/leu.2013.86

227. Jimenez-Zepeda VH, Chng WJ, Schop RF, Braggio E, Leis JF, Kay N, Fonseca R. Recurrent chromosome abnormalities define nonoverlapping unique subgroups of tumors in patients with chronic lymphocytic leukemia and known karyotypic abnormalities. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):467-76. PMID: 23876845 DOI: 10.1016/j.clml.2013.05.003

228. Jimenez-Zepeda VH, Braggio E, Fonseca R. Dissecting karyotypic patterns in non-hyperdiploid multiple myeloma: an overview on the karyotypic evolution. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):552-8. Epub 2013 Jul 12. PMID: 23856591 DOI: 10.1016/j.clml.2013.05.005

229. Van Wier S, Braggio E, Baker A, Ahmann G, Levy J, Carpten JD, Fonseca R. Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma. Haematologica. 2013 Oct; 98(10):1586-92. Epub 2013 May 28. PMID: 23716545 PMCID: 3789464 DOI: 10.3324/haematol.2012.081083

230. Fonseca R, Monge J. Myeloma: classification and risk assessment. Semin Oncol. 2013 Oct; 40(5):554-66. PMID: 24135400 DOI: 10.1053/j.seminoncol.2013.07.002

231. Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, Lin Y, Mikhael J, Kumar SK. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood. 2013 Dec 19; 122 (26):4172-81 Epub 2013 Oct 21 PMID: 24144641 PMCID: 3952477 DOI: 10.1182/blood-2013-08-520890

232. Alvarez JM, Fonseca R, Borges da Silva H, Marinho CR, Bortoluci KR, Sardinha LR, Epiphanio S, D'Imperio Lima MR. Chagas disease: still many unsolved issues. Mediators Inflamm. 2014; 2014:912965 Epub 2014 June 29 PMID: 25104883 PMCID: 4101227 DOI: 10.1155/2014/912965

233. Schuster SR, Kortuem KM, Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Ahmann G, Kumar S, Rajkumar SV, Mikhael J, Laplant B, Champion MD, Laumann K, Barlogie B, Fonseca R, Bergsagel PL, Lacy M, Stewart AK. The clinical significance of cereblon expression in multiple myeloma. Leuk Res. 2014 Jan; 38 (1):23-8 Epub 2013 Sept 05 PMID: 24129344 PMCID: 3905958 DOI: 10.1016/j.leukres.2013.08.015

234. Egan JB, Barrett MT, Champion MD, Middha S, Lenkiewicz E, Evers L, Francis P, Schmidt J, Shi CX, Van Wier S, Badar S, Ahmann G, Kortuem KM, Boczek NJ, Fonseca R, Craig DW, Carpten JD, Borad MJ, Stewart AK. Whole genome analyses of a well-differentiated liposarcoma reveals novel SYT1 and DDR2 rearrangements. PLoS One. 2014; 9 (2):e87113 Epub 2014 Feb 05 PMID: 24505276 PMCID: 3914808 DOI: 10.1371/journal.pone.0087113

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

235. Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H, International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014 Feb; 28 (2):269-77 Epub 2013 Aug 26 PMID: 23974982 DOI: 10.1038/leu.2013.247

236. Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, Bryce AH, McCullough AE, Barrett MT, Hunt K, Patel MD, Young SW, Collins JM, Silva AC, Condjella RM, Block M, McWilliams RR, Lazaridis KN, Klee EW, Bible KC, Harris P, Oliver GR, Bhavsar JD, Nair AA, Middha S, Asmann Y, Kocher JP, Schahl K, Kipp BR, Barr Fritcher EG, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Phillips L, McDonald J, Adkins J, Mastrian SD, Placek P, Watanabe AT, Lobello J, Han H, Von Hoff D, Craig DW, Stewart AK, Carpten JD. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014 Feb; 10 (2):e1004135 Epub 2014 Feb 13 PMID: 24550739 PMCID: 3923676 DOI: 10.1371/journal.pgen.1004135

237. Fonseca R, Monge J, Dimopoulos MA. Staging and prognostication of multiple myeloma. Expert Rev Hematol. 2014 Feb; 7 (1):21-31 PMID: 24483346 PMCID: 4201368 DOI: 10.1586/17474086.2014.882224

238. Ansell SM, Hodge LS, Secreto FJ, Manske M, Braggio E, Price-Troska T, Ziesmer S, Li Y, Johnson SH, Hart SN, Kocher JP, Vasmatzis G, Chanan-Kahn A, Gertz M, Fonseca R, Dogan A, Cerhan JR, Novak AJ. Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma. Blood Cancer J. 2014 Feb 14; 4:e183 PMID: 24531446 PMCID: 3944662 DOI: 10.1038/bcj.2014.4

239. Lazaridis KN, McAllister TM, Babovic-Vuksanovic D, Beck SA, Borad MJ, Bryce AH, Chanan-Khan AA, Ferber MJ, Fonseca R, Johnson KJ, Klee EW, Lindor NM, McCormick JB, McWilliams RR, Parker AS, Riegert-Johnson DL, Rohrer Vitek CR, Schahl KA, Schultz C, Stewart K, Then GC, Wieben ED, Farrugia G. Implementing individualized medicine into the medical practice. Am J Med Genet C Semin Med Genet. 2014 Mar; 166C(1):15-23. Epub 2014 Mar 10. PMID: 24616301 DOI: 10.1002/ajmg.c.31387

240. Mereuta OM, Theis JD, Vrana JA, Law ME, Grogg KL, Dasari S, Chandan VS, Wu TT, Jimenez-Zepeda VH, Fonseca R, Dispenzieri A, Kurtin PJ, Dogan A. Leukocyte cell-derived chemotaxin 2 (LECT2)-associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States. Blood. 2014 Mar 6; 123 (10):1479-82 Epub 2014 Jan 10 PMID: 24415538 DOI: 10.1182/blood-2013-07-517938

241. Cesarman-Maus G, Braggio E, Lome-Maldonado C, Morales-Leyte AL, Fonseca R. Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin. Thromb Res. 2014 Apr; 133 (4):606-9 Epub 2014 Jan 23 PMID: 24491425 PMCID: 3965198 DOI: 10.1016/j.thromres.2014.01.020

242. Patrick O'Neill B, Braggio E, O'Neill BP, Van Wier S, Ojha J, McPhail E, Asmann Y, Egan J, Ayres da Silva J, Schiff D, Lopes MB, Valdez R, Tibes R, Eckloff B, Stewart AK, Fonseca R. Genome-wide analysis uncovers recurrent alterations in primary central nervous system lymphomas (pcnsl). Neuro Oncol. 2014 Jul; 16 Suppl 3:iii43. PMID: 25165333 PMCID: 4144657 DOI: 10.1093/neuonc/nou209.7

243. Zhu YX, Braggio E, Shi CX, Kortuem KM, Bruins LA, Schmidt JE, Chang XB, Langlais P, Luo M, Jedlowski P, LaPlant B, Laumann K, Fonseca R, Bergsagel PL, Mikhael J, Lacy M, Champion MD, Stewart AK. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood. 2014 Jul 24; 124 (4):536-45 Epub 2014 June 09 PMID: 24914135 PMCID: 4110660 DOI: 10.1182/blood-2014-02-557819

244. Kortuem KM, Zidich K, Schuster SR, Khan ML, Jimenez-Zepeda VH, Mikhael JR, Fonseca R, Stewart AK. Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14 (4):284-290.e5 Epub 2013 Dec 28 PMID: 24565465 PMCID: 4092053 DOI: 10.1016/j.clml.2013.12.015

245. Affer M, Chesi M, Chen WG, Keats JJ, Demchenko YN, Roschke AV, Van Wier S, Fonseca R, Bergsagel PL, Kuehl WM. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia. 2014 Aug; 28 (8):1725-1735 Epub 2014 Feb 12 PMID: 24518206 PMCID: 4126852 DOI: 10.1038/leu.2014.70

246. Azadeh N, Kelemen K, Fonseca R. Amitriptyline-induced agranulocytosis with bone marrow confirmation. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):e183-5. Epub 2014 Jun 11. PMID: 25052053 DOI: 10.1016/j.clml.2014.06.001

247. Teoh PJ, Chung TH, Sebastian S, Choo SN, Yan J, Ng SB, Fonseca R, Chng WJ. p53 haploinsufficiency and functional abnormalities in multiple myeloma. Leukemia. 2014 Oct; 28 (10):2066-74 Epub 2014 Mar 14 PMID: 24625551 DOI: 10.1038/leu.2014.102

248. Gordon GW, Monge J, Channon MB, Wu Q, Skulan JL, Anbar AD, Fonseca R. Predicting multiple myeloma disease activity by analyzing natural calcium isotopic composition. Leukemia 2014 Oct; 28 (10):2112-5 Epub 2014 June 12 PMID: 24919808 DOI: 10.1038/leu.2014.193

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

249. Ojha J, Secreto C, Rabe K, Ayres-Silva J, Tschumper R, Dyke DV, Slager S, Fonseca R, Shanafelt T, Kay N, Braggio E. Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression. Leukemia 2014 Dec; 28 (12):2395-8 Epub 2014 July 18 PMID: 25034147 PMCID: 4302736 DOI: 10.1038/leu.2014.226

250. Borges da Silva H, Fonseca R, Alvarez JM, D'Imperio Lima MR. IFN-gamma Priming Effects on the Maintenance of Effector Memory CD4(+) T Cells and on Phagocyte Function: Evidences from Infectious Diseases. J Immunol Res. 2015; 2015:202816 Epub 2015 Oct 05 PMID: 26509177 PMCID: 4609814 DOI: 10.1155/2015/202816

251. Borges da Silva H, Fonseca R, Pereira RM, Cassado A, Alvarez JM, D'Imperio Lima MR. Splenic Macrophage Subsets and Their Function during Blood-Borne Infections. Front Immunol. 2015; 6:480 Epub 2015 Sept 22 PMID: 26441984 PMCID: 4585205 DOI: 10.3389/fimmu.2015.00480

252. Ojha J, Ayres J, Secreto C, Tschumper R, Rabe K, Van Dyke D, Slager S, Shanafelt T, Fonseca R, Kay NE, Braggio E. Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia. Blood. 2015 Jan 15; 125 (3):492-8 Epub 2014 Nov 06 PMID: 25377784 PMCID: 4296010 DOI: 10.1182/blood-2014-06-580563

253. Kumar SK, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, Fruth B, Roy V, Erlichman C, Stewart AK, Mayo Phase 2 Consortium. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood. 2015 Jan 15; 125 (3):443-8 Epub 2014 Nov 13 PMID: 25395429 PMCID: 4296007 DOI: 10.1182/blood-2014-05-573741

254. Borges da Silva H, Fonseca R, Cassado A, Machado de Salles E, de Menezes MN, Langhorne J, Perez KR, Cuccovia IM, Ryffel B, Barreto VM, Marinho CR, Boscardin SB, Alvarez JM, D'Imperio-Lima MR, Tadokoro CE. In vivo approaches reveal a key role for DCs in CD4+ T cell activation and parasite clearance during the acute phase of experimental blood-stage malaria. PLoS Pathog. 2015 Feb; 11 (2):e1004598 Epub 2015 Feb 06 PMID: 25658925 PMCID: 4450059 DOI: 10.1371/journal.ppat.1004598

255. Kortum KM, Langer C, Monge J, Bruins L, Egan JB, Zhu YX, Shi CX, Jedlowski P, Schmidt J, Ojha J, Bullinger L, Liebisch P, Kull M, Champion MD, Van Wier S, Ahmann G, Rasche L, Knop S, Fonseca R, Einsele H, Stewart AK, Braggio E. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease. Br J Haematol. 2015 Feb; 168 (4):507-10 Epub 2014 Oct 10 PMID: 25302557 PMCID: 4314325 DOI: 10.1111/bjh.13171

256. Ojha J, Secreto CR, Rabe KG, Van Dyke DL, Kortum KM, Slager SL, Shanafelt TD, Fonseca R, Kay NE, Braggio E. Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia. Br J Haematol 2015 May; 169 (3):445-8 Epub 2014 Nov 10 PMID: 25382417 PMCID: 4865407 DOI: 10.1111/bjh.13211

257. Kortum KM, Langer C, Monge J, Bruins L, Zhu YX, Shi CX, Jedlowski P, Egan JB, Ojha J, Bullinger L, Kull M, Ahmann G, Rasche L, Knop S, Fonseca R, Einsele H, Stewart AK, Braggio E. Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P). Ann Hematol. 2015 Jul; 94 (7):1205-11 Epub 2015 Mar 07 PMID: 25743686 PMCID: 4655812 DOI: 10.1007/s00277-015-2344-9

258. Dispenzieri A, Buadi F, Kumar SK, Reeder CB, Sher T, Lacy MQ, Kyle RA, Mikhael JR, Roy V, Leung N, Grogan M, Kapoor P, Lust JA, Dingli D, Go RS, Hwa YL, Hayman SR, Fonseca R, Ailawadhi S, Bergsagel PL, Chanan-Khan A, Rajkumar SV, Russell SJ, Stewart K, Zeldenrust SR, Gertz MA. Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. Mayo Clin Proc. 2015 Aug; 90(8):1054-81. PMID: 26250727 DOI: 10.1016/j.mayocp.2015.06.009

259. Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J. 2015 Aug 14; 5:e338 PMID: 26275080 PMCID: 4558585 DOI: 10.1038/bcj.2015.60

260. Braggio E, Van Wier S, Ojha J, McPhail E, Asmann YW, Egan J, da Silva JA, Schiff D, Lopes MB, Decker PA, Valdez R, Tibes R, Eckloff B, Witzig TE, Stewart AK, Fonseca R, O'Neill BP. Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas. Clin Cancer Res. 2015 Sep 1; 21 (17):3986-94 Epub 2015 May 19 PMID: 25991819 PMCID: 4558226 DOI: 10.1158/1078-0432.CCR-14-2116

261. Stewart AK, Jacobus S, Fonseca R, Weiss M, Callander NS, Chanan-Khan AA, Rajkumar SV. Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood. 2015 Sep 10; 126 (11):1294-301 Epub 2015 July 08 PMID: 26157076 PMCID: 4566809 DOI: 10.1182/blood-2014-12-613927

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

262. Bi C, Chung TH, Huang G, Zhou J, Yan J, Ahmann GJ, Fonseca R, Chng WJ. Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma. Oncotarget. 2015 Sep 22; 6 (28):26508-18 PMID: 26164366 PMCID: 4694918 DOI: 10.18632/oncotarget.4769

263. Azadeh N, Tazelaar HD, Gotway MB, Mookadam F, Fonseca R. Erdheim Chester Disease treated successfully with cladribine. Respir Med Case Rep. 2016; 18:37-40 Epub 2016 Apr 04 PMID: 27144117 PMCID: 4840400 DOI: 10.1016/j.rmcr.2016.03.008

264. Rosenthal A, Luthi J, Belohlavek M, Kortum KM, Mookadam F, Mayo A, Fonseca R, Bergsagel PL, Reeder CB, Mikhael JR, Stewart AK. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J. 2016 Jan 15; 6:e384 PMID: 26771810 PMCID: 4742629 DOI: 10.1038/bcj.2015.112

265. Kortuem KM, Braggio E, Bruins L, Barrio S, Shi CS, Zhu YX, Tibes R, Viswanatha D, Votruba P, Ahmann G, Fonseca R, Jedlowski P, Schlam I, Kumar S, Bergsagel PL, Stewart AK. Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients. Blood Cancer J. 2016 Feb 26; 6:e397 PMID: 26918361 PMCID: 4771964 DOI: 10.1038/bcj.2016.1

266. Panchabhai S, Kelemen K, Ahmann G, Sebastian S, Mantei J, Fonseca R. Tumor-associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma. Leukemia 2016 Apr; 30 (4):951-4 Epub 2015 July 23 PMID: 26202926 DOI: 10.1038/leu.2015.191

267. Coakley M, Yeneneh B, Rosenthal A, Fonseca R, Mookadam F. Extramedullary Cardiac Multiple Myeloma-A Case Report and Contemporary Review of the Literature. Clin Lymphoma Myeloma Leuk. 2016 May; 16: (5)246-52. PMID: 27009538 DOI: 10.1016/j.clml.2016.02.003

268. Qaqish I, Schlam IM, Chakkera HA, Fonseca R, Adamski J. Carfilzomib: A cause of drug associated thrombotic microangiopathy. Transfus Apher Sci. 2016 Jun; 54: (3)401-4. PMID: 27017313 DOI: 10.1016/j.transci.2016.03.002

269. Jacobus SJ, Rajkumar SV, Weiss M, Stewart AK, Stadtmauer EA, Callander NS, Dreosti LM, Lacy MQ, Fonseca R. Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen. Blood Cancer J 2016 Jul 29; 6 (7):e448 Epub 2016 July 29 PMID: 27471864 PMCID: 5030380 DOI: 10.1038/bcj.2016.55

270. Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Spicka I, Masszi T, Hajek R, Rosinol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016 Sep 1; 128 (9):1174-80 Epub 2016 July 20 PMID: 27439911 PMCID: 5009511 DOI: 10.1182/blood-2016-03-707596

271. Biran N, Jacobus S, Vesole DH, Callander NS, Fonseca R, Williams ME, Abonour R, Katz MS, Rajkumar SV, Greipp PR, Siegel DS. Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up. Blood Cancer J. 2016 Sep 2; 6 (9):e466 Epub 2016 Sept 02 PMID: 27588519 PMCID: 5056965 DOI: 10.1038/bcj.2016.68

272. Teoh PJ, Bi C, Sintosebastian C, Tay LS, Fonseca R, Chng WJ. PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation. Oncotarget. 2016 Sep 20; 7 (38):61806-61819 PMID: 27533450 PMCID: 5308692 DOI: 10.18632/oncotarget.11241

273. Chesi M, Mirza NN, Garbitt VM, Sharik ME, Dueck AC, Asmann YW, Akhmetzyanova I, Kosiorek HE, Calcinotto A, Riggs DL, Keane N, Ahmann GJ, Morrison KM, Fonseca R, Lacy MQ, Dingli D, Kumar SK, Ailawadhi S, Dispenzieri A, Buadi F, Gertz MA, Reeder CB, Lin Y, Chanan-Khan AA, Stewart AK, Fooksman D, Bergsagel PL. IAP antagonists induce anti-tumor immunity in multiple myeloma. Nat Med. 2016 Dec; 22 (12):1411-1420 Epub 2016 Nov 14 PMID: 27841872 PMCID: 5515246 DOI: 10.1038/nm.4229

274. Borad MJ, Egan JB, Condjella RM, Liang WS, Fonseca R, Ritacca NR, McCullough AE, Barrett MT, Hunt KS, Champion MD, Patel MD, Young SW, Silva AC, Ho TH, Halfdanarson TR, McWilliams RR, Lazaridis KN, Ramanathan RK, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Cuyugan L, McDonald J, Adkins J, Mastrian SD, Valdez R, Jaroszewski DE, Von Hoff DD, Craig DW, Stewart AK, Carpten JD, Bryce AH. Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers. Sci Rep. 2016 Dec 23; 6 (1):25 PMID: 28003660 PMCID: 5431338 DOI: 10.1038/s41598-016-0021-4

275. Gonzalez-Calle V, Fonseca R. [Towards precision medicine in myeloma: new evidence and challenges]. Medicina (B Aires). 2017; 77 (3):222-226 PMID: 28643680

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

276. Barrio S, Shanafelt TD, Ojha J, Chaffee KG, Secreto C, Kortum KM, Pathangey S, Van-Dyke DL, Slager SL, Fonseca R, Kay NE, Braggio E. Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome. Leukemia. 2017 Jan; 31 (1):170-176 Epub 2016 June 14 PMID: 27469216 PMCID: 5215040 DOI: 10.1038/leu.2016.172

277. Colon-Otero G, Van Wier SA, Ahmann GJ, Braggio E, Albertie ML, Weis JA, Ailawadhi S, Cerhan JR, Vishnu P, Jorgensen MS, Foran JM, Thomas CS, Fonseca R. Prevalence of BCL-2/J(H) Translocation in Healthy African Americans. Ann Hematol. 2017 Jan; 96 (1):51-55 Epub 2016 Oct 12 PMID: 27730341 PMCID: 5203940 DOI: 10.1007/s00277-016-2842-4

278. Nasr SH, Dasari S, Mills JR, Theis JD, Zimmermann MT, Fonseca R, Vrana JA, Lester SJ, McLaughlin BM, Gillespie R, Highsmith WE Jr, Lee JJ, Dispenzieri A, Kurtin PJ. Hereditary Lysozyme Amyloidosis Variant p.Leu102Ser Associates with Unique Phenotype. J Am Soc Nephrol. 2017 Feb; 28 (2):431-438 Epub 2017 Jan 03 PMID: 28049649 PMCID: 5280032 DOI: 10.1681/ASN.2016090951

279. Sebastian S, Zhu YX, Braggio E, Shi CX, Panchabhai SC, Van Wier SA, Ahmann GJ, Chesi M, Bergsagel PL, Stewart AK, Fonseca R. Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity. Blood. 2017 Feb 23; 129 (8):991-1007 Epub 2016 Dec 27 PMID: 28028022 PMCID: 5324717 DOI: 10.1182/blood-2016-09-738872

280. Panchabhai S, Schlam I, Sebastian S, Fonseca R. PKM2 and other key regulators of Warburg effect positively correlate with CD147 (EMMPRIN) gene expression and predict survival in multiple myeloma. Leukemia. 2017 Apr; 31 (4):991-994 Epub 2016 Dec 27 PMID: 28025580 DOI: 10.1038/leu.2016.389

281. Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves WI, Hayman SR, Kapoor P, Kourelis T, Kumar SK, Kyle RA, Lacy MQ, Leung N, Lin Y, Lust JA, Mikhael JR, Reeder CB, Roy V, Russell SJ, Sher T, Stewart AK, Warsame R, Zeldenrust SR, Rajkumar SV, Chanan Khan AA. Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. Mayo Clin Proc. 2017 Apr; 92 (4):578-598 Epub 2017 Mar 11 PMID: 28291589 PMCID: 5554888 DOI: 10.1016/j.mayocp.2017.01.003

282. Rosenthal A, Dueck AC, Ansell S, Gano K, Conley C, Nowakowski GS, Camoriano J, Leis JF, Mikhael JR, Keith Stewart A, Stewart AK, Inwards D, Dingli D, Kumar S, Noel P, Gertz M, Porrata L, Russell S, Colgan J, Fonseca R, Habermann TM, Kapoor P, Buadi F, Leung N, Tiedemann R, Witzig TE, Reeder C. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy. Am J Hematol. 2017 May; 92 (5):467-472 Epub 2017 Mar 22 PMID: 28230270 DOI: 10.1002/ajh.24693

283. Fonseca R. Use of genetic markers in multiple myeloma. Clin Adv Hematol Oncol. 2017 Jun; 15 (6):446-448 PMID: 28749904

284. Fonseca R, Cesarman-Maus G, Braggio E. Personalizing the Use of Circulating Microparticle-Associated Tissue Factor As a Biomarker for Recurrent Thrombosis in Patients With Cancer. J Clin Oncol 2017 Jul 1; 35 (19):2217-2218 Epub 2017 May 08 PMID: 28481704 DOI: 10.1200/JCO.2017.72.5341

285. Bryce AH, Borad MJ, Egan JB, Condjella RM, Liang WS, Fonseca R, McCullough AE, Hunt KS, Ritacca NR, Barrett MT, Patel MD, Young SW, Silva AC, Ho TH, Halfdanarson TR, Stanton ML, Cheville J, Swanson S, Schneider DE, McWilliams RR, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Cuyugan L, McDonald J, Adkins J, Mastrian SD, Von Hoff DD, Craig DW, Stewart AK, Carpten JD. Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib. Clin Genitourin Cancer. 2017 Aug; 15 (4):e727-e734 Epub 2016 Dec 01 PMID: 28057415 PMCID: 7513310 DOI: 10.1016/j.clgc.2016.11.001

286. Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB. Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. JAMA Oncol. 2017 Sep 1; 3 (9):1257-1265 PMID: 28056114 PMCID: 5556979 DOI: 10.1001/jamaoncol.2016.5763

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

287. van Beers EH, van Vliet MH, Kuiper R, de Best L, Anderson KC, Chari A, Jagannath S, Jakubowiak A, Kumar SK, Levy JB, Auclair D, Lonial S, Reece D, Richardson P, Siegel DS, Stewart AK, Trudel S, Vij R, Zimmerman TM, Fonseca R. Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2017 Sep; 17 (9):555-562 Epub 2017 July 04 PMID: 28735890 DOI: 10.1016/j.clml.2017.06.020

288. Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, Richardson P. Trends in overall survival and costs of multiple myeloma, 2000-2014. Leukemia. 2017 Sep; 31 (9):1915-1921 Epub 2016 Dec 23 PMID: 28008176 PMCID: 5596206 DOI: 10.1038/leu.2016.380

289. Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. 2017 Sep 7; 130 (10):1198-1204 Epub 2017 July 06 PMID: 28684537 PMCID: 5606008 DOI: 10.1182/blood-2017-05-782961

290. Gonzalez-Calle V, Keane N, Braggio E, Fonseca R. Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach. Clin Lymphoma Myeloma Leuk. 2017 Oct; 17 (10):621-630 Epub 2017 June 23 PMID: 28743429 DOI: 10.1016/j.clml.2017.06.021

291. Fonseca R, Salgado RM, Borges da Silva H, do Nascimento RS, D'Imperio-Lima MR, Alvarez JM. Programmed Cell Death Protein 1-PDL1 Interaction Prevents Heart Damage in Chronic Trypanosoma cruzi Infection. Front Immunol. 2018; 9:997 Epub 2018 May 07 PMID: 29867974 PMCID: 5949529 DOI: 10.3389/fimmu.2018.00997

292. Ailawadhi S, Mikhael JR, LaPlant BR, Laumann KM, Kumar S, Roy V, Dingli D, Bergsagel PL, Buadi FK, Rajkumar SV, Fonseca R, Gertz MA, Kapoor P, Sher T, Hayman SR, Stewart AK, Dispenzieri A, Kyle RA, Gonsalves WI, Reeder CB, Lin Y, Go RS, Leung N, Kourelis T, Lust JA, Russell SJ, Chanan-Khan AA, Lacy MQ. Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. Leukemia. 2018 Mar; 32 (3):719-728 Epub 2017 Sept 01 PMID: 28860655 DOI: 10.1038/leu.2017.258

293. Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2018 Mar 20; 36 (9):859-866 Epub 2018 Jan 30 PMID: 29381435 PMCID: 6905485 DOI: 10.1200/JCO.2017.75.5207

294. Fonseca R, Hinkel J. Value and Cost of Myeloma Therapy-We Can Afford It. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:647-655 PMID: 30231366 DOI: 10.1200/EDBK_200869

295. Borges da Silva H, Beura LK, Wang H, Hanse EA, Gore R, Scott MC, Walsh DA, Block KE, Fonseca R, Yan Y, Hippen KL, Blazar BR, Masopust D, Kelekar A, Vulchanova L, Hogquist KA, Jameson SC. The purinergic receptor P2RX7 directs metabolic fitness of long-lived memory CD8(+) T cells. Nature. 2018 Jul; 559 (7713):264-268 Epub 2018 July 04 PMID: 29973721 PMCID: 6054485 DOI: 10.1038/s41586-018-0282-0

296. Jain T, Kosiorek HE, Kung ST, Shah VS, Dueck AC, Gonzalez-Calle V, Luft S, Reeder CB, Adams R, Noel P, Larsen JT, Mikhael J, Bergsagel L, Stewart AK, Fonseca R. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study. Clin Lymphoma Myeloma Leuk. 2018 Jul; 18 (7):486-492.e1 Epub 2018 May 04 PMID: 29753692 DOI: 10.1016/j.clml.2018.04.006

297. Kumar SK, Buadi FK, LaPlant B, Halvorson A, Leung N, Kapoor P, Dingli D, Gertz MA, Go RS, Bergsagel PL, Lin Y, Dispenzieri A, Hwa YL, Fonder A, Hobbs M, Fonseca R, Hayman SR, Stewart AK, Lust JA, Mikhael J, Gonsalves W, Reeder C, Skacel T, Rajkumar SV, Lacy MQ. Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J. 2018 Jul 30; 8 (8):70 Epub 2018 July 30 PMID: 30061664 PMCID: 6066484 DOI: 10.1038/s41408-018-0106-3

298. Gonzalez-Calle V, Slack A, Keane N, Luft S, Pearce KE, Ketterling RP, Jain T, Chirackal S, Reeder C, Mikhael J, Noel P, Mayo A, Adams RH, Ahmann G, Braggio E, Stewart AK, Bergsagel PL, Van Wier SA, Fonseca R. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. Ann Hematol. 2018 Aug; 97 (8):1453-1462 Epub 2018 Apr 06 PMID: 29623394 DOI: 10.1007/s00277-018-3316-7

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

299. Fonseca R, Peneva D, Clancy Z, Abouzaid S, Jena AB. The Importance of Economic Trade-offs in Cancer Drug Pricing. Mayo Clin Proc. 2018 Aug; 93 (8):976-979 Epub 2018 June 23 PMID: 29945732 DOI: 10.1016/j.mayocp.2018.05.025

300. Huskey JL, Heilman RL, Khamash H, Fonseca R. Kidney Transplant in the Era of Modern Therapy for Multiple Myeloma. Transplantation. 2018 Dec; 102 (12):1994-2001 PMID: 30211830 DOI: 10.1097/TP.0000000000002449

301. Jain T, Sonbol MB, Firwana B, Kolla KR, Almader-Douglas D, Palmer J, Fonseca R. High-Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant. 2019 Feb; 25 (2):239-247 Epub 2018 Sept 20 PMID: 30244101 DOI: 10.1016/j.bbmt.2018.09.021

302. Kim C, Bhatta S, Cyprien L, Fonseca R, Hernandez RK. Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: Observations from real-world data. J Bone Oncol. 2019 Feb; 14:100215 Epub 2018 Dec 26 PMID: 30666288 PMCID: 6329702 DOI: 10.1016/j.jbo.2018.100215

303. Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R, Hayman SR, Kapoor P, Kourelis TV, Lacy MQ, Larsen JT, Muchtar E, Reeder CB, Sher T, Stewart AK, Warsame R, Go RS, Kyle RA, Leung N, Lin Y, Lust JA, Russell SJ, Zeldenrust SR, Fonder AL, Hwa YL, Hobbs MA, Mayo AA, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA, Roy V. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplant. 2019 Mar; 54 (3):353-367 Epub 2018 July 09 PMID: 29988062 PMCID: 6463224 DOI: 10.1038/s41409-018-0264-8

304. Sahin I, Kawano Y, Sklavenitis-Pistofidis R, Moschetta M, Mishima Y, Manier S, Sacco A, Carrasco R, Fonseca R, Roccaro AM, Witzig T, Ghobrial IM. Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. Blood Adv. 2019 Apr 9; 3 (7):995-1002 PMID: 30940634 PMCID: 6457230 DOI: 10.1182/bloodadvances.2018028456

305. Strouse C, Briasoulis A, Fonseca R, Jethava Y. Approach to a patient with cardiac amyloidosis. J Geriatr Cardiol. 2019 Jul; 16 (7):567-574 PMID: 31447895 PMCID: 6689519 DOI: 10.11909/j.issn.1671-5411.2019.07.010

306. Ailawadhi S, Sher T, Azzouqa AG, Meghji Z, Jain T, Jani P, Ahmed S, Diehl N, Roy V, Shah V, Hodge D, Ailawadhi M, Alegria VR, Paulus A, Chanan-Khan A, Fonseca R. Monoclonal antibody utilization characteristics in patients with multiple myeloma. Anticancer Drugs. 2019 Sep; 30 (8):859-865 PMID: 31415286 DOI: 10.1097/CAD.0000000000000810

307. LeBlanc TW, Baile WF, Eggly S, Bylund CL, Kurtin S, Khurana M, Najdi R, Blaedel J, Wolf JL, Fonseca R. Review of the patient-centered communication landscape in multiple myeloma and other hematologic malignancies. Patient Educ Couns. 2019 Sep; 102 (9):1602-1612 Epub 2019 Apr 26 PMID: 31076236 DOI: 10.1016/j.pec.2019.04.028

308. Hagiwara M, Panjabi S, Delea T, Yucel E, Fonseca R. Burden of disease progression in patients with multiple myeloma in the US. Leuk Lymphoma. 2020 Jan; 61 (1):47-55 Epub 2019 Aug 07 PMID: 31389283 DOI: 10.1080/10428194.2019.1648802

309. Jethava YS, Fonseca R, Landgren O. Management of multiple myeloma during COVID-19 pandemic. Leuk Res Rep. 2020; 14:100212 Epub 2020 June 13 PMID: 32704473 PMCID: 7293439 DOI: 10.1016/j.lrr.2020.100212

310. Misund K, Keane N, Stein CK, Asmann YW, Day G, Welsh S, Van Wier SA, Riggs DL, Ahmann G, Chesi M, Viswanatha DS, Kumar SK, Dispenzieri A, Gonzalez-Calle V, Kyle RA, O'Dwyer M, Rajkumar SV, Kortum KM, Keats JJ, Fonseca R, Stewart AK, Kuehl WM, Braggio E, Bergsagel PL, MMRF CoMMpass Network. MYC dysregulation in the progression of multiple myeloma. Leukemia 2020 Jan; 34 (1):322-326 Epub 2019 Aug 22 PMID: 31439946 PMCID: 6923575 DOI: 10.1038/s41375-019-0543-4

311. Fonseca R, Gonzalez-Velez M. Treatment of Smoldering Multiple Myeloma: Expectant Observation Should Still Be the Standard. Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-7 PMID: 32207672 DOI: 10.1200/EDBK_280179

312. Cope S, Toor K, Popoff E, Fonseca R, Landgren O, Mateos MV, Weisel K, Jansen JP. Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma. Value Health. 2020 Apr; 23 (4):441-450 Epub 2020 Apr 06 PMID: 32327161 PMCID: 7480667 DOI: 10.1016/j.jval.2019.11.003

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

313. Fonseca R, Beura LK, Quarnstrom CF, Ghoneim HE, Fan Y, Zebley CC, Scott MC, Fares-Frederickson NJ, Wijeyesinghe S, Thompson EA, Borges da Silva H, Vezys V, Youngblood B, Masopust D. Developmental plasticity allows outside-in immune responses by resident memory T cells. Nat Immunol. 2020 Apr; 21 (4):412-421 Epub 2020 Feb 17 PMID: 32066954 PMCID: 7096285 DOI: 10.1038/s41590-020-0607-7

314. Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O'Brien T, Matous JV, Anderson DM, Emmons RV, Mahindra A, Wagner LI, Dhodapkar MV, Rajkumar SV. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. J Clin Oncol. 2020 Apr 10; 38 (11):1126-1137 Epub 2019 Oct 25 PMID: 31652094 PMCID: 7145586 DOI: 10.1200/JCO.19.01740

315. Cinar P, Kubal T, Freifeld A, Mishra A, Shulman L, Bachman J, Fonseca R, Uronis H, Klemanski D, Slusser K, Lunning M, Liu C. Safety at the Time of the COVID-19 Pandemic: How to Keep our Oncology Patients and Healthcare Workers Safe. J Natl Compr Canc Netw. 2020 Apr 15; 1-6 [Epub ahead of print] PMID: 32294617 DOI: 10.6004/jnccn.2020.7572

316. Zavidij O, Haradhvala NJ, Mouhieddine TH, Sklavenitis-Pistofidis R, Cai S, Reidy M, Rahmat M, Flaifel A, Ferland B, Su NK, Agius MP, Park J, Manier S, Bustoros M, Huynh D, Capelletti M, Berrios B, Liu CJ, He MX, Braggio E, Fonseca R, Maruvka Y, Guerriero JL, Goldman M, van Allen E, McCarroll SA, Azzi J, Getz G, Ghobrial IM. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020 May; 1 (5):493-506 Epub 2020 Apr 27 PMID: 33409501 PMCID: 7785110 DOI: 10.1038/s43018-020-0053-3

317. Bonolo de Campos C, Meurice N, Petit JL, Polito AN, Zhu YX, Wang P, Bruins LA, Wang X, Lopez Armenta ID, Darvish SA, Ahmann GJ, Henderson KJ, Tian S, Kruse JJ, Stewart WM, Larsen JT, Reeder CB, Dingli D, Kapoor P, Kumar SK, Fonseca R, Bergsagel PL, Braggio E, Stewart AK. "Direct to Drug" screening as a precision medicine tool in multiple myeloma. Blood Cancer J. 2020 May 11; 10 (5):54 PMID: 32393731 PMCID: 7214452 DOI: 10.1038/s41408-020-0320-7

318. Sidiqi MH, Al Saleh AS, Leung N, Jevremovic D, Aljama MA, Gonsalves WI, Buadi FK, Kourelis TV, Warsame R, Muchtar E, Hobbs MA, Lacy MQ, Dingli D, Go RS, Hayman SR, Rajkumar SV, Dispenzieri A, Gertz MA, Kumar SK, Fonseca R, Kapoor P. Venetoclax for the treatment of translocation (11;14) AL amyloidosis. Blood Cancer J 2020 May 11; 10 (5):55 PMID: 32393733 PMCID: 7214448 DOI: 10.1038/s41408-020-0321-6

319. Baughn LB, Sharma N, Elhaik E, Sekulic A, Bryce AH, Fonseca R. Targeting TMPRSS2 in SARS-CoV-2 Infection. Mayo Clin Proc. 2020 Sep; 95 (9):1989-1999 Epub 2020 July 19 PMID: 32861340 PMCID: 7368885 DOI: 10.1016/j.mayocp.2020.06.018

320. Mountjoy L, Sebastian S, Jain T, Hilal T, Gonzalez-Velez M, Girardo M, Ahmann G, Larsen J, Bergsagel L, Fonseca R. Prediction of immunomodulatory drugs (IMiDs) sensitivity in myeloma via determination of baseline anti-oxidative stress capacity. Leukemia 2020 Nov; 34 (11):3060-3063 Epub 2020 June 05 PMID: 32503975 DOI: 10.1038/s41375-020-0881-2

321. Fonseca R, Usmani SZ, Mehra M, Slavcev M, He J, Cote S, Lam A, Ukropec J, Maiese EM, Nair S, Potluri R, Voorhees PM. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer. 2020 Nov 10; 20 (1):1087 PMID: 33172403 PMCID: 7656738 DOI: 10.1186/s12885-020-07503-y

Books 1. Fonseca R. Manual for the introductory course. Book published as a study aid to the Medical School

candidates. Universidad Anahuac, School of Medicine, Mexico City, March 1988.

Book Chapters 1. Fonseca R, Ahmann GJ, Jalal SM, Dewald GW, Gertz MA, Greipp PR. A descriptive study chromosomal

abnormalities in systemic amyloidosis and correlation with biologic/prognostic variables. In:. Kyle RA, Gertz MA, editors. Amyloid and Amyloidosis 1998. New York: The Parthenon Publishing Group; 1999. p. 133-5.

2. Fonseca R, Greipp PR. Prognosis in multiple myeloma. In:. Tallman MS, Gordon LI, editors. Diagnostic and therapeutic advances in hematologic malignancies. Norwell: Kluwer Academic Publishers; 1999. p. 155-70.

3. Fonseca R. Practical aspects in the diagnosis and management of aplastic anemia. In:. Tefferi A, editor. Primary Hematology. Totowa: Humana Press; 2001. p. 83-91.

4. Fonseca R, Bergsagel PL, Kuehl WM. Cytogenetic abnormalities in the monoclonal gammopathies. In:. Wiernik PH, Goldman JM, Dutcher JP, Kyle RA, editors. Neoplastic diseases of the blood. 4th Edition. Cambridge: Cambridge University Press; 2003. p. 470-6.

5. Fonseca R, Greipp PR. Plasma cell disorders; general considerations. In: Gree JP. Wintrobe's Clinical Hematology 11th ed. Lippincott, Williams & Wilkins; 2003.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

6. Fonseca R. Role of cytogenetics in myeloma. In: Malpas J, Bergsagel DE, Kyle RA, Anderson K. Myeloma: Biology and Management 3rd ed. Elseviere Science; 2003.

7. Fonseca R. Cytogenetics of multiple myeloma. In:. Malpas JS, et al, editors. Myeloma: biology and management. 3rd Edition. Philadelphia: Saunders; 2004. p. 67-81.

8. Greipp PR, Fonseca R. Practical aspects of the clinical approach to patients with monoclonal immunoglobulin disorders. In:. Greer JP, et al, editors. Wintrobe's clinical hematology. 11th Edition. Volume 2. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 2555-64.

9. San Miguel J, Fonseca R, Greipp PR. Prognostic factors and classification for multiple myeloma (contribution to clinical management). In:. Malpas JS, et al, editors. Myeloma: biology and management. 3rd Edition. Philadelphia: Saunders; 2004. p. 189-99.

10. Fonseca R, Witzig TE. Waldenstrom macroglobulinemia. In:. Greer JP, et al, editors. Wintrobe's clinical hematology. 11th Edition. Volume 2. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 2667-81.

11. Winkler JM, Fonseca R. Waldenstrom macroglobulinemia. In:. Gertz MA, Greipp PR, editors. Hematologic malignancies: multiple myeloma and related plasma cell disorders. Berlin: Springer; 2004. p. 205-25.

12. Kyle RA, Fonseca R. Waldenstrom's macroglobulinemia. In:. Malpas JS, et al, editors. Myeloma: biology and management. 3rd Edition. Philadelphia: Saunders; 2004. p. 411-28.

13. VanWier S, Fonseca R. Detection of chromosome 13 deletions by fluorescent in situ hybridization. In:. Brown RD, Ho PJ, editors. Multiple myeloma: methods and protocols. Volume 113. Totowa: Humana Press; 2005. (Methods in Molecular Medicine.). p. 59-69.

14. Shanafelt TD, Fonseca R. Neutropenia. In:. Oliveira GHM, Nesbitt GC, Murphy JG, editors. Mayo Clinic medical manual. Boca Raton: Mayo Clinic Scientific Press, Taylor & Francis Group; 2006. p. 661-5.

15. Shanafelt TD, Fonseca R. Thrombocytopenia. In:. Oliveira GHM, Nesbitt GC, Murphy JG, editors. Mayo Clinic medical manual. Boca Raton: Mayo Clinic Scientific Press, Taylor & Francis Group; 2006. p. 259-69.

16. Braggio E, Sebag M, Fonseca R. Cytogenetic abnormalities in multiple myeloma: the importance of FISH and cytogenetics. In:. Lonial S, editor. Myeloma therapy: pursuing the plasma cell. Totowa: Humana; 2008. (Contemporary Hematology.). p. 57-76.

17. Fonseca R, Tonon G, Drach J. Diagnosis and genetic classification of multiple myeloma. In: Greer JP. Wintrobe's Clinical Hematology 12th ed. Lippincott Williams & Wilkins; 2009.

18. Fonseca R, Bergsagel PL. Diagnosis and genetic classification of multiple myeloma. In:. Rajkumar SV, Kyle RA, editors. Treatment of multiple myeloma and related disorders. Cambridge; New York: Cambridge University Press; 2009. p. 1-17.

19. Greipp PR, Fonseca R. Practical aspects of the clinical approach to patients with monoclonal immunoglobulin disorders. In:. Greer JP, et al, editors. Wintrobe's clinical hematology. 12th Edition. Volume 2. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2009. p. 2342-51.

20. Fonseca R, Ansell SM. Waldenstrom macroglobulinemia. In:. Greer JP, et al, editors. Wintrobe's clinical hematology. 12th Edition. Volume 2. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2009. p. 2471-83.

21. Fonseca R, Bergsagel PL, Kuehl WM. Cytogenetic abnormalities in MGUS and myeloma. In:. Wiernik PH; et al editor. Neoplastic diseases of the blood. 5th Edition. New York: Springer; 2013. p. 589-99.

22. Schuster S, Braggio E, Fonseca R. Genetics of multiple myeloma. In:. Genetic and molecular epidemiology of multiple myeloma. 2013. p. 1-16.

23. Braggio E, Fonseca R. Genomic strategies determining progression from MGUS to multiple myeloma. In: Munshi N, Anderson K. Advances in biology and therapy of multiple myeloma. Vol. 1. 2013. p. 3-24.

24. Kumar S, Fonseca R, Stewart K. Molecular classification and risk stratification. In:. Gertz MA; Rajkumar SV editor. Multiple myeloma: diagnsis and treatment. New York: Springer; 2014. p. 55-64.

25. Braggio E, Fonseca R. Multiple myeloma and other plasma cell disorders. In:. Murray MF; et al editor. Clinical genomics: practical applications in adult patient care. New York: McGraw-Hill Education/Medical; 2014. p. 171-4.

26. Fonseca R, Hayman SR, Ansell SM. Waldenstrom macroglobulinemia. In:. Greer JP; et al editor. Wintrobe's clinical hematology. Thirteenth Edition. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2014. p. 2124-40.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

27. Rajkumar SV, Fonseca R, San Miguel JF. Diagnosis and staging of multiple myeloma and related disorders. In:. Dimopoulos M; Facon T; Terpos E editors., Multiple myeloma and other plasma cell neoplasms. 2018. (Hematologic Malignancies). p. 17-28.

28. Bergsagel PL, Stewart AK, Russell SJ, Fonseca R. Molecular genetic aspects of plasma cell disorders. In:. Greer JP; Et al editors., Wintrobe's clinical hematology. Fourteenth Edition. Philadelphia: Wolters Kluwer; 2018. p. 6311-27.

29. Fonseca R, Hayman SR, Ansell SM. Waldenstrom macroglobulinemia. In: Greer JP, et al, editor(s). Wintrobe's Clinical Hematology. Thirteenth ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2018. p. 2124-40.

30. Fonseca R, Ansell SM. Waldenstrom macroglobulinemia. In:. Greer JP; Et al editors., Wintrobe's clinical hematology. Fourteenth Edition. Philadelphia: Wolters Kluwer; 2018. p. 6625-49.

31. Bergsagel PL, Stewart AK, Russell SJ, Fonseca R. Molecular genetic aspects of plasma cell disorders. In:. Wintrobe's clinical hematology. Fourteenth Edition. 2019.

32. Fonseca R, Ansell SM. Waldenstrom macroglobulinemia. In:. Wintrobe's clinical hematology. Fourteenth Edition. 2019. p. 2198-206.

Editorials 1. Fonseca R. A "not so micro" model for a "macro" problem. Blood. 2005 Aug 15; 106(4):1143-4. 2. Fonseca R. Multiple myeloma and FISH (but no CHIPS). Blood. 2007 Apr 15; 109(8):3132-3. 3. Braggio E, Fonseca R. Unraveling the multiple myeloma genome in the next-generation sequencing era:

challenges to translating knowledge into the clinic. Expert Rev Hematol. 2011 Dec; 4(6):579-81. 4. Fonseca R, Jain T. Bone Disease in Myeloma: The Claws of CRAB. Clin Cancer Res 2016 Mar 15; 22

(6):1301-3 Epub 2016 Jan 20 5. Fonseca R. Allowing Medicare to Directly Negotiate Drug Prices Will Hurt Seniors' Access to New Drugs.

The Hill. 2017 Feb. 6. Chesi M, Fonseca R. Antibodies Create Killer Bonds in Myeloma. Cancer Cell 2017 Mar 13; 31 (3):305-307

7. Fonseca R. Patients Deserve More Options. The Detroit News. 2018 Mar.

Commentaries 1. Fonseca R. Many and multiple myeloma(s). Leukemia 2003 Oct; 17 (10):1943-

4 PMID:14513042 DOI:10.1038/sj.leu.2403090 2. Chng WJ, Fonseca R. Cell lines of hyperdiploid myeloma, are we there yet? Br J Haematol. 2008 Mar;

140(5):579-80; author reply 580-1. Epub 2007 Nov 19. PMID:18028478 DOI:10.1111/j.1365-2141.2007.06905.x

3. Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA. Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4. PMID:20118399 DOI:10.4065/mcp.2009.0559

4. Fonseca R. Continuing medical education--limiting industry's influence. N Engl J Med. 2010 Mar 18; 362(11):1053; author reply 1053-4. PMID:20301802 DOI:

5. Fonseca R. Innovation in myeloma treatments PARP excellence! Blood 2011 Dec 8; 118 (24):6234-5 PMID:22161848 DOI:10.1182/blood-2011-10-381129

6. Weber MA, Fonseca R, Stossel TP. In response: the ethics and value of professional medical writing assistance. Endocr Pract. 2013 Mar-Apr; 19(2):379-80. PMID:23512399 DOI:10.4158/EP13076.LT

7. Fonseca R, Braggio E. The MYDas touch of next-gen sequencing. Blood 2013 Mar 28; 121 (13):2373-4 PMID:23538227 DOI:10.1182/blood-2013-02-481986

8. Fonseca R. Non-secretory myeloma: clinical and biologic implications. Oncology (Williston Park) 2013 Sep; 27 (9):932-3 PMID:24282995 DOI:

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

9. Fonseca RD. 2016 top stories in oncology: panobinostat as treatment for myeloma. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/2016-top-stories-in-oncology-panobinostat-as-treatment-for-myeloma/46480/65/1/3. Accessed January 7, 2021. 2016 Dec.

10. Fonseca RD. Borezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial. PracticeUpdate website. Available at: https://www.practiceupdate.con/content/bortezomib-and-thalidomide-maintenance-after-stem-cell-transplantation-for-multiple-myeloma-a -pethemagem-trial/49668/65/1/1. Accessed January 7, 2021. 2017 Feb.

11. Fonseca RD. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/carfilzomib-lenalidomide-and-dexamethasone-in-patients-with-relapsed-multiple-myeloma-categorised-by-age-secondary-analysis-from-the-phase-3-aspire-study/49734/65/1/1. Accessed January 7, 2021. 2017 Feb.

12. Fonseca RD. Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. Practice Update website. Available at: https://www.practiceupdate.com/content/upfront-lower-does-lenalidomide-is-less-toxic-and-does-not-compromise-efficacy-for-vulnerable-patients-with-relapsed-refractory-multiple-myeloma-final-analysis-of-the-phase-ii-revlite-study/49671/65/1/1. Accessed January 7, 2021. 2017 Feb.

13. Fonseca RD. Pembrolizumab, pomalidomide and low dose dexamethasone for relapsed/refractory multiple myeloma. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/pembrolizumab-pomalidomide-and-low-dose-dexamethasone-for-relapsedrefractory-multiple-myeloma/52851/65/1/1. Accesssed January 7, 2021. 2017 May.

14. Fonseca RD. ASCO 2017: abstract recommendations from Dr. Rafael Fonseca - plasma cell disorders. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/asco-2017-abstract-recommendations-from-dr-rafael-fonseca-plasma-cell-disorders/53735/65/1/3. Accessed January 7, 2021.. 2017 May.

15. Fonseca RD. Practice changers in myeloma from ASCO 2017. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/practice-changers-in-myeloma-from-asco-2017/54387/65/1/3. Accessed January 7, 2021. 2017 Jun.

16. Fonseca RD. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Practice Update website. Available at: https://www.practiceupdate.com/content/daratumumab-plus-pomalidomide-and-dexamethasone-in-relapsed-andor-refractory-multiple-myeloma/54950/65/1/1. Accessed January 7, 2021. 2017 Jun.

17. Fonseca RD. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/updated-analysis-of-calgb-alliance-100104-assessing-lenalidomide-versus-placebo-maintenance-after-single-autologous-stem-cell-transplantation-for-multiple-myeloma-a-randomised-double-blind-phase-3-trial/57154/65/1/1. Accessed January 7, 2021. 2017 Aug.

18. Fonseca RD. Promising new therapies for myeloma. Available at: https://www.practiceupdate.com/content/promising-new-therapies-for-myeloma/54388/65/1/3. Accessed January 7, 2021. 2017 Oct.

19. Fonseca RD. 2017 top stories in oncology: multiple myeloma. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/2017-top-stories-in-oncology-multiple-myeloma/62049/65/1/3. Accessed January 7, 2021. 2017 Dec.

20. Fonseca RD. Multiple myeloma at ASCO 2018. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/multiple-myeloma-at-asco-2018/69173/65/1/3. Accessed January 7, 2021. 2018 Jun.

21. Fonseca RD. Applying clinical trial findings in patients with multiple myeloma. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/applying-clinical-trial-findings-in-patients-with-multiple-myeloma/69172/65/1/3. Accessed January 7, 2021. 2018 Jun.

22. Fonseca RD. R-ISS for transplant-eligible multiple myeloma patients. PracticeUpdate website. Available at:https://www.practiceupdate.com/content/r-iss-for-transplant-eligible-multiple-myeloma-patients/69174/65/1/3. Accessed January 7, 2021. 2018 Aug.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

23. Singer J, Fonseca R. Polictics, Confirmation Bias, and Opiods CATO AT LIBERTY. 2018 Aug. 24. Fonseca RD. Bortezomib-based chemotherapy and light chain amyloidosis. PracticeUpdate website.

Available at: https://www.practiceupdate.com/content/bortezomib-based-chemotherapy-and-light-chain-amyloidosis/69175/65/1/3. Accessed January 7, 2021. 2018 Sep.

25. Fonseca RD. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. Practice Update website. Available at: https://www.practiceupdate.com/content/elotuzumab-plus-ponalidomide-and-dexamethasone-for-multiple-myeloma/65917/65/1/1. Accessed January 7, 2021. 2018 Nov.

26. Fonseca RD. 2018 Top stories in oncology: multiple myeloma. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/2018-top-stories-in-oncology-multiple-myeloma/75855/65/1/3. Accessed January 7, 2021. 2018 Nov.

27. Fonseca RD. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/lenalidomide-maintenance-versus-observation-for-patients-with-newly-diagnosed-multiple-myeloma-myeloma-xi-a-multicentre-open-label-randomised-phase-3-trial/77511/65/1/1. Accessed January 7, 2021. 2018 Dec.

28. Fonseca RD. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. PracticeUpdate website. Available at: https://www.practiceupdate.con/content/oral-ixazomib-maintenance-following-autologous-stem-cell-transplantation-tourmaline-mm3-a-double-blind-randomised-placebo-controlled-phase-3-trial/77512/65/1/1. Accessed January 7, 2021. 2018 Dec.

29. Fonseca RD. Randomized phase 3 study of carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible, NDMM patients. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/randomized-phase-3-study-of-carfilzomib-or-bortezomib-with-melphalan-prednisone-for-transplant-ineligible-ndmm-patients/80488/65/1/1. Accessed January 7, 2021. 2019 Mar.

30. Fonseca RD. Melphalan is (almost) dead. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/melphalan-is-almost-dead/81370/65/1/3. Accessed January 7, 2021. 2019 Apr.

31. Fonseca RD. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/pomalidomide-bortezomib-and-dexamethasone-for-patients-with-relapsed-or-refractory-multiple-myeloma-previously-treated-with lenalidomide-optimismm-a-randomised-open-label-phase-3-trial/83770/65/1/1. Accessed January 7, 2021. 2019 May.

32. Fonseca RD. ASCO 2019: abstract recommendations from Dr. Rafael Fonseca for multiple myeloma. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/asco-2019-abstract-recommendations-from-dr-rafael-fonseca-for-multiple-myeloma/84445/65/1/3. Accessed January 7, 2021. 2019 May.

33. Fonseca RD. Daratumumab plus borlezomib, thalidomide, and dexamethasone in newly diagnosed myeloma. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/daratumumab-plus-bortezomib-thalidomide-and-dexamethasone-in-newly-diagnosed-myeloma/84878/65/1/3. Accessed January 7, 2021. 2019 Jun.

34. Fonseca RD. Isatuximab, pomalidomide, and dexamethasone for relapsed/refractory myeloma. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/isatuximab-pomalidomide-and-dexamethasone-for-relapsedrefractory-myeloma/84879/65/1/3. Accessed January 7, 2021. 2019 Jun.

35. Fonseca RD. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/pembrolizumab-plus-lenalidomide-and-dexamethasone-for-patients-with-treatment-naive-multiple-myeloma-keynote-185-a-randomised-open-label-phase-3-trial/86853/65/1/1. Accessed January 7, 2021. 2019 Jul.

36. Fonseca RD. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. PracticeUpdate website. Available at: https://www.practiceupdate.com/conent/pembrolizumab-plus-pomalidomide-and-dexamethasone-for-patients-with-relapsed-or-refractory-multiiple-myeloma-keynote-183-a-randomised-open-label-phase-3-trial/86855/65/1/1. Accessed January 7, 2021. 2019 Jul.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

37. Fonseca RD. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/oral-selinexor-dexamethasone-for-triple-class-refractory-multiple-myeloma/88419/65/1/1. Accessed January 7, 2021. 2019 Aug.

38. Fonseca RD. Patient-centered communication among patients with hematologic malignancies. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/patient-centered-communication-among-patients-with-hematologic-malignancies-84880/65/1/3. Accessed January 7, 2021. 2019 Sep.

39. Fonseca RD. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/levofloxacin-prophylaxis-in-patients-with-newly-diagnosed-myeloma-teamm-a-multicentre-double-blind-placebo-controlled-randomised-phase-3-trial/91576/65/1/1. Accessed January 7, 2021. 2019 Oct.

40. Fonseca RD. 2019 Top stories in oncology: MRD testing in myeloma: finish the job. PracticeUpdate website. Available at: https://www.practiceupdate.con/content/2019-top-stories-in-oncology-mrd-testing-in myeloma-finish-the-job/93728/65/1/3. Accessed January 7, 2021. 2019 Dec.

41. Fonseca RD. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomized, open-label, phase 3 trial. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/overall-survival-with-daratumumab-bortezomib-melphalan-and-presnisone-in-newly-diagnosed-multiple-myeloma-alcyone-a-randomised-open-label-phase-3-trial/93862/65/1/1. Accessed January 7, 2021. 2019 Dec.

42. Fonseca RD. Multiple myeloma in the COVID era: general approaches. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/multiple-myeloma-in-the-covid-era-general-approaches/100223/65/1/3. Accessed January 7, 2021. 2020 May.

43. Fonseca RD. Multiple myeloma in the COVID era: specific clinical scenarios. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/multiple-myeloma-in-the-covid-era-specific-clinical-scenarios/100224/65/1/3. Accessed January 7, 2021. 2020 May.

44. Fonseca RD. ASCO: carfilzomib vs bortezomib for newly-diagnosed multiple myeloma. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/asco-carfilzomib-vs-bortezomib-for-newly-diagnosed-multiple-myeloma/101719/65/1/3/. Accessed January 7, 2021. 2020 Jun.

45. Fonseca RD. Selinexor, bortezomib, and dexamethasone for relapsed multiple myeloma. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/selinexor-bortezomib-and-dexamethasone-for-relapsed-multiple-myeloma/101720/65/1/3. Accessed January 7, 2021. 2020 Jun.

46. Fonseca RD. Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/bortezomib-melphalan-and-dexamethasone-for-light-chain-amyloidosis/104416/65/1/1. Accessed January 7, 2021. 2020 Aug.

47. Fonseca RD. Rational approaches to combination therapy after relapse in multiple myeloma. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/rational-approaches-to-combination-therapy-after-relapse-in-multiple-myeloma/107745/65/1/3. Accessed January 7, 2021. 2020 Oct.

48. Fonseca RD. Current approach to smoldering multiple myeloma. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/current-approach-to-smoldering-multiple-myeloma. Accessed January 7, 2021. 2020 Oct.

49. Fonseca RD. Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the Phase III TOURMALINE-MM4 trial. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/ixazomib-as-postinduction-maintenance-for-patients-with-newly-diagnosed-multiple-myeloma-not-undergoing-autologous-stem-cell-transplantation-the-phase-iii-tourmaline-mm4-trial/107835/65/1/1. Accessed January 7, 2021. 2020 Oct.

50. Fonseca RD. 2020 Top stories in oncology: the BOSTON (selinexor) party. 2020 Top stories in oncology: the BOSTON (Selinexor) party. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/2020-top-stories-in oncologythe-boston-selinexor-party/108217/65/1/3. Accessed January 7, 2021. 2020 Dec.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

51. Fonseca RD. Melflufen and Dexamethasone in heavily pretreated relapsed and refractory multiple myeloma. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/melflufen-and-dexamethasone-in-heavily-pretreated-relapsed-and-refractory-multiple-myeloma/110858/65/1/1/. Accessed: January 07, 2021. 2020 Dec.

52. Fonseca RD. Overview of multiple myeloma presentations at ASH. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/overview-of-multiple-myeloma-pesentations-at-ash/111398/65/1/3. Accessed January 7, 2021. 2020 Dec.

53. Fonseca RD. Subcutaneous daratumumab with pomalidomide and dexamethasone for relapsed/refractory multiple myeloma. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/subcutaneous-daratumumab-with-pomalidomide-and-dexamethasone-for-relapsed/refractory-multiple-myeloma/111399/65/1/3. Accessed January 7, 2021. 2020 Dec.

54. Fonseca RD. Frontline treatment and attrition rates among patients with multiple myeloma. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/frontline-treatment-and-attrition-rates-among-patients-with-multiple-myeloma/111400/65/1/3. Accessed January 07, 2021. 2021 Jan.

Audio/Video/CD-ROM/etc. 1. Fonseca R. Innovation in Medicine, Episode 1, Bruce Gingles, Device Approval by the FDA. YouTube

Channel.2018 May; 2. Fonseca R. Innovation in Medicine, Episode 2, Jeff Singer, MD, Opiod Epidemic. YouTube Channel.2018

Jun; 3. Fonseca R. Innovation in Medicine, Episode 3, Sharona Hoffman, JD. YouTube Channel.2018 Aug; 4. Fonseca R. Innovation in Medicine, Episode 4, David C. Norris, MD. YouTub Channel.2018 Sep; 5. Fonseca R. Innovation in Medicine, Episode 5, Lanny Kirsch, MRD Testing in Myeloma. YouTube

Channel.2018 Dec;

Abstracts 1. Fonseca R, Inwards DJ, Habermann TM, Colgan JP, White WL, Witzig TE, Martenson JA, Burgart

L. Testicular lymphoma; high incidence of extranodal relapse. Poster Presentation, Mayo Clinic Internal Medicine Research Forum, 1995 Dec.

2. Fonseca R, Gertz MA, Witzig TE, Greipp PR. Plasma cell leukemia with extensive liver involvement and the translocation T(11:14)(Q13,Q32). (Abstract 1287). Proc Am Assoc Cancer Res. 1996 Mar; 37:188.

3. Fonseca R, Frytak S, Foote RL, Grill JP, Sloan JA, O'Neill BP. Leukoencephalopathy in patients treated for small cell lung cancer with combination chemotherapy plus radiation therapy to the chest, and prophylactic cranial irradiation. American Radium Society, San Francisco, California, 1996 Apr 1-5.

4. Fonseca R, Gertz MA, Witzig TE, Greipp PR. Plasma cell leukemia with the translocation t(11;14)(q13;q32) with extensive liver involvement. [Abstract 1287] Poster Presentation. American Association for Cancer Research 1996 Apr; Proc. AACR 37: 188, 1287A, 1996.

5. Liu JJ, Kennel KA, Fonseca R, Edmonson JH, Rubin J, Burritt MF. Creatinine kinase release post hepatic artery embolization in patients with carcinoid tumors. American College of Physicians State Meeting, Minneapolis, MN. 1996 Nov 8.

6. Fonseca R, Rajkumar SV, White WL, Tefferi A, Hoagland HC. Anemia after orchiectomy. (Abstract no. 2769). Blood. 1996 Nov 15; 88(Suppl 1):10b.

7. Fonseca R, Witzig TE, Gertz MA, Hoyer JD, Jalal SM, Greipp PR. Multiple myeloma, circulating plasma cells, and the translocation t(11;14)(q13;q32) (Abstract 1541). Blood. 1996 Nov 15; 88(10 Suppl 1):388a.

8. Fonseca R, Inwards DJ, Habermann TM, Colgan JP, White WL, Witzig TE, Martenson JA Jr, Burgart LJ. Testicular lymphoma, high incidence of extranodal relapse. (Abstract no. 2122). Blood. 1996 Nov 15; 86(Suppl 1):533A.

9. Fonseca R, Tefferi A. Essential thrombocytosis (ET) in young women. (Abstract 20). Program/Proc Am Soc Clin Oncol. 1997; 16:6a.

10. Fonseca R, Witzig TE, Greipp PR, Gertz MA, Lust JA, Lacy MQ, Kyle RA, Hoyer JE, Jalal SM. Multiple myeloma and the translocation t(11;14)(q13;q32) Poster Presentation. Mayo Clinic Internal Medicine Research Forum, 1997.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

11. Fonseca R, Goldberg RM, Erlichman C, Kaufmann SH, Sloan JA, Miller LL. Phase I study of cpt-11/5-FU/leucovorin . Proc Annu Meet Am Assoc Cancer Res. 1997; 38:A513.

12. Liu JJ, Kennel KA, Fonseca R, Edmonson JH, Rubin J, Burritt MF. Creatinine kinase release post hepatic artery embolization in patients with carcinoid tumors American College of Physicians National Meeting, Philadelphia, PA. March 22-23, 1997.

13. Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA. Abnormal cytogenetics predict for poor survival after peripheral blood stem cell transplantation in relapsed multiple myeloma. (Abstract 2348 407-IV). Blood. 1997 Nov 15; 90(10 Suppl 1 part 1):527a.

14. Fonseca R, Stenson MJ, Habermann TM, Witzig TE. Cell surface syndecan-1 expression in Non-Hodgkin lymphomas. (Abstract 3892). Blood. 1997 Nov 15; 90(10 Suppl 1 part 2):256b.

15. Fonseca R, Ahmann GJ, Juneau AL, Jalal SM, Dewald GW, Larson DR, Therneau TM, Greipp PR. Cytogenetic abnormalities in multiple myeloma and related plasma cell disorders: a comparison of conventional cytogenetic analysis to fluorescent in-situ hybridization with simultaneous cytoplasmic immunoglobulin staining. (Abstract 1558 377-iii). Blood. 1997 Nov 15; 90(10 Suppl 1 part 1):349a.

16. Fonseca R, Ahmann GJ, Juneau AL, Jalal SM, Dewald GW, Larson DR, Therneau TM, Gertz MA, Greipp PR. Cytogenetic abnormalities in systemic amyloidosis: a comparison of conventional cytogenetic analysis to fluorescent in-situ hybridization with simultaneous cytoplasmic immunoglobulin staining. (Abstract 1559 378-iii). Blood. 1997 Nov 15; 90(10 Suppl 1 part 1):350a.

17. Pereira D, Fonseca R, Witzig TE, Habermann TM. Use of nitrogen mustard in critically ill patients with lymphomas. (Abstract 3979). Blood. 1997 Nov 15; 90(10 Suppl 1 part 2):274b.

18. Fonseca R, Witzig TE, Stenson M, Habermann TM. Cell surface syndecan-1 expression in non-Hodgkin lymphomas. Annual Meeting American Society of Hematology, San Diego, CA, 1997 Dec.

19. Pereira D, Fonseca R, Witzig TE, Habermann TM. Use of nitrogen mustard in critically ill patients with hematological malignancies. Annual Meeting American Society of Hematology, San Diego, CA, 1997 Dec.

20. Fonseca R, Ahmann GJ, Jalal SM, Dewald GW, Gertz MA, Greipp PR. A descriptive study of chromosomal abnormalities in systemic amyloidosis and correlation with biologic/prognostic variables. Proceedings of the VII International Symposium on Amyloidosis, Parthenon Publishing, RA Kyle and MA Gertz editors. New York, 1998

21. Fonseca R, Ahmann GJ, Jalal SM, Dewald GW, Gertz MA, Greipp PR. A descriptive study of chromosomal abnormalities in systemic amyloidosis and correlation with biologic/prognostic variables. Mayo Clinic Internal Medicine Research Forum, 1998.

22. Pereira DL, Fonseca R, Silverstein MN, Hoagland HC, Tefferi A. A long-term study of essential thrombocythemia (ET) in women under age 50 years. Blood. 1998; 92(10 Suppl 1 Part 1-2):423a.

23. Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, Therneau TM, Kyle RA, Litzow MR, Gertz MA. Autologous stem cell transplantation overcomes chemotherapy resistance and is effective in patients with primary refractory myeloma. (Abstract A2735). Blood. 1998; 92(10 Suppl 1 Part 1-2):663a.

24. Lacy MQ, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA. Beta-2-microglobulin (beta-2M) and bone marrow plasma cell involvement identify complete responders among patients undergoing stem cell transplantation (SCT) for myeloma. (Abstract 133). Program/Proceedings of the American Society of Clinical Oncology. 1998; 17:34a.

25. Rajkumar SV, Fonseca R, Witzig TE, Gertz MA, Greipp PR. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. (Abstract A407). Blood. 1998; 92(10 Suppl 1 Part 1-2):99a.

26. Rajkumar SV, McElroy EA Jr, Ansell SM, Fonseca R, Dispenzieri AD, Lacy MQ, Lust JA, Greipp PR, Kyle RA, Gertz MA, Witzig TE. Circulating peripheral blood plasma cells have prognostic significance in primary systemic amyloidosis. (Abstract A1070). Blood. 1998; 92(10 Suppl 1 Part 1-2):261a.

27. Rajkumar SV, Fonseca R, Ansell SM, Witzig TE, Gertz MA, Greipp PR. Computerized image analysis in the assessment of bone marrow angiogenesis in multiple myeloma. (Abstract A408). Blood. 1998; 92(10 Suppl 1 Part 1-2):100a.

28. Rajkumar SV, Fonseca R, Dewald GW, Therneau TM, Lacy MQ, Kyle RA, Greipp PR, Gertz MA. Cytogenetic abnormalities and percentage of abnormal metaphases correlate with the plasma cell labeling index and bone marrow involvement in myeloma. (Abstract A1069). Blood. 1998; 92(10 Suppl 1 Part 1-2):260a-261a.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

29. Fonseca R, Ahmann GJ, Juneau AL, Jalal SM, Dewald GW, Larson DR, Therneau TM, Greipp PR. Cytogenetic abnormalities in multiple myeloma and related plasma cell disorders; A comparison of conventional cytogenetic analysis to fluorescent in-situ hybridization with simultaneous cytoplasmic immunoglobulin staining. Mayo Clinic Internal Medicine Research Forum. 1998.

30. Fonseca R, Ahmann GJ, Juneau AL, Jalal SM, Dewald GW, Larson DR, Therneau TM, Gertz MA, Greipp PR. Cytogenetic abnormalities in systemic amyloidosis; A comparison of conventional cytogenetic analysis to fluorescent in-situ hybridization with simultaneous cytoplasmic immunoglobulin staining. Mayo Clinic Internal Medicine Research Forum. 1998.

31. Fonseca R, Greiner CW, Schrenzel J, Rajkumar SV, Ahmann GJ, Witzig TE, Kyle RA, Gertz MA, Lust JA, Lacy MQ, Dispenzieri A, Greipp PR, Persing D. Detection of KSHV in patients with osteosclerotic myeloma as determined by PCR-ELISA. (Abstract A392). Blood. 1998; 92(10 Suppl 1 Part 1-2):96a.

32. Fonseca R, Rajkumar SV, Ahmann GJ, Jalal SM, Dewald GW, Greipp PR. FISH and immunodetection (CLG-FISH) elucidates origin of abnormal cytogenetics in patients with prior exposure to melphalan. (Abstract A4190). Blood. 1998; 92(10 Suppl 1 Part 1-2):276b.

33. Fonseca R, Rajkumar SV, Inwards D. Granulomatous angitis and Hodgkin's disease. Mayo Clin Proc. 1998; 73(4); 390-1.

34. Fonseca R, Borset M, Rajkumar SV, Ahmann GA, Kyle RA, Witzig TE, Dispenzieri A, Lust J, Lacy MQ, Gertz MA, Jalal SM, Larson DM, Therneau TM, Dewald GW, Greipp PR. Hepatocyte growth factor (HGF) and chromosome 7 trisomy correlation in multiple myeloma (MM) and other plasma cell disorders. Blood. 1998; 92(Suppl 1):263b.

35. Fonseca R, Goldberg RM, Erlichman C, Sloan JA, Kaufmann SH, Miller LL. Phase I study of the combination of cpt-11/5-FU and leucovorin (Lv). (Abstract 781). Program/Proceedings of the American Society of Clinical Oncology. 1998; 17:203a.

36. Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Therneau TM, Kyle RA, Litzow MR, Gertz MA, Greipp PR. Plasmablastic morphology is an independent predictor of poor survival following autologous stem cell transplantation for relapsed or primary refractory myeloma. (Abstract A406). Blood. 1998; 92(10 Suppl 1 Part 1-2):99a.

37. Fonseca R, Ahmann GJ, Jalal SM, Law ME, Greipp PR. Successful analysis of specific chromosomal loci using the fiber-fluorescent in-situ hybridization technique on frozen plasma cells. Proc Annu Meet Am Assoc Cancer Res. 1998; 39:238.

38. Fonseca R, Rajkumar SV, Ahmann GJ, Witzig TE, Gertz MA, Lust JA, Dispenzieri A, Lacy MA, Kyle RA, Jala SM, Dewald GW, Therneau TM, Larson DM, Greipp PR. Survival analysis for numerical chromosomal abnormalities in primary systemic amyloidosis (AL) patients. (Abstract A4137). Blood. 1998; 92(10 Suppl 1 Part 1-2):263b.

39. Mow B, Kumar S, Monahan KH, Severson CJ, Schroeder G, Fonseca R, McGoon MD, Phyliky RL. Thrombocytopenia during epoprostenol infusion for primary pulmonary hypertension: is there a relation to dose? Blood. 1998; 92(10 Suppl 1 Part 1-2):87b.

40. Loprinzi CL, Pisansky TM, Fonseca R, Sloan JA, Zahasky KM, Quella SK, Rummans TA, Dumesic DA, Perez EA, Novotny PJ. Venlafaxine-associated hot flash reduction in cancer survivors. (Abstract 170). Program/Proceedings of the American Society of Clinical Oncology. 1998; 17:44A.

41. Fonseca R, Ahmann GJ, Griepp PR. Successful performance of halo-DNA and in-situ hybridization on frozen cytospin plasma cell preparations. Annual Meeting American Association for Cancer Research, New Orleans, LA, 1998 Mar.

42. Fonseca R, Goldberg RM, Erlichman C, Kaufmann SH, Sloan JA, Miller LL. Phase I trial of CPT-11/5-FU/folinic acid. Poster Presentation American Society of Clinical Oncology, Los Angeles, CA, 1998 May.

43. Fonseca R, Rajkumar SV, Ahmann GJ, Jalal SM, Dewald GW, Greipp PR. Fish and immunodetection (cIg-Fish) elucidates origin of abnormal cytogenetics in patients with prior exposure to melphalan (Abstract a5192). Blood. 1998 Nov 15; 92(10 Suppl 1 part 2):276b.

44. Fonseca R, Hoyer JD, Ahmann GJ, Vaandrager JW, Schuuring E, Kluin PM, Rajkumar SV, Witzig TE, Gertz MA, Lust JA, Lacy MA, Kyle RA, Dispenzieri AD, Jalal SM, Dewald GW, Greipp PR. The t(11;14)(q13;q32) is strongly associated with cyclin D1 over-expression in bone marrow plasma cells of multiple myeloma (MM) patients. Blood. 1998 Nov 15; 92(10 Suppl 1 Part 1-2):260a.

45. Pereira DL, Fonseca R, Tefferi A, Hoagland HC, Silverstein MN. ET in young women. Blood a1748, American Society of Hematology 40th Annual Meeting, Miami, FL, December 4-8, 1998.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

46. Rajkumar SV, Leong T, Fonseca R, Dispenzieri A, Lacy MQ, Witzig TE, Lust JA, Gertz MA, Kyle RA, Greipp PR. Bone marrow angiogenesis has prognostic value in multiple myeloma: an Eastern Cooperative Oncology Group Study. (Abstract 68). Program/Proc Am Soc Clin Oncol. 1999; 18:19a.

47. Dispenzieri A, Lacy MQ, Kyle RA, Greipp PR, Witzig TE, Lust JA, Fonseca R, Rajkumar SV, Therneau TM, Gertz MA. Eligibility for PBSCT for AL amyloidosis is a favorable independent prognostic factor for survival: survival of 234 patients with primary systemic amyloidosis (AL) functionally eligible for peripheral blood stem cell transplantation. (Abstract 71). Program/Proc Am Soc Clin Oncol. 1999; 18:20a.

48. Alberts S, Goldberg RM, Fonseca R, Erlichman C, Sloan J, Kaufmann SH, Pitot HC, Rubin J, Adjei A, Burch P, Miller LL. Phase I Study of CPT-11/5-FU and leucovorin (Lv) in advanced cancer. (Abstract 778). Program/Proc Am Soc Clin Oncol. 1999; 18:202a.

49. Hogan WJ, Fonseca R, Rajkumar SV, Witzig TE, Gertz MA, Lust JA, Lacy MQ, Dispenzieri A, Greipp PR, Kyle RA. Plasma cell leukemia: long term follow-up information. (Abstract 109). Program/Proc Am Soc Clin Oncol. 1999; 18:30a.

50. Hoyer JD, Fonseca R, Greipp PR, Hanson CA, Kurtin PJ. The (11;14)(q13;qq32) translocation in multiple myeloma (MM): a morphologic and immunohistochemical study. Mod Pathol. 1999 Jan; 12(1):139A.

51. Fonseca R, Aguayo P, Ahmann GJ, Jalal S, Rajkumar SV, Kyle RA, Gertz MA, Greipp PR. Translocations at 14q32 are common in patients with the monoclonal gammopathy of undetermined significance (MGUS). International Myeloma Workshop Stockholm, 1999 Sep.

52. Alberts S, Goldberg RM, Fonseca R, Erlichman C, Sloan J, Kaufmann SH, Pitot HC, Rubin J, Adjei A, Burch P, Miller LL. Phase I trial of CPT-11/5-FU/folinic acid. Proceedings of the American Society of Clinical Oncology 18:202a, 1999 May.

53. Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Therneau TM, Kyle RA, Gertz MA, Greipp PR. Correlaton between plasmacytosis evaluation by aspirate, biopsy and labeling index assays. International Myeloma Workshop, Stockholm. 1999 Sept.

54. Kyle RA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord J, Therneau T. Multiple Myeloma: Review of 1,027 newly diagnosed cases. (Poster). 1999 Sept 1-5:128.

55. Fonseca R, Trendle MC, Leong T, Kyle RA, Oken MM, Kay NE, Van Ness B, Greipp PR. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients enrolled in E9487. Second North American Symposium on Skeletal Complications of Malignancy Montreal, Canada. 1999 Oct 15-16.

56. Johnston PB, Aguayo P, Ahmann GJ, Dewald GW, Jalal S, Rajkumar SV, Kyle RA, Gertz MA, Greipp PR, Fonseca R. Deletions of the long arm of chromosome 13 are rare in the monoclonal gammopathy of undetermined significance (MGUS). Blood. 1999 Nov; 94(Suppl I):545a.

57. Kyle RA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Therneau TM. An analysis of 1027 newly diagnosed cases of multiple myeloma. Blood. 1999 Nov 15; 94(10 Suppl 1 part 1):537a.

58. Rajkumar SV, Yoon SY, Li CY, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Gertz MA, Kyle RA, Greipp PR, Witzig TE. Angiogenesis in myeloma: expression of basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and their receptors by neoplastic plasma cells. Blood. 1999 Nov 15; 94(10 Suppl 1 Part 2):303b.

59. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Therneau TM, Kyle RA, Greipp PR, Gertz MA. Bone marrow plasma cell percentage in myeloma: estimation and predictive value for response and survival among patients undergoing autologous stem cell transplantation for relapsed and refractory disease. Blood. 1999 Nov 15; 94(10 Suppl 1 Part 2):303b.

60. Lacy MQ, Wettstein P, Gastineau DA, Greipp PR, Fonseca R, Dispenzieri A, Lust J, Witzig T, Rajkumar SV, Valone F, Kyle RA, Gertz MA. Dendritic cell-based idiotype vaccination for primary systemic amyloidosis. Blood. 1999 Nov 15; 94(10 Suppl 1 Part 1):122a.

61. Lacy MQ, Wettstein P, Gastineau DA, Greipp PR, Fonseca R, Dispenzieri A, Lust J, Witzig T, Rajkumar SV, Valone F, Kyle RA, Gertz MA. Dendritic cell-based idiotype vaccination in post transplant multiple myeloma. Blood. 1999 Nov 15; 94(10 Suppl 1 part 1):122a.

62. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Witzig TE, Lust JA, Therneau TM, Kyle RA, Litzow MR, Greipp PR, Gertz MA. Effect of complete response on outcome following autologous stem cell transplantation for myeloma: implications for high risk patients. Blood. 1999 Nov 15; 94(10 Suppl 1 Part 1):576a.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

63. Storen EC, Pereira DL, Fonseca R, Petitt RM, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood. 1999 Nov 15; 94(10 Suppl 1 Part 1):701a.

64. Inwards D, Brown D, Fonseca R, Kurtin P, Schroeder G, Allmer C, Witzig T. NCCTG phase II trial of 2-chlorodeoxyadenosine (2-CDA) as initial therapy for mantle cell lymphoma: a well-tolerated treatment with promising activity. Blood. 1999 Nov 15; 94(10 Suppl 1 Part 1):660a.

65. Dispenzieri A, Gertz MA, Lacy MQ, Fonseca R, Rajkumar SV, Greipp PR, Witzig TE, Lust JA, Kyle RA. POEMS syndrome: review of 93 cases. Blood. 1999 Nov 15; 94(10 Suppl 1 Part 1):538a.

66. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Witzig TE, Lust JA, Kyle RA, Gertz MA, Greipp PR. Thalidomide in the treatment of relapsed and refractory myeloma. Blood. 1999 Nov 15; 94(10 Suppl 1 Part 1):316a.

67. Fonseca R, Aguayo P, Ahmann GJ, Jalal SM, Rajkumar SV, Kyle RA, Gertz MA, Dewald GW, Dispenzieri A, Lust JA, Lacy MQ, Witzig TE, Greipp PR. Translocations at 14q32 are common in patients with the monoclonal gammopathy of undetermined significance (MGUS) and involve several partner chromosomes. Blood. 1999 Nov 15; 94(10 Suppl 1 Part 1):663a.

68. Fonseca R, Dispenzieri A, Lacy MQ, Witzig TE, Lust JA, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Angiogenesis in patients with monoclonal gammopathy of undetermined significance and multiple myeloma. (Abstract #98). Proc Am Soc Clin Oncol. 19:27a, 2000.

69. Thome SD, Fonseca R, Dispenzieri A, Lacy M, Witzig TE, Lust JA, Gertz MA, Kyle RA, Greipp PR, Rajkuma SV. Increased angiogenesis in patients with monoclonal gammopathy of undetermined significance and multiple myeloma. (Abstract 98). Program/Proc Am Soc Clin Oncol. 2000; 19:27a.

70. Fonseca R, Bailey RJ, Bergsagel PL, Kuehl WM. The t(14;16)(q32;q23) in myeloma cell lines is associated with c-maf overexpression despite breakpoints at 16q23 being located as far as 1 Mb away from c-maf. Program proceedings of the Fragile Sites Gene Amplification and Cancer Meeting, Rochester, Minnesota, August 25-26. 2000; 0:0.

71. Fonseca R, Trendle MC, Leong T, Kyle RA, Oken MM, Kay NE, Van Ness B, Greipp PR. Prognostic value of serum markers of bone metabolism in untreated patients with multiple myeloma enrolled in E9487. Cancer. 2000 Jun 15; 88(12):3095-3096.

72. Rajkumar SV, Timm MM, Go R, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Kyle RA, Greipp PR, Gertz MA, Russell SJ, Witzig TE. 2-Methoxy-estradiol (2ME2) induces cell cycle arrest and apoptosis in myeloma (mm) and inhibits angiogenesis in the rat aortic ring assay: results of pre-clinical studies. Blood. 2000 Nov 16; 96(11 Part 1):361a.

73. Dispenzieri A, Wiseman GA, Lacy MQ, Litzow MR, Tefferi A, Inwards DJ, Gastineau DA, Ansell S, Micalef I, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Kyle RA, Greipp PR, Gertz MA. A phase I study of a conditioning regimen for peripheral stem cell transplantation (PBSCT) for multiple myeloma (MM): 153Samarium ethylenediaminetetramethylenephosphonate (153Sm-EDMTP) and melphalan. Blood. 2000 Nov 16; 96(11 Part 1):558a.

74. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Geyer S, Wellik L, Hayman S, Lust JA, Kyle RA, Greipp PR, Gertz MA, Witzig TE. A phase II trial of thalidomide in the treatment of relapsed multiple myeloma (mm) with laboratory correlative studies. Blood. 2000 Nov 16; 96(11 Part 1):168a.

75. Schop RFJ, Jalal SM, Van Wier SA, Ahmann GJ, Bailey RJ, Yusuf RZ, Rajkumar SV, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Greipp PR, Kyle RA, Fonseca R. Absence of the t(9;14)(p13;q32) translocation in clinically defined Waldenstrom macroglobulinemia. Blood. 2000 Nov 16; 96(11 Part 2):162b.

76. Kumar S, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Bone marrow (BM) angiogenesis in multiple myeloma (MM): effect of therapy and prognostic value. Blood. 2000 Nov 16; 96(11 Part 1):363a.

77. Rajkumar SV, Mesa RA, Fonseca R, Dispenzieri A, Lacy MQ, Wellik L, Plevak M, Lust JA, Witzig TE, Gertz MA, Kyle RA, Greipp PR. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma (SMM), active myeloma (MM), relapsed myeloma (RMM) and primary amyloidosis (AL). Blood. 2000 Nov 16; 96(11 Part 1):836a.

78. Hayman SR, Fonseca R, Dispenzieri A, Lacy MQ, Wellik L, Plevak M, Witzig TE, Gertz MA, Kyle RA, Greipp PR, Lust JA, Rajkumar SV. Bone marrow angiogenesis in Waldenstrom's macroglobulinemia (WM). Blood. 2000 Nov 16; 96(11 Part 1):754a.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

79. Fonseca R, Harrington D, Oken MM, Bailey RJ, Van Wier SA, Henderson KJ, Kay NE, Van Ness B, Greipp PR, Blood EA, Dewald GW. Deletions of 13q14 in myeloma plasma cells usually represent large deletions of the q arm or monosomy. Blood. 2000 Nov 16; 96(11 Part 1):151a.

80. Schop RFJ, Jalal SM, Van Wier SA, Ahmann GJ, Bailey RJ, Yusuf RZ, Rajkumar SV, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Greipp PR, Kyle RA, Fonseca R. Deletions of 17p13.1 and 13q14 are rare in Waldenstrom's macroglobulinemia clonal cells. Blood. 2000 Nov 16; 96(11 Part 1):372a.

81. Lacy MQ, Wettstein P, Dispenzieri A, Gastineau DA, Greipp PR, Fonseca R, Lust J, Witzig T, Rajkumar SV, Valone F, Kyle RA, Gertz MA. Dendritic cell-based idiotype vaccination for primary systemic amyloidosis. Blood. 2000 Nov 16; 96(11 Part 1):164a.

82. Lacy MQ, Wettstein P, Gertz MA, Gastineau DA, Greipp PR, Fonseca R, Dispenzieri A, Lust J, Witzig T, Rajkumar SV, Valone F, Kyle RA. Dendritic cell-based idiotype vaccination in post transplant multiple myeloma. Blood. 2000 Nov 16; 96(11 Part 1):374a.

83. Fonseca R, Bailey RJ, Bergsagel PL, Kuehl WM. Dysregulation of c-MAF is associated with t(14; 16)(q32;q23) breakpoints that flank the fra 16D fragile site within the WWOX gene, and can be greater than 1 Mb from c-maf (Abstract 4389). Blood. 2000 Nov 16; 96(11 Part 2):158b.

84. Rajkumar SV, Timm M, Mesa RA, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Gertz MA, Kyle RA, Griepp PR, Witzig TE. Effect of thalidomide on myeloma cell apoptosis and VEGF secretion. Blood. 2000 Nov 16; 96(11 Part 1):364a.

85. Hayman SR, Bailey RJ, Ahmann GJ, Dispenzieri A, Gertz MA, Greipp PR, Kyle RA, Lacy MQ, Rajkumar SV, Witzig TE, Lust JA, Fonseca R. IgH translocations are common in patients with primary systemic amyloidosis (AL). Blood. 2000 Nov 16; 96(11 Part 1):152a.

86. Fonseca R, Harrington D, Oken MM, Hoyer JD, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Kay NE, van Ness B, Blood EA, Greipp PR. Myeloma (MM) and the t(11;14)(q13;q32); increasing evidence for a biologically distinct subset of patients. Blood. 2000 Nov 16; 96(11 Part 1):151a.

87. Inwards DJ, Fonseca R, Kurtin PJ, Habermann TM, Knost J, Hillman DW, Witzig TE. Ncctg phase II trial of 2-chlorodeoxyadenosine (2-CDA) as therapy for previously treated mantle cell lymphoma: promising single agent activity limited by brief response duration. Blood. 2000 Nov 16; 96(11 Part 1):140a.

88. Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Kay NE, Van Ness B, Blood EA, Greipp PR. Prognostic significance of 13q deletions and the t(11;14)(q13;q32) in myeloma (MM); an interphase FISH study of 351 patients entered into the eastern cooperative oncology group E9487 clinical trial. Blood. 2000 Nov 16; 96(11 Part 1):547a.

89. Rajkumar SV, Hayman S, Fonseca R, Dispenzieri A, Lacy MQ, Geyer S, Wellik L, Lust JA, Kyle RA, Greipp PR, Gertz MA, Witzig TE. Thalidomide plus dexamethasone (thal/dex) and thalidomide alone (thal) as first line therapy for newly diagnosed myeloma (mm). Blood. 2000 Nov 16; 96(11 Part 1):168a.

90. Dispenzieri A, Wiseman G, Lacy MQ, Litzow MR, Tefferi A, Inwards DJ, Micallef I, Gastineau DA, Ansell A, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Kyle RA, Greipp PR, Gertz MA. A phase I dose escalation study of 153-samarium ethylenediaminetetramethylenephosphonate (153-SM-EDMTP) as part of the conditioning regimen for peripheral stem cell transplantation (PBSCT) for multiple myeloma (MM). American Society of Hematology 42nd Annual Meeting, San Francisco, CA, 2000 Dec.

91. Fonseca R, Harrington D, Oken MM, Bailey RJ, Van Wier SA, Henderson KJ, Blood EA, Kay NE, Van Ness B, Greipp PR, Dewald GW. Deletions of 13q14 in myeloma plasma cells usually represent large deletions of the q arm or monosomy. American Society of Hematology 42nd Annual Meeting San Francisco, CA. 2000 Dec.

92. Fonseca R, Bailey RJ, Bergsagel PL, Kuehl WM. Dysregulation of c-MAF is associated with t(14;16)(q32;q23) breakpoints that flank the fra 16D fragile site within the WWOX gene, and can be greater than 1 Mb from c-maf. American Society of Hematology 42nd Annual Meeting, San Francisco, CA, 2000 Dec.

93. Fonseca R, Bailey RJ, Bergsagel PL, Kuehl WM. Dysregulation of e-maf is Associated with t(14;16)(q32;q23) Breakpoints that Flank the Fral6D Fragile Site within the WWOX Gene, and can be Greater Than 1Mb from c-maf. American Society of Hematology 42nd Annual Meeting, San Francisco, CA, 2000 Dec

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

94. Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA, Henderson KA, Blood EA, Rajkumar SV, Kay NE, Van Ness B, Greipp PR. Clone features of plasma cells with 13q14 deletions and potential mechanistic roles for their association with an adverse outcome in myeloma (Abstract P11). Proceedings from the VIII International Myeloma Workshop. 2001.

95. Lacy MQ, Wettstein P, Gertz MA, Gastineau DA, Greipp PR, Fonseca R, Dispenzieri A, Lust JA, Witzig TE, Rajkumar SV, Valone F, Kyle RA. Dendritic cell-based idiotype vaccination for primary systemic amyloidosis and post transplant multiple myeloma (Abstract P132). Proceedings from the VIII International Myeloma Workshop. 2001.

96. Schop RFJ, Jalal SM, Van Wier SA, Ahmann GJ, Bailey RJ, Kyle RA, Greipp PR, Kuehl WM, Fonseca R. Genomic aberrations in Waldenstrom's macroglobulinemia clonal cells (Abstract P20). Proceedings from the VIII International Myeloma Workshop. 2001.

97. Rajkumar SV, Gertz MA, Dispenzieri A, Lacy MQ, Fonseca R, Hayman S, Geyer S, Lust JA, Kyle RA, Greipp PR, Witzig TE. Thalidomide therapy for previously untreated, smoldering, and relapsed multiple myeloma (mm). Proc Am Soc Clin Oncol. 2001; 20(1 of 2):299a. Abstract no. 1194.

98. Hayman SR, Jalal SM, Bailey RJ, Ahmann GJ, Dispenzieri A, Gertz MA, Greipp PR, Kyle RA, Lacy MQ, Rajkumar SV, Witzig TE, Lust JA, Fonseca R. Translocations involving the IgH locus are common in primary systemic amyloidosis with a high frequency of partner chromosome 11q13 (Abstract P19). Proceedings from the VIII International Myeloma Workshop. 2001.

99. Fonseca R. Prognostic implications of chromosomal abnormalities as detected by FISH. Proceedings from the VIII International Myeloma Workshop Banff, Alberta, Canada. 2001 May.

100. Fonseca R, Harrington D, Blood E, Rue M, Oken MM, Dewald GW, Kyle RA, Van Wier SA, Henderson KJ, Bailey RJ, Greipp PR. A molecular classification of multiple myeloma (MM), based on cytogenetic abnormalities detected by interphase FISH, is powerful in identifying discrete groups of patients with dissimilar prognosis. Blood. 2001 Nov 16; 98(11 Part 1):733a-734a.

101. Dispenzieri A, Wiseman G, Lacy MQ, Litzow MR, Tefferi A, Inwards DJ, Micallef IN, Gastineau DA, Ansell S, Rajkumar SV, Fonseca R, Porrata L, Witzig TE, Lust JA, Kyle RA, Greipp PR, Gertz MA. A phase I/II dose escalation study of 153-Samarium EDTMP (153-Sm-EDTMP) with fixed dose melphalan peripheral stem cell transplantation (PBSCT) for multiple myeloma (MM). Blood. 2001 Nov 16; 98(11 Part 1):682a-683a.

102. Ahmann GJ, Henderson KJ, Finke CM, Fonseca R, Greipp PR. A quick and efficient method for isolating plasma cells from bone marrow aspirates. Blood. 2001 Nov 16; 98(11 Part 2):294b-295b.

103. Abraham RS, Price-Troska TL, Gertz MA, Kyle RA, Fonseca R. Association of rearranged light chain variable (V) region genes with organ tropism in light chain-associated (AL) amyloidosis. Blood. 2001 Nov 16; 98(11 Part 2):151b.

104. Bailey RJ, Ahmann GJ, Kyle RA, Greipp PR, Fonseca R. Biclonal gammopathies are diseases of two isotype switched clones with the same cell of origin. Blood. 2001 Nov 16; 98(11 Part 1):562a.

105. Abraham RS, Bergen HR, Naylor S, Katzmann JA, Bradwell AR, Kyle RA, Fonseca R. Characterization of free immunoglobulin light chains (LC) by mass spectrometry in light chain-associated (AL) amyloidosis. Blood. 2001 Nov 16; 98(11 Part 2):31b.

106. Marun CSD, Bryant SC, Dewald GW, Greipp PR, Fonseca R. Clustering analysis of conventional cytogenesis karyotypes of 259 multiple myeloma patients. Blood. 2001 Nov 16; 98(11 Part 1):370a.

107. Rajkumar SV, Hayman SR, Gertz MA, Dispenzieri A, Lacy M, Greipp PR, Geyer S, Itturia N, Fonseca R, Lust JA, Kyle K, Witzig TE. Combination therapy with thalidomide plus dexamethasone (THAL/DEX) for newly diagnosed myeloma (MM). Blood. 2001 Nov 16; 98(11 Part 1):849a.

108. Debes Marun CS, Timm MM, Witzig TE, Greipp PR, Fonseca R. Correlation between chromosome 13 abnormalities (DELTA13) detected by interphase fluorescent in-situ hybridization (FISH) and apoptosis in multiple myeloma (MM) plasma cells. Blood. 2001 Nov 16; 98(11 Part 2):296b.

109. Winkler JM, Gonzalez-Paz N, McClure RF, Van Wier S, Greipp PR, Fonseca R. Deletion of the tumor suppressor gene p16 in multiple myeloma (MM) as determined by interphase fluorescent in-situ hybridization (FISH) and its relation to methylation of its promoter region. Blood. 2001 Nov 16; 98(11 Part 2):174b.

110. Schop RFJ, Kuehl WM, Van Wier SA, Price-Troska T, Bailey RJ, Ahmann GJ, Greipp PR, Jalal SM, Fonseca R. Genomic aberrations in Waldenstrom's macroglobulinemia clonal cells detected by FISH. Blood. 2001 Nov 16; 98(11 Part 1):154a.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

111. Schop RFJ, Tschumper RC, Jelinek DF, Greipp PR, Kyle RA, Fonseca R. Heavy chain somatic hypermutation status in Waldenstrom's macroglobulinemia. Blood. 2001 Nov 16; 98(11 Part 1):154a.

112. Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar VS, Hoyer JD, Lust JA, Kyle RA, Gertz MA, Greipp PR, Dewald GW. Immunoglobulin loci translocations, including the t(4;14)(p16.3;q32) and t(14;16)(q32;q23) and translocations involving IgL-lambda are observed in MGUS without transformation to multiple myeloma and result in oncogene up-regulation. Blood. 2001 Nov 16; 98(11 Part 1):370a.

113. Marun CSD, Bailey RJ, Dewald GW, Greipp PR, Fonseca R. In multiple myeloma the combination of an elevated plasma cell labeling index (PCLI) and chromosome 13 deletion, detected by interphase FISH, can identify patients with chromosome 13 abnormalities detected by karyotype. Blood. 2001 Nov 16; 98(11 Part 1):156a.

114. Price-Troska TL, Bailey RJ, Van Wier SA, Ahmann GJ, Snow K, Greipp PR, Fonseca R. Mutation analysis of hBUB1, hBUBR1 MAD1L1, MAD2, MAD2B and APC genes in multiple myeloma cell lines. Blood. 2001 Nov 16; 98(11 Part 2):303b.

115. Schop RFJ, Price-Troska T, Kuehl WM, Kyle RA, Fonseca R. Mutation analysis of the CD40 gene in Waldenstrom's macroglobulinemia. Blood. 2001 Nov 16; 98(11 Part 2):155b.

116. Black CS, Lacy M, Rajkumar SV, Dispenzieri A, Witzig TE, Lust JA, Fonseca R, Gertz MA, Kyle R, Pruthi R. Natural history of thromboembolism in amyloidosis. Blood. 2001 Nov 16; 98(11 part 1):54a.

117. McClure RF, Schop RFJ, Kyle RA, Greipp PR, Fonseca R. p16INK4A gene methylation and deletion in Waldenstrom's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Blood. 2001 Nov 16; 98(11 Part 2):170b.

118. Dispenzieri A, Lacy MQ, Litzow MR, Tefferi A, Inwards DJ, Micallef IN, Gastineau DA, Ansell S, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Kyle RA, Greipp PR, Gertz MA. Peripheral blood stem cell transplant (PBSCT) in patients with POEMS syndrome. Blood. 2001 Nov 16; 98(11 Part 2):391b.

119. VanWier SA, Greipp PR, Fonseca R. Probes spanning the breakpoints for the t(4;14)(p16.3;q32) in multiple myeloma improve the sensitivity of the test. Blood. 2001 Nov 16; 98(11 Part 2):305b-306b.

120. Rajkumar SV, Dispenzieri A, Lacy M, Geyer S, Iturria N, Fonseca R, Hayman SR, Lust JA, Kyle R, Greipp PR, Gertz MA, Witzig TE. Response rate and durability of response with thalidomide therapy for relapsed multiple myeloma (MM). Blood. 2001 Nov 16; 98(11 Part 1):162a-163a.

121. Zeldenrust S, Dispenzieri A, Gertz M, Kyle R, Greipp P, Lacy M, Fonseca R, Rajkumar V, Lust J, Ganju V, Witzig T. Amyloidomas of soft tissue and bone: Mayo Clinic experience. (Abstract 8.1.12.). Amyloid. 2001 Dec; 8(Suppl. 2):133.

122. Naylor S, Abraham RS, Bradwell AR, Fonseca R, Katzmann J, Kyle RA, Bergen HR III. Analysis of immunoglobulin light chains in primary amyloidosis--direct on-line assay for amyloidogenic kappa and lambda light chains directly from serum. (Abstract 4.3.6.). Amyloid. 2001 Dec; 8(Suppl. 2):86.

123. Pardanani A, Rajkumar SV, McElroy EC, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Kyle RA, Greipp PR, Gertz MA, Witzig TE. Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. (Abstract 4.2.13.). Amyloid. 2001 Dec; 8(Suppl. 2):79.

124. Lacy MQ, Wettstein P, Dispenzieri A, Gastineau DA, Greipp PR, Fonseca R, Lust J, Witzig T, Rajkumar SV, Valone F, Kyle RA, Gertz MA. Dendritic cell-based idiotype vaccination for primary systemic amyloidosis. (Abstract 4.3.1.). Amyloid. 2001 Dec; 8(Suppl. 2):82.

125. Dispenzieri A, Kyle RA, Lacy MQ, Greipp PR, Witzig T, Lust JA, Fonseca R, Rajkumar SV, Larson D, Therneau TA, Gertz MA. Eligibility for hematopoietic stem cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. (Abstract 4.2.2.). Amyloid. 2001 Dec; 8(Suppl. 2):70.

126. Hayman SR, Bailey RJ, Jalal SM, Hoyer J, Ahmann GJ, Dispenzieri A, Gertz MA, Greipp PR, Kyle RA, Lacy MQ, Rajkumar SV, Witzig TE, Lust JA, Fonseca R. Translocations involving the IgH locus are common in primary systemic amyloidosis with a high frequency of partner chromosome 11q13 and cyclin D1 overexpression. (Abstract 4.3.4.). Amyloid. 2001 Dec; 8(Suppl. 2):84-5.

127. Lacy M, Wettstein P, Gertz MA, Gastineau DA, Greipp PR, Fonseca R, Dispenzieri A, Lust J, Witzig T, Rajkumar SV, Geyer S, Valone F, Kyle RA. Post autologous transplantation consolidation of multiple myeloma with idiotype-pulsed antigen presenting (dendritic) cells (APC8020). Proc Annu Meet Am Soc Clin Oncol. 2002; 21(1):31a.

128. Brockman S, Paternoster S, Fonseca R, Dewald G. Practical interphase FISH for t(11;14)(q13;q34) and 13q deletions in multiple myeloma. Association of Genetic Technologist Meeting. 2002.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

129. Ghobrial I, Dispenzieri A, Bundy K, Gastineau DA, Lacy M, Rajkumar S, Witzig T, Litzow M, Tefferi A, Inwards D, Ansell SM, Fonseca R, Greipp PR, Lust J, Gertz MA. Pretransplant induction with thalidomide-dexamethasone does not adversely affect stem cell collection or engraftment in patients with multiple myeloma (Abstract 1670). Program/Proc Am Soc Clin Oncol. 2002; 21(1):418a.

130. Winkler JM, Dispenzieri A, Lacy M, Geyer S, Rajkumar S, Lust J, Witzig T, Greipp PR, Kyle R, Fonseca R, Gertz MA. The plasma cell labeling index (PCLI) supercedes the prognostic significance of karyotypic chromosome 13 abnormalities (delta 13) in multiple myeloma (MM) patients undergoing high-dose chemotherapy with stem cell support (HD) (Abstract 1075). Program/Proc Am Soc Clin Oncol. 2002; 21(1):269a.

131. Price-Troska TL, Fonseca R. p53 analysis using conformation sensitive gel electrophoresis (CSGE): sensitive, comprehensive, and inexpensive. RNA Meditations Molecular Analysis for Research Diagnostics San Diego, CA. 2002 Feb; Gene Quantification:Introspection and.

132. Abraham RS, Price-Troska TL, Allmer C, Geyer SM, Kyle RA, Gertz MA, Fonseca R. Immunoglobulin light chain variable (V) region gene usage determines organ tropism and overall survival in light chain-associated (AL) amyloidosis. FASEB J. 2002 Mar 20; 16(4):A351.

133. Dispenzieri A, Witzig TE, Lacy MQ, Rajkumar SV, Geyer SM, Kimlinger T, Greipp PR, Fonseca R, Lust JA, Gertz MA. A phase II trial of GleevecTM in patients with refractory/relapsed myeloma (Abstract 3217). Blood. 2002 Nov 16; 100(11):814a.

134. Ma CX, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Greipp PR, Kyle RA, Gertz MA. Acquired Fanconi's syndrome is an indolent disorder in the absence of overt multiple myeloma (Abstract 5067). Blood. 2002 Nov 16; 100(11):376b.

135. Thompson MA, Witzig TE, Timm MM, Haug J, Kumar S, Fonseca R, Greipp PR, Rajkumar SV. Angiogenesis and angiogenic cytokines in patients receiving thalidomide for multiple myeloma (MM) (Abstract 3205). Blood. 2002 Nov 16; 100(11):811a.

136. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Iturria N, Allmer C, Lust JA, Witzig TE, Greipp PR, Kyle RA, Litzow MR, Gertz MA. Autologous peripheral blood stem cell transplantation for primary refractory multiple myeloma (Abstract 1674). Blood. 2002 Nov 16; 100(11):432a-433a.

137. Van Wier SA, Greipp PR, Oken MM, Fonseca R. Deletions of ATM (11q23) using cIg-FISH are rarely seen in multiple myeloma (Abstract 1517). Blood. 2002 Nov 16; 100(11):391a.

138. Dispenzieri A, Lacy MQ, Rajkumar SV, Geyer SM, Fonseca R, Witzig TE, Lust JA, Greipp PR, Kyle RA, Gertz MA. High doses of thalidomide are not well tolerated in patients with primary systemic amyloidosis (Abstract 1545). Blood. 2002 Nov 16; 100(11):398a.

139. Abraham RS, Geyer SM, Ramirez-Alvarado M, Price-Troska TL, Allmer C, Kyle RA, Gertz MA, Fonseca R. Immunoglobulin variable (V) region germline genes and mutational hotspots potentially influence protein misfolding in light chain amyloidosis (AL) (Abstract 2375). Blood. 2002 Nov 16; 100(11):603a-604a.

140. Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Van Wier SA, Henderson KJ, Greipp PR. Isotype switch mediated IgH translocations (IgH-TRX) in multiple myeloma (MM) Are recurrent, frequently unbalanced and favored with clonal evolution (Abstract 1508). Blood. 2002 Nov 16; 100(11):389a.

141. Winkler JM, Ahmann GJ, Henderson KJ, Oken MM, Greipp PR, Fonseca R. Ploidy category in multiple myeloma (MM) clonal plasma cells (PC) is stable when measured serially (Abstract 1537). Blood. 2002 Nov 16; 100(11):396a.

142. Lacy MQ, Geyer S, Wettstein P, Gertz MA, Gastineau DA, Greipp PR, Fonseca R, Dispenzieri A, Lust JA, Witzig TE, Rajkumar SV, Zeldenrust S, Maas M, Iturria N, Weiden P, Kyle RA. Post autologous transplantation consolidation of multiple myeloma with idiotype-pulsed antigen presenting (Dendritic) cells (APC8020) is associated with a trend to longer time to progression (TTP) (Abstract 1675). Blood. 2002 Nov 16; 100(11):433a.

143. Kumar S, Fonseca R, Dispenzeri A, Lacy MQ, Lust JA, Wellik L, Witzig TE, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Prognostic value of angiogenesis in solitary plasmacytoma (Abstract 2355). Blood. 2002 Nov 16; 100(11):599a.

144. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Allmer C, Iturria N, Witzig TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA. Single agent dexamethasone for induction in patients with multiple myeloma undergoing autologous stem cell transplants (Abstract 1673). Blood. 2002 Nov 16; 100(11):432a.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

145. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer S, Iturria N, Kumar S, Lust JA, Kyle RA, Greipp PR, Witzig TE. Single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma (Abstract 1567). Blood. 2002 Nov 16; 100(11):403a-404a.

146. Paz NG, Kyle RA, Buijs A, Gertz MA, Dispenzieri A, Rajkumar SV, Lacy MQ, Lust JA, Witzig TE, Bailey RJ, Ahmann GJ, Greipp PR, Fonseca R. The pattern of clonal evolution to multiple myeloma (MM) from biclonal gammopathy of undetermined significance (BGUS) indicates evolution to MM is inherent to the cell and not dependent on the microenvironment (Abstract 3197). Blood. 2002 Nov 16; 100(11):809a-810a.

147. Fonseca R, Blood EA, Paz NG, Picken EB, Davila RS, Oken MM, Kyle RA, Dewald GW, Ahmann GJ, Van Wier SA, Henderson KJ, Bailey RJ, Greipp PR. Two major cytogenetic subtypes of multiple myeloma (MM) can be discerned, hyperdiploid-MM and non-hyperdiploid-MM, the latter with a strong association with IgH translocations (IgH-TRX) (Abstract 370). Blood. 2002 Nov 16; 100(11):100a.

148. Ma CS, Lacy MQ, Rompala JF, Dispenzieri A, Rajkumar SV, Greipp PR, Fonseca R, Kyle RA, Gertz MA. Acquired Faconi's syndrome is an indolent disorder in the absence of overt multiple myeloma. IXth International Workshop on Multiple Myeloma Salamanca, Spain. 2003.

149. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Iturria N, Allmer C, Witzig TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA. Autologous peripheral blood stem cell transplantation for primary refractory multiple myeloma. IXth International Workshop on Multiple Myeloma Salamanca, Spain. 2003.

150. Lacy MQ, Geyer S, Foster N, Wettstein P, Dispenzieri A, Gastineau DA, Greipp PR, Fonseca R, Lust J, Witzig T, Rajkumar SV, Zeldenrust S, Peshwa M, Kyle RA, Gertz MA. Dendritic cell-based idiotype vaccination for primary systemic amyloidosis. Presented at the Multiple Myeloma 9th International Workshop, May 23-27, 2004, Salamanca Spain. The Hematology Journal. 2003; 4(suppl 1):S271(411).

151. Tschumper RC, Fonseca R, Van Weir SA, Price-Troska TL, Jelinek DF. Establishment of the JMW myeloma cell line: in vitro analysis of multiple myeloma clonal evolution. Hematol J. 4(Suppl. 1):S92, 2003.

152. Zhao F, Kiffmeyer WR, Blood E, Rue M, Fonseca R, Oken MM, Kay NE, Kyle RA, Greipp PR, Van Ness BG. Polymorphic variations in myeloma cytokine genes are associated with treatment outcomes in phase III ECOG trial E9486. (ASH Abstract 2511). Blood. 2003; 102:678a.

153. Gonzalez Paz N, Manske M, Price-Troska TL, Timm M, Ahmann GJ, Fonseca R, Abraham RS. Regulation of SDF-1CXCR4 interactions by SOCS3 in myeloma and MGUS bone marrow. IXth International Workshop on Multiple Myeloma Salamanca, Spain. 2003.

154. Abraham R, Manske M, Ballman K, Dispenzieri A, Price-Troska T, Fonseca R. Molecular classification of light chain (AL) amyloidosis by gene expression profiling. Xth International Symposium on Amyloid and Amyloidosis Tours, France. 2003 Apr 19.

155. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Iturria N, Allmer C, Witzig TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA. Single agent dexamethasone for induction in patients with multiple myeloma undergoing autologous stem cell transplants. (Abstract 241). Hematol J. 2003 May; 4(Suppl 1):S195.

156. Greipp PR, San Miguel JF, Durie BG, Loiseau HA, Fonseca R, Jacobson JL, Rasmussen E, Crowley JJ. A new International Staging System (ISS) for multiple myeloma (MM) from the International Myeloma Working Group. Blood. 2003 Nov 16; 102(11):190a-1a.

157. Witzig TE, Geyer SM, Salim M, Inwards DJ, Fonseca R, Kaufmann SH, Kurtin P, Colgan JP, Call TG, Moore D Jr, White WL. A phase II trial of the rapamycin analog CCI-779 in previously treated mantle cell non-Hodgkin's lymphoma: Interim analysis of 18 patients. Blood. 2003 Nov 16; 102(11):643a.

158. Dispenzieri A, Lacy MQ, Therneau T, Larson D, Rajkumar SV, Fonseca R, Greipp PR, Lust JA, Zeldenrust S, Snow D, Abraham R, Plevak M, Gertz MA. Case control study suggests that survival is superior in amyloid patients undergoing peripheral blood stem cell transplant. Blood. 2003 Nov 16; 102(11):118a.

159. Ahmann GJ, Henderson KJ, Salisbury JL, Greipp PR, Fonseca R. Centrosomal expression and amplification in bone marrow plasma cells (PC) from healthy individuals, and patients with plasma proliferative disorders. Blood. 2003 Nov 16; 102(11):681a.

160. Gonzalez-Paz N, Qu G, McClure R, Price-Troska T, Blood E, Rajkumar SV, Oken MM, Kay NE, Kyle RA, Van Wier SA, Henderson KJ, Greipp PR, Van Ness BG, Fonseca R. Clinical and biological implications of p16 methylation in of multiple myeloma (MM). Blood. 2003 Nov 16; 102(11):677a.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

161. Xu R, Van Wier SA, Ghobrial I, Schop RFJ, Ahmann GJ, Greipp PR, Kyle RA, Rajkumar V, Gertz MA, Fonseca R. Deletions of 6q predominantly involve band q23 and distinguish Waldenstrom macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Blood. 2003 Nov 16; 102(11):681a.

162. Kumar S, Witzig TE, Wellik L, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Kyle RA, Gertz MA, Greipp PR, Rajkumar SV. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Blood. 2003 Nov 16; 102(11):387b.

163. Lacy MQ, Dispenzieri A, Gertz MA, Witzig TE, Greipp PR, Fonseca R, Lust JA, Kumar S, Zeldenrust S, Kyle RA, Snow D, Hayman SR, Sidor CF, Treston AM, Zeldis JB, Rajkumar SV. ENMD-0995 (S 3-APG), a novel thalidomide analogue, has promising clinical activity for patients with relapsed refractory multiple myeloma. Preliminary results of a Phase I clinical trial. Blood. 2003 Nov 16; 102(11):453a.

164. Manske MK, Gonzalez-Paz NC, Ballman KV, Dispenzieri A, Price-Troska TL, Fonseca R, Abraham RS. Gene expression profiling of clonal plasma cells in light chain (AL) amyloidosis by microarray analysis. Blood. 2003 Nov 16; 102(11):369a.

165. Santana-Davila R, Rajkumar SV, Ahmann GJ, Van Wier SA, Witzig TE, Gertz MA, Lust JA, Lacy MQ, Dispenzieri A, Kyle RA, Greipp PR, Fonseca R. High incidence of p53 deletion in plasma cell leukemia (PCL), and multiple myeloma (MM) with leukemic transformation (MMLT). Blood. 2003 Nov 16; 102(11):680a.

166. Qu G, Price-Troska TL, Ahmann GJ, Greipp PR, Gertz MA, Kyle RA, Ehrlich M, Fonseca R. Hypomethylation of chromosome 1 satellite 2 sequences and hypermethylation of p16 gene in multiple myeloma and amyloidosis. Blood. 2003 Nov 16; 102(11):677a-678a.

167. Fonseca R, Price-Troska T, Blood E, Rajkumar SV, Oken MM, Kay NE, Kyle RA, Van Wier SA, Henderson KJ, Greipp PR, Van Ness BG. Implications of N-ras and K-ras mutations in clinical outcome and the biology of multiple myeloma (MM). Blood. 2003 Nov 16; 102(11):36a.

168. Lust JA, Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Witzig TE, Zeldenrust SR, Geyer SM, Moon-Tasson LL, Dahlgren GR, Kyle RA, Rajkumar SV, Fonseca R, Donovan KA. In smoldering/indolent multiple myeloma (SMM/IMM) patients, interleukin-1 receptor antagonist (IL-1Ra) can decrease the C-reactive protein (CRP), plasma cell labeling index (PCLI), and percent bone marrow plasma cells: Relevance of the IL-1beta/IL-6 axis. Blood. 2003 Nov 16; 102(11):685a.

169. Price-Troska TL, Van Wier SA, Greipp PR, Fonseca R. Molecular analysis of the mitotic checkpoint genes BUB1, BUBR1, BUB3, MAD1L1, MAD2, MAD2B and RAE1 in multiple myeloma. Blood. 2003 Nov 16; 102(11):679a-80a.

170. Ghobrial IM, Fonseca R, Gertz MA, Plevak MF, Larson DR, Therneau TM, Wolf RC, Hoffmann RJ, Lust JA, Witzig TE, Lacy MQ, Dispenzieri A, Rajkumar SV, Zeldenrust SR, Snow DS, Greipp PR, Kyle RA. Prognostic factors, disease specific and overall mortality in 506 patients diagnosed with Waldenstrom macroglobulinemia (WM). Blood. 2003 Nov 16; 102(11):934a.

171. Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Wellik L, Fonseca R, Lust JA, Witzig TE, Kyle RA, Greipp PR, Rajkumar SV. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high dose therapy. Blood. 2003 Nov 16; 102(11):983a-4a.

172. Kumar S, Rajkumar SV, Dispenzieri A, Lacy MQ, Fonseca R, Lust JA, Kyle RA, Witzig TE, Greipp PR, Gertz MA. Prognostic value of bone marrow plasma cell labeling index in primary systemic amyloidosis. Blood. 2003 Nov 16; 102(11):377b.

173. Kumar S, Rajkumar SV, Kyle RA, Lacy MQ, Dispenzieri A, Fonseca R, Lust JA, Gertz MA, Greipp PR, Witzig TE. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. Blood. 2003 Nov 16; 102(11):938a.

174. Price-Troska TL, Ballman KV, Van Wier SA, Ahmann GJ, Grill DE, Therneau TM, Rajkumar SV, Greipp PR, Fonseca R. Simultaneous gene expression analysis and molecular cytogenetic analysis for IgH translocations in multiple myeloma (MM); The Mayo-100 Study. Blood. 2003 Nov 16; 102(11):196b.

175. Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, Vesole D, Gertz M. The initial "flare" of IgM level after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia (WM): An Eastern Cooperative Oncology Group (ECOG) study. Blood. 2003 Nov 16; 102(11):448a-9a.

176. Ghobrial IM, Wolf R, Pereira D, Fonseca R, White W, Colgan J, Habermann T, Inwards D, Markovic S, Ansell S, Micallef I, Porrata L, Witzig T. Therapeutic options in patients with lymphoma and severe liver dysfunction. Blood. 2003 Nov 16; 102(11):284b.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

177. Dispenzieri A, Witzig TE, Lacy MQ, Geyer SM, Kimlinger T, Rajkumar SV, Greipp PR, Fonseca R, Lust JA, Zeldenrust SR, Hayman SR, Gertz MA. A phase II trial of Gleevec (TM) in patients with refractory/relapsed myeloma. Blood. 2004 Nov 16; 104(11 Part 1):665A.

178. Arendt BK, Fonseca R, Ahmann G, Jelinck DF. Analysis of intratumor heterogeneity in multiple myeloma using methylcellulose clonogenic assays. Blood. 2004 Nov 16; 104(11 Part 1):645A-6A.

179. Witzig T, Geyer S, Ghobrial I, Inwards D, Fonseca R, Kaufmann S, Kurtin P, Colgan J, Morice W, Alberts S, Salim M, Rowland K, Dakhil S, Morton R, Stella P. Anti-tumor activity of single-agent CCI-779 for relapsed mantle cell lymphoma: A phase II trial in the north central cancer treatment group. Blood. 2004 Nov 16; 104(11 Part 1):40A.

180. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ, Van Wier SA, Ahmann GJ, Fonseca R. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32) and - 17p13 (p53) deletions in myeloma patients treated with high dose therapy. Blood. 2004 Nov 16; 104(11 Part 1):99A.

181. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Hoering A, Geyer SM, Zeldenrust SR, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA. Combination therapy with CC-5013 (Lenalidomide; Revlimid (TM)) plus dexamethasone (Rev/Dex) for newly diagnosed myeloma (MM). Blood. 2004 Nov 16; 104(11 Part 1):98A.

182. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ, VanWier S, Ahmann G, Fonseca R. Deletion 13 by FISH provides prognostic information on overall survival and time to progression independent of serum beta 2 microglobulin and bone marrow plasma cell labeling index in myeloma patients undergoing stem cell transplantation. Blood. 2004 Nov 16; 104(11 Part 1):295B-6B.

183. Dispenzieri A, Lacy MQ, Geyer SM, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Rajkumar SV, Kyle RA, Fonseca R, Gertz MA. Low dose single agent thalidomide is tolerated in patients with primary systemic amyloidosis, but responses are limited. Blood. 2004 Nov 16; 104(11 Part 1):312B.

184. Greipp P, Cascino G, Kimlinger T, Rajkumar V, Prendergast FG, Fonseca R, Bergsagel PL, Low PS, Greipp PR. Plasma cell folate receptor overexpression differentiates multiple myeloma from monoclonal gammopathy of undetermined significance and smoldering myeloma. Blood. 2004 Nov 16; 104(11 Part 1):992A.

185. Dispenzieri A, Bible KC, Lacy MQ, Fitch TR, Geyer SM, Fenton R, Fonseca R, Getman CR, Ziesmer SC, Erlichman C, Gertz MA. The lack of clinical efficacy of flavopiridol in patients with relapsed refractory myeloma. Blood. 2004 Nov 16; 104(11 Part 1):943A.

186. Schop RFJ, Ocio EM, Gonzalez B, Gutierrez NC, Moro MJ, Aguilera C, Hernandez J, Garcia-Sanz R, Xu R, Hernandez-Rivas JM, Greipp PR, Dispenzieri A, Jalal SM, Lacy MQ, Gonzalex-Paz N, Gertz MA, San Miguel JF, Fonseca R. 6q deletion in Waldenstrom macroglobulinemia is the most common cytogenetic abnormality and is associated with aggressive disease with a trend towards worse survival (Abstract 986). Blood. 2005 Nov; 106(11):290a.

187. Baker AS, Chung TH, Pidgeon TS, Mancini C, Price-Troska T, Van Wier S, Ahmann GJ, Rempel R, Greipp PR, Kyle RA, Rajkumar SV, Dispenzieri A, Gertz MA, Bruhn L, Anderson P, Barrett M, Bittner M, Kim S, Bergsagel PL, Fonseca R, Carpten J. A comparative analysis of chromosome 13 gene expression and copy number changes in multiple myeloma using array- based methods (Abstract 1557). Blood. 2005 Nov; 106(11):447a.

188. Ahmann GJ, Henderson KJ, Price-Troska T, Timm MM, Rempel R, DeGoey RW, Finke CM, Dispenzieri A, Greipp PR, Sable-Hunt A, Bergsagel L, Fonseca R. A local versus centralized processing comparison of plasma cell isolation, viability, and RNA integrity Abstract 3413). Blood. 2005 Nov; 106(11):953a.

189. Dispenzieri A, Blood E, Vesole D, Fonseca R, Callander N, Greipp PR. A phase II study of PS-341 for patients with high risk, newly diagnosed multiple myeloma: a trial of the Eastern Cooperative Oncology Group (E2A02) (Abstract 2546). Blood. 2005 Nov; 106(11):715a.

190. Chng WJ, Gonzalez-Paz N, Kumar S, Van Wier S, Ahmann G, Price-Troska T, Henderson K, Chesi M, Gertz M, Rajkumar SV, Lacy M, Dispenzieri A, Kyle R, Greipp P, Fonseca R, Bergsagel PL. Cancer/testis antigen profiling in multiple myeloma define a cohort of patients with poor prognosis regardless of genetic subtypes (Abstract 3381). Blood. 2005 Nov; 106(11):945a.

191. Gonzalez-Paz NC, Chng WJ, Kumar S, Price-Troska T, Van Wier S, Ahmann G, Henderson K, Gertz M, Kyle R, Greipp P, Fonseca R. Clinical significance of the tumor suppression p53 codon 72 polymorphic variants in multiple myeloma (Abstract 5102). Blood. 2005 Nov; 106(11):358b.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

192. Rajkumar SV, Hayman S, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma (Abstract 781). Blood. 2005 Nov; 106(11):230a-231a.

193. Kumar S, Greipp PR, Haug J, Kline M, Blood E, Chng WJ, Lust JA, Bergsagel L, Gertz MA, Fonseca R, Rajkumar SV. Comparison of myeloma cell gene expression profiles pre and post thalidomide - dexamethasone therapy provides insight into potential mechanisms (Abstract 3480). Blood. 2005 Nov; 106(11):971a-972a.

194. Kumar S, Greipp PR, Haug JL, Kline M, Chng WJ, Blood E, Lust JA, Bergsagel L, Gertz MA, Fonseca R, Rajkumar SV. Comparison of newly diagnosed and relapsed refractory multiple myeloma using transcriptional profiling of myeloma cells (Abstract 1555). Blood. 2005 Nov; 106(11):446a.

195. Chng WJ, Van Wier S, Ahmann G, Santana-Davila R, Jalal S, Ketterling R, Bergsagel PL, Chesi M, Trendle M, Oken M, Blood E, Henderson K, Kyle R, Gertz M, Lacy M, Dispenzieri A, Greipp P, Fonseca R. Compendium of karyotypic abnormalities and their clinical implications of hyperdiploid multiple myeloma (H-MM) (Abstract 1539). Blood. 2005 Nov; 106(11):442a.

196. Al Masri A, Tschumper R, Van Wier S, Price-Troska T, Jelinek DF, Fonseca R. Functional analysis of p53 in the JMW myeloma cell line (Abstract 5112). Blood. 2005 Nov; 106(11):360b.

197. Chng WJ, Gonzalez-Paz N, Kumar S, Van Wier S, Ahmann G, Price-Troska T, Henderson K, Chesi M, Gertz M, Rajkumar SV, Kyle R, Lacy M, Dispenzieri A, Greipp P, Bergsagel PL, Fonseca R. Gene expression profiling identifies 4 sub-classes with distinct clinical associations in hyperdiploid myeloma (Abstract 1537). Blood. 2005 Nov; 106(11):441a.

198. Chng WJ, Van Wier S, Ahmann G, Price-Troska T, Henderson K, Chesi M, Chung TH, Kim S, Carpten J, Gertz M, Rajkumar SV, Lacy M, Kyle R, Greipp P, Dispenzieri A, Bergsagel PL, Fonseca R. Gene expression profiling of hyperdiploid multiple reveal complex gene dosage effects and an mRNA translation/protein synthesis signature (Abstract 1538). Blood. 2005 Nov; 106(11):441a.

199. Kumar S, Greipp PR, Haug J, Kline M, Chng WJ, Blood E, Bergsagel L, Lust JA, Gertz MA, Fonseca R, Rajkumar SV. Gene expression profiling of myeloma cells at diagnosis can predict response to therapy with thalidomide and dexamethasone combination (Abstract 508). Blood. 2005 Nov; 106(11):152a.

200. Chng WJ, Van Wier S, Ahmann G, Price-Troska T, Henderson K, Chesi M, Gertz M, Rajkumar SV, Kyle R, Lacy M, Dispenzieri A, Greipp P, Bergsagel PL, Fonseca R. Genomic analysis of high hyperdiploid acute lymphoblastic leukemia and hyperdiploid multiple myeloma suggests differential gene dosage effect on expression and provide clues to preferential selection of recurrently trisomic chromosomes (Abstract 3006). Blood. 2005 Nov; 106(11):842a.

201. Kline M, Rajkumar SV, Haug J, Wellik L, Lust JA, Fonseca R, Greipp PR, Kumar S. Identification of genes associated with increased bone marrow angiogenesis in multiple myeloma (Abstract 5109). Blood. 2005 Nov; 106(11):359b-360b.

202. Fonseca R, Van Wier S, Chng WJ, Ketterling R, Lacy M, Dispenzieri A, Bergsagel PL, Rajkumar SV, Greipp P, Litzow M, Kumar S, Gonzalez-Paz N, Henderson K, Ahmann G, Gertz M. Low level amplification (duplication) of 1q21 in myeloma and prognosis; the role of CKS1B (Abstract 624). Blood. 2005 Nov; 106(11):185a.

203. Al Masri A, Price-Troska T, Chesi M, Chung TH, Kim S, Carpten J, Bergsagel PL, Fonseca R. MicroRNA expression analysis in multiple myeloma (Abstract 1554). Blood. 2005 Nov; 106(11):446a.

204. Ludwig H, Durie B, Bolejack V, Hoering A, Dimopoulos M, Kyle R, Fonseca R, Beksac M, San Miguel J, Crowley J, Blade J, Boccadoro M, Avet Loiseau P, Morgan G, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. Multiple myeloma (MM) in young patients (pts): clinical features and outcome in 259 patients younger than 40 years in comparison to 8,296 pts aged =>40 years (Abstract 3414). Blood. 2005 Nov; 106(11):953a.

205. Greipp PT, Fonseca R, Dewald G, Rajkumar SV, Morice WG, Greipp PR. Myeloma with t(11;14) and CD20+ plasma cells: response to rituximab (Abstract 5178). Blood. 2005 Nov; 106(11):378b.

206. Van Wier S, Chng WJ, Ahmann G, Rempel R, Al Masri A, Gertz M, Dispenzieri A, Greipp P, Schop RFJ, Fonseca R. One half of patients with Waldenstrom macroglobulinemia have large deletions of chromosome 6q (Abstract 1546). Blood. 2005 Nov; 106(11):444a.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

207. Gonzalez-Paz NC, Van Wier S, Santana-Davila R, Ahmann G, Price-Troska T, Henderson K, Gertz M, Kyle R, Greipp P, Fonseca R. Plasma cells from secondary plasma cell leukemia display different cytogenetics pattern when compared with primary plasma cell leukemia (Abstract 3267). Blood. 2005 Nov; 106(11):913a.

208. Al Masri A, Tschumper R, Van Wier S, Price-Troska T, Jelinek D, Fonseca R. The "trans-amplicon" in myeloma; a mechanism of clonal selection favoring retention of derivative chromosomes involved in translocations (Abstract 4346). Blood. 2005 Nov; 106(11):166b.

209. Van Wier SA, Ahmann GJ, Henderson KJ, Greipp PR, Rajkumar SV, Larson DM, Dispenzieri A, Gertz MA, Kyle RA, Fonseca R. The t(4;14) is present in patients with early stage plasma cell proliferative disorders including MGUS and smoldering multiple myeloma (SMM) (Abstract 1545). Blood. 2005 Nov; 106(11):443a-444a.

210. Kumar S, Gertz MA, Hayman SR, Lacy MQ, Dispenzieri A, Zeldenrust SR, Lust JA, Greipp PR, Kyle RA, Fonseca R, Rajkumar SV. Use of the serum free light chain assay in assessment of response to therapy in multiple myeloma: validation of recently proposed response criteria in a prospective clinical trial of lenalidomide plus dexamethasone for newly diagnosed multiple myeloma (Abstract 3479). Blood. 2005 Nov; 106(11):971a.

211. Lonial S, Alsina M, Anderson KC, Richardson P, Stewart K, Fonseca R, Heise C, Fox J, Allen A, Michelson G. Phase I trial of chir-258 in multiple myeloma (Abstract 17502). J Clin Oncol. 2006 Jun; 24(18S):680s.

212. Chng WJ, Fonseca R. A gene expression based centrosome index is a powerful prognostic factor in myeloma (Abstract 3388). Blood. 2006 Nov; 108(11 part 1):967a.

213. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Greipp P. A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group (Abstract 799). Blood. 2006 Nov; 108(11 part 1):239a-40a.

214. Chng WJ, Baker A, Henry T, Price Troska T, Van Wier S, Chung TH, Henderson K, Ahmann G, Lacy M, Dispenzieri A, Gertz MA, Greipp P, Bergsagel PL, Carpten J, Fonseca R. Combined high resolution array comparative genomic hybridization and gene expression profiling reveal Rb1 haploinsufficiency as a possible tumorigenic mechanism in myeloma (Abstract 113). Blood. 2006 Nov; 108(11 part 1):37a-8a.

215. Stewart K, Trudel Z, Chang H, Anderson KC, Richardson P, Alsina M, Reece DE, Greipp P, Young S, Sable Hung A, Li ZH, Keats J, Van Wier S, Ahmann G, Price Troska T, Giusti K, Fonseca R. Diagnostic evaluation of t[4;14] in multiple myeloma (Abstract 3501). Blood. 2006 Nov; 108(11 part 1):998a.

216. Arendt BK, Ahmann GJ, Mulvihill EM, Sikkink LA, Dispenzieri A, Ramirez Alvarado M, Zeldenrust SR, Fonseca R, Jelinek DF. Establishment and characterization of an Ig and Lambda secreting cell line from a patient with AL amyloidosis (Abstract 3520). Blood. 2006 Nov; 108(11 part 1):1004a.

217. Schop RFJ, Mancini C, Chng WJ, Tschumper RC, Jelinek DF, Kay NE, Bergsagel PL, Carpten JD, Fonseca R. High density oligonucleotide array CGH analysis of CLL reveals areas of recurrent genomic gain or loss (Abstract 2093). Blood. 2006 Nov; 108(11 part 1):593a.

218. Kumar S, Fonseca R, Dispenzieri A, Katzmann JA, Kyle RA, Clark R, Rajkumar SV. High incidence of IgH translocations in monoclonal gammopathies with abnormal free light chain levels (Abstract 3514). Blood. 2006 Nov; 108(11 part 1):1002a.

219. Keats J, Tiedemann R, Schop R, Sebag M, Chesi M, Van Wier S, Shi CX, Zhu YX, Greipp P, Dispenzieri A, Barrett M, Bruhin L, Stewart K, Carpten J, Fonseca R, Bergsagel PL. High resolution array CGH identifies TRAF3 as a novel tumor suppressor in multiple myeloma (Abstract 3407). Blood. 2006 Nov; 108(11 part 1):973a.

220. Lacy M, Gertz M, Dispenzieri A, Hayman S, Geyer S, Zeldenrust S, Kumar S, Greipp P, Fonseca R, Lust J, Russell S, Kyle R, Witzig T, Gergsagel L, Rajkumar SV. Lenalidomide plus dexamethasone (Rev/Dex) in newly diagnosed myeloma: response to therapy, time to progression, and survival (Abstract 798). Blood. 2006 Nov; 108(11 part 1):239a.

221. Hayman S, Gertz M, Lacy M, Dispenzieri A, Fonseca R, Geyer S, Kumar S, Zeldenrust S, Russell S, Lust J, Kyle R, Greipp P, Witzig T, Rajkumar SV. Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma (Abstract 3568). Blood. 2006 Nov; 108(11 part 1):1019a.

222. Tiedemann RE, Gonzalez Paz N, Santana Davila R, Chng WJ, Ketterling R, Gertz MA, Price Troska T, Henderson K, Greipp PR, Rajkumar SV, Kyle R, Dispenzieri A, Lacy M, Fonseca R. Natural history, genetic aberrations and survival distinguish primary plasma cell leukemia from multiple myeloma with leukemia (Abstract 3587). Blood. 2006 Nov; 108(11 part 1):1024a-5a.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

223. Bergsagel PL, Carpten J, Chesi M, VanWier S, Keats JJ, Sebag M, Chng WJ, Schop R, Baker A, Chng TH, Fogle H, Zhu YX, Shi CX, Bruhn LK, Barrett M, Mancini C, Price Troska T, Ahmann G, Henderson K, Greipp PR, Dispenzieri A, Trent J, Stewart A, Fonseca R. Promiscuous mutations frequently activate the non-canonical NFkB pathway in multiple myeloma (MM) (Abstract 109). Blood. 2006 Nov; 108(11 part 1):36a.

224. Dispenzieri A, Zhang L, Fonseca R, Vesole DH, Greipp PR. Single agent bortezomib is associated with a high response rate in patients with high risk myeloma. A phase II study from the Eastern Cooperative Oncology Group (E2A02) (Abstract 3527). Blood. 2006 Nov; 108(11 part 1):1006a.

225. Braggio E, Keats JJ, Chng W-J, Jimenez VH, Schop R, Sekulik A, Baker A, Van Wier S, Price-Troska T, Barrett M, Carpten J, Remstein E, Dogan A, Bergsagel PL, Fonseca R. Comparative high resolution array-based CGH in B-cell malignancies. Blood. 2007; 110(11):2479a.

226. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M, Abonour R, Siegel D, Greipp P. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2007; 25(18S).

227. Chang WJ, Keats JJ, Chesi M, Baker A, Bruhn LK, Dispenzieri A, Stewart AK, Carpten J, Fonseca R, Bergsagel PL. Prediction of response to bortezomib and dexamethasone resistance in myeloma (MM) by novel mutations in the NFKB pathway. J Clin Oncol. 2007; 25(18S):8007.

228. Ahmann GJ, Henderson KJ, Price-Troska TL, Chng WJ, DeGoey RW, Zincke SA, Greipp PR, Fonseca R. Assessing the purity, sensitivity and specificity of two plasma cell selection methods. Haematologica. 2007 Jun; 92(6 Suppl 2):107-8.

229. Fonseca R. Clinical and pathological implications for myeloma subtypes. Haematologica. 2007 Jun; 92(6 Suppl 2):4-5.

230. Chng WJ, Keats JJ, Bergsagel PL, Fonseca R. Disease stage, sample purity and impact on gene expression profiling (GEP) studies in plasma cell proliferative disease (PPD). Haematologica. 2007 Jun; 92(6 Suppl 2):108.

231. Arendt BK, Ahmann GJ, Fonseca R, Mulvihill EM, Dispenzieri A, Sikkink LA, Ramirez-Alvarado M, Zeldenrust SR, Jelinek DF. Establishment of an amyloid-forming human cell line. Haematologica. 2007 Jun; 92(6 Suppl 2):38.

232. Fonseca R, Braggio E. Genetics and genomics of Waldenstrom macroglobulinemia. Haematologica. 2007 Jun; 92(6 Suppl 2):81-2.

233. Van Wier SA, Larson DM, Chng W, Rempel R, Ahmann GJ, Henderson KM, Figueroa G, Kyle RA, Rajkumar SV, Dispenzieri AD, Bersagel PL, Stewart AK, Therneau TM, Greipp PR, Fonseca R. Genomic aberrations in monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) and the risk of progression to multiple myeloma (MM). Haematologica. 2007 Jun; 92(6 Suppl 2):99.

234. Keats J, Chng WJ, Braggio E, Shanmugam V, Pushparaj V, Schop R, Baker A, Mancini C, Price-Troska T, Ahmann G, Henderson K, Greipp P, Dispenzieri A, Bruhin L, Bergsagel PL, Carpten J, Fonseca R. High-resolution mapping of common gains and losses in myeloma. Haematologica. 2007 Jun; 92(6 Suppl 2):64.

235. Nowakowski GS, Lacy MQ, Gertz MA, Dispenzieri A, Dingli D, Greipp PR, Kumar S, Geyer S, Fonseca R, Vivek R, Hayman S, Lust JA, Kyle RA, Witzig TE, Rajkumar SV. Initial therapy with thalidomide/dexamethasone versus lenalidimide/dexamethasone in newly diagnosed multiple myeloma: A retrospective analysis of two phase II trials. Haematologica. 2007 Jun; 92(6 Suppl 2):179.

236. Bergsagel PL, Chesi M, Keats J, Chng WJ, Sebag M, Tiedemann R, Henry T, Braggio E, Kuehl WM, Stewart AK, Fonseca R. Molecular principles underlying myeloma. Haematologica. 2007 Jun; 92(6 Suppl 2):1.

237. Sebag M, Stewart AK, Chng WJ, Keats J, Tiedemann R, Fonseca R, Bergsagel PL. Mutually exclusive activation of NF kappa B or STAT3 signaling pathways in multiple myeloma. Haematologica. 2007 Jun; 92(6 Suppl 2):98.

238. Henry T, Chng WJ, Baker A, Price-Troska T, Van Wier S, Chung TH, Henderson K, Ahmann G, Dispenzieri A, Greipp PR, Bergsagel PL, Carpten J, Fonseca R. Pathogenesis of RB1 haploinsufficiency in cent 13 myeloma. Haematologica. 2007 Jun; 92(6 Suppl 2):98.

239. Price-Troska T, Henderson K, Ahmann G, Fonseca R. RNA-FISH detects clonal IGH in PCS of MM patients. Haematologica. 2007 Jun; 92(6 Suppl 2):109.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

240. Keats JJ, Tiedemann R, Van Wier S, Schop R, Baker A, Chng WJ, Shi CX, Fogle H, Price-Troska T, Ahmann G, Henderson K, Mancini C, Greipp P, Dispenzieri A, Bruhin L, Barrett M, Chesi M, Stewart AK, Carpten J, Fonseca R, Bergsagel PL. TRAF3 is a novel tumor suppressor that is frequently inactivated in myeloma. Haematologica. 2007 Jun; 92(6 Suppl 2):106.

241. Bryce AH, Ketterling RP, Gertz MA, Kyle RA, Lust JA, Fonseca R, Lacy M, Greipp PR, Witzig T, Rajkumar S, Dispenzieri A. Cytogenetic analysis using multiple myeloma targets in POEMS syndrome. (Abstract 8116). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. 2007 Jun 20; 25(18 Suppl).

242. Smith BE, Bosch EP, Suarez GA, Witzig TE, Stevens JC, Dyck PJB, Fonseca R, Hentz JG. Treatment of paraproteinemic peripheral neuropathy with rituximab. J Peripher Nerv Syst. 2007 Jul; 12(Suppl 1):82.

243. Bryce AH, Ketterling R, Gertz M, Zeldenrust S, Lacy M, Kumar S, Hayman S, Buadi F, Greipp P, Lust J, Rajkumar V, Fonseca R, Dingli D, Russell S, Kyle R, Dispenzieri A. 14q32 abnormalities and 13q deletions are common in primary systemic amyloidosis using cytoplasmic immunoglobulin fluorescence in situ hybridization (cIg-FISH). Blood. 2007 Nov; 110(11):730A-1A.

244. Reeder CB, Reece DE, Fonseca R, Bergsagel PL, Hentz J, Pirooz NA, Boesiger JE, Pisa JG, Kukreti V, Chen C, Trudel S, Mikhael JR, Lacy M, Rajkumar SV, Stewart AK. A phase II trial of myeloma induction therapy with cyclophosphamide, bortezomib, and dexamethasone (Cybor-D): Improved response over historical lenalidomide-dexamethasone controls. Blood. 2007 Nov; 110(11):1053A.

245. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M, Abonour R, Siegel D, Greipp P. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the eastern cooperative oncology group. Blood. 2007 Nov; 110(11):31A.

246. Chng WJ, Chesi M, Price-Troska T, Ahmann G, Henderson K, Greipp P, Kyle R, Rajkumar SV, Gertz M, Fonseca R, Bergsagel PL. Activation of MYC pathway is a unifying pathological event in the progression from monoclonal gammopathy of undetermined significance (MGUS) to myeloma (MM). Blood. 2007 Nov; 110(11):78A.

247. Jimenez-Zepeda VH, Chng WJ, Fonseca R. Dissecting karyotypic patterns in non hyperdiploid multiple myeloma: An overview on the karyotypic evolution. Blood. 2007 Nov; 110(11):734A-5A.

248. Chng WJ, Fonseca R, Bergsagel PL, Vrana JA, Kurtin PJ, Remstein E, Dogan A. Gene expression profiling of pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma identifies new diagnostic markers, biological heterogeneity and therapeutic targets. Blood. 2007 Nov; 110(11):172A.

249. Keats J, Chapman M, Carpten J, Chng WJ, Baker A, Ahmann G, Trudel S, Siegel D, Rajkumar SV, Alsina M, Richardson P, Anderson K, Auclair D, Perkins LM, Trent J, Golub TR, Fonseca R. Genome-wide profiling of gene expression and DNA copy number alterations in multiple myeloma. Blood. 2007 Nov; 110(11):123A.

250. Chng WJ, Chung TH, Keats JJ, Baker A, Bergsagel PL, Carpten J, Fonseca R. Identification of survival critical genomic gains or losses in myeloma (MM) using array-comparative genomic hybridization (aCGH). Blood. 2007 Nov; 110(11):729A.

251. Dispenzieri A, Kyle RA, Katzmann JA, Larson D, Benson J, Clark R, Melton LJ, Gertz MA, Kumar SK, Fonseca R, Jelinek DF, Rajkumar SV. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering multiple myeloma. Blood. 2007 Nov; 110(11):445A.

252. Braggio E, Keats JJ, Van Wier S, Price-Troska T, Henderson K, Chesi M, Carpten J, Bergsagel LP, Fonseca R. Inactivation of tumor necrosis factor 3 gene (TRAF3) is frequently identified in Waldenstrom's macroglobulinemia patients. Blood. 2007 Nov; 110(11):730A.

253. Chng WJ, Keats JJ, Braggio E, Baker A, Bergsagel PL, Carpten J, Fonseca R. Multiple myeloma (MM) is characterized by genomic instability regardless of ploidy categories and degree of karyotypic complexity is an important prognostic factor. Blood. 2007 Nov; 110(11):442A.

254. Lacy MQ, Alsina M, Roberts L, Fonseca R, Melvin C, Yin D, Sharma A, Pollak M, Jagannath S, Richardson P, Gualberto A. Phase I dose escalation study of the monoclonal antibody against the insulin like growth factor I receptor CP-751,871 in patients with multiple myeloma. Blood. 2007 Nov; 110(11):355A.

255. Abonour R, Zhang LA, Rajkumar V, Srkalovic G, Greipp PR, Fonseca R, Gertz M. Phase II pilot study of rituximab plus CHOP in patients with newly diagnosed Waldenstrom's macroglobulinemia, an eastren cooperative oncology group trial (Study E1A02). Blood. 2007 Nov; 110(11):1058A.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

256. Kumar S, Hayman SR, Buadi FK, Lacy MQ, Stewart K, Greipp PR, Russell S, Zeldenrust S, Gertz MA, Bergsagel L, Fonseca R, Allred J, Campbell M, Lust JA, Witzig TE, Kyle RA, Rajkumar SV, Dispenzieri A. Phase II trial of lenalidomide, cyclophosphamide, and dexamethasone (CRd) for newly diagnosed myeloma. Blood. 2007 Nov; 110(11):64A.

257. Sebag M, Stewart K, Shi CX, Zhu YX, Cling WJ, Keats J, Tiedemann RE, Fonseca R, Chesi M, Bergsagel PL. PRL3 is a mediator of IL6/STAT3 signaling and defines a population of multiple myeloma patients distinct from those that activate NFkB. Blood. 2007 Nov; 110(11):206A.

258. Henry TJ, Chng WJ, Carpten J, Bergsagel PL, Fonseca R. RB1 haploinsufficiency confers a proliferation advantage in myeloma cell lines. Blood. 2007 Nov; 110(11):734A.

259. Trent J, Carpten J, Reich M, Liefeld T, Keats J, Mousses S, Hahn W, Trudel S, Siegel D, Rajkumar SV, Alsina M, Richardson P, Anderson K, Auclair D, Perkins LM, Giusti K, Fonseca R, Golub TR. The Multiple Myeloma Research Consortium Genomics Initiative. Blood. 2007 Nov; 110(11):736A.

260. Jimenez-Zepeda VH, Chng WJ, Fonseca R. Waldenstrom macroglobulinaemia: The impact of cytogenetic analysis. Blood. 2007 Nov; 110(11):734A.

261. Stewart AK, Reeder B, Fonseca R, Bergsagel PL, Pirooz A, Hentz G, Boesiger E, Pisa G, Kukreti V, Chen C, Trudel S, Mikhael R, Leis F, Reece E. Induction with cybord produces high complete responses in newly diagnosed multiple myeloma. Haematologica-the Hematology Journal. 2008 Jun; 93(Suppl 1):82.

262. Kumar S, Zhang L, Dispenzieri A, Van Wier S, Katzmann J, Snyder M, Blood E, DeGoey R, Henderson K, Bradwell A, Kyle R, Greipp P, Rajkumar SV, Fonseca R. Association of high levels of free light chain and the presence of Igh translocations in multiple myeloma and prognostic implications. Blood. 2008 Nov; 112(11):592-3.

263. Keats JJ, Arendt BK, Braggio E, Barrett M, Price-Troska T, Fonseca R, Bergsagel PL, Jelinek DF. Comparison of multiple myeloma donor patient samples and derived cell lines identifies a confirmed hyperdiploid myeloma cell line and demonstrates remarkable genetic similarity between cell lines and patient samples. Blood. 2008 Nov; 112(11):944.

264. Jacobus S, Kumar S, Callander NS, Abonour R, Fonseca R, Siegel D, Greipp P, Rajkumar SV. Effect of venous thrombotic events on overall survival in multiple myeloma: analysis of thrombotic events occurring in E4A03A randomized trial of Lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma, a trial coordinated by the Eastern Cooperative Oncology Group (ECOG). Blood. 2008 Nov; 112(11):613-4.

265. Chng WJ, Lee I, Jimenez-Zepeda V, Braggio E, Keats J, Bergsagel PL, Fonseca R. Genomic complexity and recurrent aberration in multiple myeloma: analysis of a compendium of aCGH and gene expression profiles. Blood. 2008 Nov; 112(11):594.

266. Braggio E, Remstein E, Chng WJJ, Huang G, Barrett M, Witzig TE, Dogan A, Fonseca R. High resolution array-based analysis in marginal zone lymphomas and lymphoplasmacytic lymphomas identified disease-specific patterns of chromosome abnormalities. Blood. 2008 Nov; 112(11):231-2.

267. Chng WJ, Huang GF, Bergsagel PL, Fonseca R. Identification of cellular pathways mediating progression of monoclonal gammopathy (MGUS) to multiple myeloma (MM) using gene expression profiling (GEP). Blood. 2008 Nov; 112(11):591.

268. Chapman MA, Brunet JP, Baker A, Keats J, Ahmann G, Schinzel AC, Moore A, Shanmugam V, Perkins LM, Auclair D, Hahn WC, Bergsagel PL, Fonseca R, Carpten J, Trent J, Golub TR. Interim analyses of the MMRC reference collection identifies recurrent genomic-level events in multiple myeloma and demonstrates that CDKN2C/p18 deletion is the pre-eminent copy number alteration in poor prognosis disease. Blood. 2008 Nov; 112(11):188-9.

269. Molnar S, Jimenez Zepeda VJ, Van Wier S, Braggio E, Keats J, Kuehl M, Price-Troska T, Ahmann G, Rempel R, Henderson K, Rajkumar SV, Greipp PR, Auclair D, Carpten J, Baker A, Stewart K, Bergsagel PL, Chng WJ, Fonseca R. Loss of p53 is a marker of progression in plasma cell neoplasias and is a negative prognostic factor in relapsed disease. Blood. 2008 Nov; 112(11):587.

270. Henry TJ, Fonseca R. MicroRNA 15a and 16-1 target identification in deletion 13 multiple myeloma. Blood. 2008 Nov; 112(11):235.

271. Roy V, Stewart AK, Bergsagel PL, Dispenzieri A, Laumann K, Allred J, Lacy MQ, Fonseca R, Reeder CB, Kumar S, Rivera CE, Gertz MA, Greipp PR, Buadi FK, Hayman SR, Rajkumar SV. Phase II study of melphalan, prednisone and lenalidomide combination for newly diagnosed multiple myeloma patients who are not candidates for stem cell transplantation. Blood. 2008 Nov; 112(11):955.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

272. Kumar S, Hayman S, Buadi F, Lacy M, Stewart K, Allred J, Laumann K, McCarty T, Bergsagel L, Dingli D, Fonseca R, Gertz M, Greipp P, Lust J, Russell S, Reeder C, Witzig T, Zeldenrust S, Kyle R, Rajkumar SV, Dispenzieri A. Phase II trial of lenalidomide (Revlimid (TM)) with cyclophosphamide and dexamethasone (RCd) for newly diagnosed myeloma. Blood. 2008 Nov; 112(11):40.

273. Lacy MQ, Hayman SR, Gertz MA, Allred JB, Mandrekar SJ, Dispenzieri A, Zeldenrust SR, Kumar S, Greipp PR, Lust JA, Russell SJ, Buadi F, Kyle RA, Bergsagel PL, Fonseca R, Roy V, Mikhael J, Stewart AK, Rajkumar SV. Pomalidomide (CC4047) plus low-dose dexamethasone (Pom/dex) is highly effective therapy in relapsed multiple myeloma. Blood. 2008 Nov; 112(11):320.

274. Ngo HT, Hatjiharissi E, Leontovich AA, Chng W, Farag M, Leleu X, Jia XY, Runnels J, Roccaro A, Azab AK, Azab F, Sacco A, Burwick N, Melhem MR, Anderson KC, Fonseca R, Witzig TE, Ghobrial IM. Proteomic analysis of multiple myeloma identifies upregulation of CRIK protein, a novel protein regulating migration and adhesion. Blood. 2008 Nov; 112(11):239-40.

275. Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz M, Dalton R, Mikhael J, Dingli D, Reeder CB, Lust JA, Russell S, Roy V, Zeldenrust SR, Stewart K, Kyle RA, Greipp PR, Rajkumar SV. Survival in patients with newly diagnosed myeloma undergoing therapy with lenalidomide and dexamethasone: impact of high-risk cytogenetic risk status on outcome. Blood. 2008 Nov; 112(11):42-3.

276. Braggio E, Keats JJ, Lelcu X, Remstein E, Van Wier S, Jimenez-Zepeda VH, Valdez R, Schop R, Price-Troska T, Sacco A, Azab F, Greipp PR, Gertz M, Rajkumar SV, Chesi M, Stewart K, Dogan A, Bergsagel PL, Ghobrial I, Fonseca R. TRAF3 and TNFAIP3, two negative regulators of NF-Kb signaling pathways, are mutated in Waldenstrom's macroglobulinemia. Blood. 2008 Nov; 112(11):231.

277. Dogan A, Zepeda VJ, Vrana JA, Theis JD, Gamez JD, Valdez R, Williams JW, Fonseca R. Leukocyte chemotactic factor 2: a novel cause of renal and hepatic amyloidosis associated with nephrotic syndrome and chronic liver disease. Mod Pathol. 2009 Jan; 22(Suppl 1):1367.

278. Dogan A, Zepeda VJ, Vrana JA, Theis JD, Gamez JD, Valdez R, Williams JW, Fonseca R. Leukocyte chemotactic factor 2: a novel cause of renal and hepatic amyloidosis associated with nephrotic syndrome and chronic liver disease. Lab Invest. 2009 Jan; 89(Suppl 1):1367.

279. Bosler DS, Remstein ED, Braggio E, Chng WJ, Huang G, Menon SP, McClure RF, Fonseca R, Sun DX, Maurer MJ, Dogan A. Molecular prognostic factors in splenic marginal zone lymphoma (SMZL): correlation of clinical behavior with immunoglobulin heavy chain (IgH) somatic mutation status, array comparative genomic hybridization (aCGH) and gene expression profiling (GEP). Mod Pathol. 2009 Jan; 22(Suppl 1):1163.

280. Bosler DS, Remstein ED, Braggio E, Chng WJ, Huang G, Menon SP, McClure RF, Fonseca R, Sun DX, Maurer MJ, Dogan A. Molecular prognostic factors in splenic marginal zone lymphoma (SMZL): correlation of clinical behavior with immunoglobulin heavy chain (IgH) somatic mutation status, array comparative genomic hybridization (aCGH) and gene expression profiling (GEP). Lab Invest. 2009 Jan; 89(Suppl 1):1163.

281. Remstein ED, Braggio E, Chng WJ, Huang G, Barrett M, Sun D, Fonseca R, Feldman A, Dogan A. Post-follicular B-cell lymphomas: a high resolution array-based analysis identifies disease-specific patterns of chromosome abnormalities. Mod Pathol. 2009 Jan; 22(Suppl 1):1278.

282. Remstein ED, Braggio E, Chng WJ, Huang G, Barrett M, Sun D, Fonseca R, Feldman A, Dogan A. Post-follicular B-cell lymphomas: a high resolution array-based analysis identifies disease-specific patterns of chromosome abnormalities. Lab Invest. 2009 Jan; 89(Suppl 1):1278.

283. Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Zeldenrust SR, Kumar S, Greipp PR, Lust JA, Russell SJ, Buadi F, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Allred JB, Laumann K, Thompson M, Mandrekar SJ, Rajkumar SV, Dingli D, Reeder C. Pomalidomide (CC4047) plus low-dose dexamethasone (pom/dex) as therapy for relapsed multiple myeloma. Clin Lymphoma Myeloma. 2009 Feb; 9(Suppl 2):S46-7.

284. Ngo HT, Ahmann G, Leleu X, Jia X, Hatjiharissi E, Leontovich AA, Chng W, Farag M, Timm M, Melhem M, George D, Runnels J, Roccaro AM, Azab AK, Azab F, Sacco A, Burwick N, Melhem MM, Greipp P, Fonseca R, Gertz MA, Anderson KC, Witzig TE, Ghobrial IM. Proteomic analysis of multiple myeloma identifies upregulation of the novel protein CRIK Clinical Lymphoma & Myeloma. 2009 Feb; 9(Suppl 1):S146

285. Fonseca R. Role of fluorescence in situ hybridization in myeloma risk stratification. Clin Lymphoma Myeloma. 2009 Feb; 9(Suppl 2):S6-8.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

286. Salhia B, Baker A, Keats JJ, Ahmann G, Auclair D, Mfuko B, Perkins LM, Levy J, Bergsagel L, Fonseca R, Carpten J. CpG methylation profiling in multiple myeloma. Blood. 2009 Nov 20; 114(22):250.

287. Jimenez-Zepeda VH, Reeder CB, Mikhael JR, Dispenzieri A, Gertz M, Mayo A, Spong J, Fanning JI, Bergsagel L, Stewart AK, Fonseca R. Cyclophosphamide, bortezomib and dexamethasone (CyBORD) induces rapid and complete responses in patients with amyloidosis not eligible for peripheral blood stem cell transplant. Blood. 2009 Nov 20; 114(22):737.

288. Kapoor P, Fonseca R, Rajkumar SV, Sinha S, Gertz MA, Stewart AK, Bergsagel PL, Lacy MQ, Dingli D, Ketterling RP, Kyle R, Greipp PR, Dispenzieri A, Kumar S. Evidence for cytogenetic and fluorescence in situ hybridization (FISH) risk stratification of newly diagnosed multiple myeloma in the era of novel therapies. Blood. 2009 Nov 20; 114(22):716.

289. Chapman MA, Brunet JP, Keats JJ, Baker A, Adli M, Schinzel AC, Ahmann G, Christina H, Moore A, Shanmugam V, Perkins LM, Auclair D, Hahn WC, Bernstein BE, Bergsagel L, Fonseca R, Carpten J, Trent J, Golub TR. HOXA9 is a novel therapeutic target in multiple myeloma. Blood. 2009 Nov 20; 114(22):343.

290. Avet-Loiseau H, Durie BGM, Haessler J, Crowley J, Hoering A, Barlogie B, Shaughnessy JD, Sezer O, Shustik C, Hajek R, Goldschmidt H, Sonneveld P, Moreau P, Attal M, Palumbo A, Boccadoro M, Lee JH, Westin J, Turesson I, San Miguel JF, Blade J, Lahuerta JJ, Pavlovsky S, Fantl DB, Rajkumar SV, Fonseca R. Impact of FISH and cytogenetics on overall and event free survival in myeloma: an IMWG analysis of 9,897 patients. Blood. 2009 Nov 20; 114(22):309.

291. Leis JF, Braggio E, Van Wier S, Keats JJ, Jelinek DF, van Dyke D, Zent CS, Shanafelt TD, Call TG, Kay NE, Fonseca R. Impact of IgVH gene mutational status and VH family usage on chromosomal aberrations detected by high-resolution array-CGH in B-CLL. Blood. 2009 Nov 20; 114(22):513.

292. Tiedemann RE, Zhu YX, Schmidt J, Yin HW, Que Q, Azorsa D, Perkins LM, Braggio E, Reeder CB, Fonseca R, Bergsagel PL, Mousses S, Stewart AK. Kinome-wide RNAI studies in human multiple myeloma identify a lymphoid restricted kinase grk6 as a selectively vulnerable target that regulates STAT3/MCL1. Blood. 2009 Nov 20; 114(22):249.

293. Gay F, Rajkumar SV, Falco P, Kumar S, Dispenzieri A, Gertz M, Di Raimondo F, Lacy MQ, Crippa C, Buadi F, Falcone A, Hayman SR, Giuliani N, Short KED, Musto P, Roy V, Corradini P, Fonseca R, Petrucci MT, Greipp PR, Boccadoro M, Stewart AK, Palumbo A. Lenalidomide plus dexamethasone versus lenalidomide plus melphalan and prednisone: a case-control study in newly diagnosed elderly myeloma patients. Blood. 2009 Nov 20; 114(22):1123.

294. Keats JJ, Chesi M, Braggio E, Palmer S, Baker A, Barrett M, Carpten J, Fonseca R, Bergsagel PL. Loss of KDM6A/UTX function is a common event in a mouse model of multiple myeloma, human cell lines and patients. Blood. 2009 Nov 20; 114(22):251.

295. Chng WJ, Huang GF, Ng SB, Chesi M, Bergsagel L, Fonseca R. MYC activation is a common transformation event in myeloma and associated with poor prognosis. Blood. 2009 Nov 20; 114(22):344.

296. Lacy MQ, Gertz MA, Hayman SR, Short KD, Dispenzieri A, Kumar S, Zeldenrust SR, Greipp PR, Lust JA, Russell SJ, Buadi F, Kyle R, Fonseca R, Bergsagel L, Roy V, Mikhael JR, Stewart AK, Reeder CB, Dingli D, Allred J, Laumann K, Mandrekar S, Rajkumar SV. Pomalidomide (CC4047) plus low dose dexamethasone (pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Blood. 2009 Nov 20; 114(22):178.

297. O'Neill BP, Braggio E, Remstein ED, Giannini C, Decker PA, Kurtz DM, Dogan A, Fonseca R. Brief report: array comparative genomic hybridization (ACGH) confirms fluorescent in situ hybridization (FISH) 6q deletion in poor-prognosis diffuse large b-cell, CD20-positive primary central nervous system lymphoma (PCNSL). Neuro-oncol. 2009 Dec; 11(6):915.

298. Dogan A, Theis JD, Vrana JA, Jimenez-Zepeda VH, Lacy MQ, Leung N, Dispenzieri A, Zeldenrust SR, Fonseca R, Gilbertson JA, Hunt T, Wechalekar AD, Lachmann HJ, Rowczenio D, Hawkins PN, Gillmore JD. Clinical and pathological phenotype of leukocyte cell-derived chemotaxin-2 (LECT2) amyloidosis (ALECT2). Amyloid. 2010 Apr; 17(Suppl 1):69-70.

299. Mikhael J, Jimenez-Zepeda VH, Reeder CB, Stewart AK, Bergsagel PL, Fonseca R. Cyclophosphamide-bortezomib-dexamethasone (CYBORD) is highly effective in producing rapid and complete responses in patients with AL amyloidosis not eligible for transplant. Amyloid. 2010 Apr; 17(Suppl 1):171.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

300. Dispenzieri A, Gertz MA, Hayman SR, Buadi F, Kumar SK, Reeder C, Zeldenrust SR, Rajkumar SV, Detweiler-Short K, Lust JA, Witzig TE, Kyle RA, Greipp PR, Russell SJ, Dingli D, Allred JB, Laumann K, Thompson M, Fonseca R, Bergsagel L, Stewart K, Mikhael J, Roy V, Lacy MQ. Pomalidomide and dexamethasone for previously treated AL: a phase 2 study. Amyloid. 2010 Apr; 17(Suppl 1):87.

301. Chng WJ, Huang G, Mulligan G, Bergsagel P, Fonseca R. A MYC activation signature is common in MM and associated with shorter survival that can be overcome by bortezomib. Haematologica. 2010 Jun; 95(Suppl 2):0391.

302. Jacobus S, Callander N, Siegel D, Abonour R, David D, Fonseca R, Williams M, Katz M, Greipp P, Rajkumar V. Outcome of elderly patients 70 years and older with newly diagnosed myeloma in the ecog randomized trial of lenalidomide/high-dose dexamethasone (RD) versus lenalidomide/low-dose dexamethasone (RD). Haematologica. 2010 Jun; 95(Suppl 2):0370.

303. Keats JJ, Braggio E, Van Wier S, Blackburn P, Baker A, Barrett M, Carpten J, Fonseca R, Stewart K, Bergsagel PL. Analysis of serial patient samples reveals a variety of clonal dynamics in multiple myeloma. Blood. 2010 Nov 19; 116(21):801.

304. Braggio E, Dogan A, Chng WJ, Keats JJ, Matthews JM, Lossos IS, Witzig TE, Fonseca R. Dissecting the genetic basis of marginal zone lymphoma reveals a predilection for NF Kb activation by clonal MZL located at extranodal. Blood. 2010 Nov 19; 116(21):1693.

305. Vesole DH, Jacobus S, Rajkumar V, Abonour R, Callander NS, Greipp PR, Fonseca R, Katz MS, Siegel DSD. Lenalidomide plus low dose dexamethasone (LD) superior one and two year survival regardless of age compared to lenalidomide plus high-dose dexamethasone (LD). Blood. 2010 Nov 19; 116(21):140.

306. Braggio E, Kay NE, Van Wier, Smoley S, Passow JE, Sassoon T, Van Dyke, Jelinek DF, Shanafelt T, Tschumper R, Barrett M, Kipps TJ, Byrd JC, Fonseca R. Longitudinal genomic analyses in chronic lymphocytic leukemia (CLL) patients reveal clonal relationship and genomic evolution in disease progression and after therapy. Blood. 2010 Nov 19; 116(21):1484.

307. Lacy M, Mandrekar S, Gertz MAA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Zeldenrust S, Dingli D, Greipp PR, Lust J, Russell S, Kyle R, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Allred J, Laumann K, Reeder CB, Rajkumar SV, Mikhael JR. Pomalidomide plus low dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide comparison of two dosing strategies in dual refractory disease. Blood. 2010 Nov 19; 116(21):377. Abstract no. 863.

308. Kay NE, Eckel-Passow JE, Braggio E, Van Wier, Shanafelt T, Van Dyke, Jelinek DF, Tschumper R, Kipps TJ, Byrd JC, Fonseca R. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmuno-therapy. Blood. 2010 Nov 19; 116(21):998.

309. Mikhael JR, Schuster SR, Zepeda VHJ, Bello N, Spong J, Reeder CB, Stewart AK, Bergsagel PL, Fonseca R. The combination of cyclophosphamide bortezomib dexamethasone (CYBOR D) is a highly effective and well tolerated regimen that produces rapid and complete hematological response in patients with AL amyloidosis. Blood. 2010 Nov 19; 116(21):1263.

310. Love N, Lonial S, Anderson KC, Fonseca R, Elder M, Paley D, Ziel K. Tolerance and response to initial systemic therapy in older patients with multiple myeloma (MM) observations from 276 unselected recent cases in the practices of us based medical oncologists (MOS). Blood. 2010 Nov 19; 116(21):645.

311. Pashos CL, Durie BG, Mehta J, Toomey K, Terebelo HR, Abonour R, Fonseca R, Gasparetto C, Narang M, Rifkin RM, Shah JJ, Sullivan KA, Street TK, Khan ZM. Association of health-related quality of life (HRQOL) with ISS stage and ECOG status in multiple myeloma. Value Health. 2011 May; 14(3):A175-6.

312. Braggio E, Robetorye R, Macon WR, Lopes MB, Schiff D, O'Neill BP, Fonseca R. High-resolution copy-number analysis reinforces the existence of a specific molecular signature in primary CNS lymphomas (PCNSL). Ann Oncol. 2011 Jun; 22(Suppl 4):209.

313. Smith BE, Suarez GA, Witzig TE, Stevens JC, Bosch EP, Ross MA, Rubin DI, Dyck PJB, Boylan KB, Gornet MK, Fonseca R, Moreno-Aspitia A, Hentz JG. A phase II trial of rituximab for peripheral neuropathy associated with monoclonal gammopathy of undetermined significance (MGUS). J Peripher Nerv Syst. 2011 Sep; 16(3):S130.

314. Chung TH, Fonseca R, Chng WJ. A novel measure of chromosome instability is an independent prognostic factor in multiple myeloma. Blood. 2011 Nov 18; 118(21):796.

315. Van Wier S, Braggio E, Fonseca R. Comprehensive high-resolution studies differentiate and characterize hypodiploid multiple myeloma. Blood. 2011 Nov 18; 118(21):1238.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

316. Weiss M, Jacobus S, Wagner LI, Cella D, Katz MS, Rajkumar V, Fonseca R. Development of the functional assessment of cancer therapy-multiple myeloma (FACT-MM) scale and validation in the eastern cooperative oncology group trial E1A05. Blood. 2011 Nov 18; 118(21):1790.

317. Novak AJ, Akasaka T, Manske MK, Braggio E, Price-Troska T, Ziesmer S, Frank S, Fonseca R, Gupta M, Law ME, Witzig TE, Dyer MJS, Dogan A, McPhail E, Cerhan JR, Ansell S. Dysregulation of GPR34 in indolent lymphomas and its function as a novel regulator of cell growth and gene expression. Blood. 2011 Nov 18; 118(21):682.

318. Braggio E, Keats JJ, Kumar S, Ahmann G, Mantei J, Stewart K, Bergsagel PL, Fonseca R. Generation of an automated tool for the identification of genetics markers and signatures in multiple myeloma risk-stratification. Blood. 2011 Nov 18; 118(21):1243.

319. Mikhael JR, Hayman SR, Laumann K, Roy V, LaPlant BR, Kumar S, Buadi FK, Reeder CB, Gertz MA, Dispenzieri A, Lust JA, Stewart AK, Russell S, Bergsagel PL, Dingli D, Zeldenrust S, Fonseca R, Greipp PR, Hall RL, Rajkumar SV, Lacy MQ. Long term outcomes of pomalidomide and dexamethasone in patients with relapsed multiple myeloma: analysis 4 years after the original cohort. Blood. 2011 Nov 18; 118(21):1269-70. Abstract no. 2942.

320. Lacy MQ, LaPlant BR, Laumann K, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Kumar S, Lust JA, Russell S, Dingli D, Zeldenrust SR, Greipp PR, Fonseca R, Bergsagel PL, Roy V, Stewart K, Reeder CB, Hall RL, Rajkumar SV, Mikhael JR. Pomalidomide and dexamethasone in relapsed myeloma: results of 225 patients treated in five cohorts over three years. Blood. 2011 Nov 18; 118(21):1695. Abstract no. 3963.

321. Braggio E, O'Neill BP, Robetorye R, Macon W, Schiff D, Lopes B, McPhail E, Fonseca R. Comprehensive genomic analysis of primary CNS lymphomas (PCNSL) identifies multiple dysregulated genes involved in immune response, regulation of apoptosis, lymphocyte maturation and activation. Cancer Res.. 2012; 72(Suppl 1):5081.

322. Cesarman-Maus G, Braggio E, Maldonado H, Fonseca R. Absence of tissue factor expression by plasma cells may explain why thrombosis is not predictive of poor outcome in myeloma. Am J Hematol. 2012 May; 87:S197.

323. Pashos CL, Durie BG, Rifkin RM, Abonour R, Fonseca R, Gasparetto C, Mehta J, Narang M, Shah JJ, Terebelo HR, Thomas S, Toomey K, Swern AS, Harding G, Yu R, Sullivan KA, Street TK, Khan ZM. Association of health-related quality of life among patients with multiple myeloma with insurance coverage. Value Health. 2012 Jun; 15(4):A233-4.

324. Lapa P, Correia J, Costa G, Pedroso De Lima J, Casanova J, Fonseca R, Simoes P, Ruivo C, Tavares P, Laranjo A, Freitas J. FDG-PET/CT versus CT alone in the diagnosis of ganglionar metastasis of soft tissue sarcomas. Embase European Journal of Nuclear Medicine and Molecular Imaging. Conference: 25th Annual Congress of the European Association of Nuclear Medicine, EANM 2012 Milan Italy. 2012 Oct; 39:S211.

325. Kortuem KM, Schuster SR, Khan ML, Zidich KE, Jimenez-Zepeda VH, Fonseca R, Stewart K. Activity of single agent drugs in phase i and ii trials best predicts future clinical utility in multiple myeloma. Blood. 2012 Nov 16; 120(21).

326. Schuster SR, Kortuem KM, Zhu YX, Braggio E, Shi CX, Bruins L, Schmidt J, Ahmann G, Kumar SK, Rajkumar SV, Mikhael JR, Roy V, LaPlant BR, Laumann K, Barlogie B, Shaughnessy JD Jr, Fonseca R, Bergsagel L, Lacy MQ, Stewart K. Cereblon expression predicts response, progression free and overall survival after pomalidomide and dexamethasone therapy in multiple myeloma. Blood. 2012 Nov 16; 120(21).

327. Jung S, Seungchan K, Gale M, Fonseca R, Carpten J, Salhia B. Dna methylation in multiple myeloma is weakly associated with gene transcription. Blood. 2012 Nov 16; 120(21).

328. Braggio E, O'Neill BP, Egan J, Valdez R, McPhail E, Lopes M, Schiff D, Tibes R, Stewart K, Fonseca R. Genome-wide analysis uncovers recurrent alterations in primary central nervous system lymphomas. Blood. 2012 Nov 16; 120(21).

329. Sebastian S, Chesi M, Braggio E, Bergsagel L, Stewart K, Ahmann G, Fonseca R. Parp inhibition (olaparib) enhance melphalan and nutlin-3a sensitivity in TP53 positive multiple myeloma. Embase Blood. Conference: 54th Annual Meeting of the American Society of Hematology, ASH 2012 Atlanta, GA. 2012 Nov 16; 120(21).

330. Lonial S, Jacobus S, Weiss M, Fonseca R, Dhodapkar MV, Rajkumar SV. Phase ii trial of initial safety and toxicity prior to the phase iii trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma (e3a06): a trial coordinated by the Eastern cooperative oncology group. Blood. 2012 Nov 16; 120(21).

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

331. Lacy MQ, Kumar SK, LaPlant BR, Laumann K, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Russell S, Dingli D, Zeldenrust SR, Fonseca R, Bergsagel PL, Stewart K, Roy V, Sher T, Chanan-Khan A, Reeder C, Rajkumar SV, Mikhael JR. Pomalidomide plus low-dose dexamethasone (POM/DX) in relapsed myeloma: long term follow up and factors predicing outcome in 345 patients. Blood. 2012 Nov 16; 120(21).

332. Bergsagel PL, Affer M, Glebov OK, Chen WDD, Keats JJ, Brents LA, Chesi M, Van Wier S, Badar SK, Fonseca R, Kuehl WM. Promiscuous cryptic rearrangements of the myc locus cis-dysregulate myc expression and are present in the majority of patients with hyperdiploid myeloma. Blood. 2012 Nov 16; 120(21).

333. LoBello J, Gale M, Watanabe A, Hostetter G, Fonseca R, Salhia B. The role of the histone demethyltransferase gene jmjd1c and h3k9 methylation in multiple myeloma. Blood. 2012 Nov 16; 120(21).

334. Cesarman-Maus GN, Braggio E, Lome C, Morales-Leyte AL, Fonseca R. Tissue factor and hematological neoplasias. Blood. 2012 Nov 16; 120(21).

335. Fonseca R, Skulan J, Anbar A, Gordon G. Early detection of osteolytic lesions in multiple myeloma using natural calcium (CA) isotopes. Embase Clinical Lymphoma, Myeloma and Leukemia. Conference: 14th International Myeloma Workshop Kyoto Japan. 2013 Apr; 13:S38.

336. Fonseca R. Ras mutations and multiple myeloma. Embase Clinical Lymphoma, Myeloma and Leukemia. Conference: 14th International Myeloma Workshop Kyoto Japan. 2013 Apr; 13:S6.

337. Callander NS, Jacobus SJ, Weiss M, Kumar S, Fonseca R, DiCapua Siegel DS, Katz MS, Abonour R, Williams ME, Greipp PR, Rajkumar V. Evaluation of protocol mandated testing in E4A03, a randomized phase III study of CC-5013 plus dexamethasone versus CC-5013 plus low-dose dexamethasone in multiple myeloma (MM). Embase Journal of Clinical Oncology. Conference: 2013 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL. 2013 May 20; 31:15 Suppl 1.

338. Braggio E, O'Neill B, VanWier S, Ojha J, Valdez R, Tibes R, Stewart K, Fonseca R. The genomic landscape of primary central nervous system lymphoma. Embase Hematological Oncology. Conference: 12th International Conference on Malignant Lymphoma Lugano Switzerland. 2013 Jun; 31:153.

339. Ferreira J, Gasparinho G, Fonseca R, Andre S. Cyto-morphological features of blastic plasmacytoid dendritic cell neoplasm on fine needle aspiration and cerebrospinal fluid cytology: A review of 5 cases. Embase Virchows Archiv. Conference: 25th European Congress of Pathology, ECP 2013 Lisbon Portugal. 2013 Aug; 463(2):271.

340. Stewart AK, Jacobus S, Fonseca R, Weiss M, Callander NS, Chanan-Khan AA, Rajkumar SV. E1a06: a phase iii trial comparing melphalan, prednisone, and thalidomide (mpt) versus melphalan, prednisone, and lenalidomide (mpr) in newly diagnosed multiple myeloma mm). Haematologica. 2014 Jun 1; 99:220.

341. Vasmatzis G, Feldman AL, Johnson SH, Thorland EC, Fonseca R, Braggio E, Gliem TJ. Copy number detection using genomics technologies: a comparison between acgh and ngs. Cancer Res. 2014 Oct 1; 74(19).

342. Egan JB, Bryce AH, Champion MD, Liang WS, Fonseca R, McCullough AE, Barrett MT, Hunt K, Condjella RM, McWilliams RR, Mastrian SD, LoBello J, Von Hoff D, Craig DW, Stewart AK, Carpten JD, Borad MJ. Indices of actionability and clinical utility in a CLIA-enabled study of whole genome/exome/rna sequencing in 33 cancer patients: actionable vs. utility. Cancer Res. 2014 Oct 1; 74(19).

343. Kortuem KM, Stewart AK, Bruins LA, Ahmann G, Vasmatzis G, Rajkumar SV, Kumar S, Dispenzieri A, Lacy MQ, Gertz MA, Fonseca R, Champion M, Bergsagel PL, Braggio E. Development and results of a multiple myeloma specific custom 77-gene mutation panel for clinical targeted sequencing. Blood. 2014 Dec 6; 124(21).

344. Lacy MQ, LaPlant BR, Laumann KM, Kumar S, Gertz MA, Hayman SR, Buadi F, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell S, Dingli D, Go RS, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Ailawadhi S, Chanan-Khan A, Stewart AK, Reeder CB, Rajkumar SV, Mikhael JR. Pomalidomide plus low-dose dexamethasone (pom/dex) in relapsed lenalidomide refractory myeloma: long term follow up and comparison of 2 mg vs 4 mg doses. Blood. 2014 Dec 6; 124(21).

345. Lacy MQ, LaPlant BR, Laumann KM, Kumar S, Gertz MA, Hayman SR, Buadi F, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Ailawadhi S, Chanan-Khan A, Stewart AK, Reeder CB, Rajkumar SV, Mikhael JR. Pomalidomide, bortezomib and dexamethasone (pvd) for patients with relapsed lenalidomide refractory multiple myeloma (mm). Blood. 2014 Dec 6; 124(21):304.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

346. Teoh PJ, Bi CL, Sebastian S, Fonseca R, Chng WJ. Prima-1 (p53 reactivation and induction of massive apoptosis) mediates anti-myeloma effect through the er stress pathway. Blood. 2014 Dec 6; 124(21).

347. Rosenthal AC, Luthi J, Belohlavek M, Mookadam F, Mayo A, Fonseca R, Bergsagel PL, Reeder CB, Mikhael JR, Stewart K. The cardiovascular impact of carfilzomib in multiple myeloma. Blood. 2014 Dec 6; 124(21):4748.

348. Rosenthal AC, Fonseca R, Mikhael J, Stewart AK, Mayo A, Chesi M, Kosiorek H, Bergsagel PL. Interim analysis of a phase ii trial of nab-paclitaxel in patients with very advanced relapsed/refractory multiple myeloma (rr-mm). J Clin Oncol. 2015 May 20; 33(15).

349. Rosenthal A, Dueck AC, Ansell SM, Gano K, Conley C, Nowakowski GS, Curtis K, Camoriano J, Leis JF, Slack J, Valdez R, Mikhael JR, Stewart AK, Inwards D, Dingli D, Kumar S, Noel P, Gertz M, Porrata L, Russell S, Colgan J, Fonseca R, Habermann TM, Kapoor P, Buadi F, Leung N, Tiedemann R, Witzig TE, Reeder C. A phase 2 study of lenalidomide, rituximab, cyclophosphamide and dexamethasone (lr-cd) for untreated low grade non-Hodgkin lymphoma requiring therapy Clinical Lymphoma Myeloma & Leukemia. 2015 Jun; 15:S225-6.

350. Cesarman-Maus GN, Reichel J, Roshal M, Braggio E, Fonseca R, Cesarman E. The Reed Sternberg cell coagulome. J Thromb Haemost. 2015 Jun; 13:309.

351. Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Spicka I, Masszi T, Hajek R, Rosinol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Tonda M, Obreja M, Moreau P. Efficacy and safety of carfilzomib, lenalidomide, and dexamethasone vs lenalidomide and dexamethasone in patients with relapsed multiple myeloma based on cytogenetic risk status: subgroup analysis from the phase 3 study aspire (nct01080391) Blood. 2015 Dec 3; 126: (23)731.

352. Chirackal SS, Zhu YX, Braggio E, Shi CX, Panchabhai S, Ahmann G, Van Wier SA, Chesi M, Bergsagel L, Stewart K, Fonseca R. Immunomodulatory drugs inhibit h2o2 decomposition in multiple myeloma cells and its mediated cytotoxicity is determined by cellular antioxidative capacity Blood. 2015 Dec 3; 126: (23)2475.

353. van Beers E, van Vliet M, de Best L, Anderson KC, Chari A, Jagganath S, Jakubowiak A, Kumar SK, Lebovic D, Levy J, Auclair D, Lonial S, Reece D, Richardson PG, Siegel D, Stewart AK, Trudel S, Vij R, Zimmerman T, Fonseca R. Low-risk multiple myeloma by sky92+iss validated in the multiple myeloma genomics initiative study Blood. 2015 Dec 3; 126: (23)5322.

354. Barrio S, Ojha J, Secreto C, Chaffee KG, Kortum KM, Pathangey S, Slager SL, Fonseca R, Kay NE, Shanafelt TD, Braggio E. Mutations in driver genes and changes in clonal dynamics are associated with shorter time to treatment in mbl cases Blood. 2015 Dec 3; 126: (23)5264.

355. Panchabhai S, Schlam IM, Chirackal SS, Fonseca R. Ornithine decarboxylase: novel prognostic marker and target for multiple myeloma therapy Blood. 2015 Dec 3; 126: (23)1824.

356. Biran N, Jacobus S, Siegel D, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Katz MS, Rajkumar SV, Greipp PR. Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in the ecog-acrin e4a03 randomized clinical trial: long-term follow-up Blood. 2015 Dec 3; 126: (23)3174.

357. Van Wier S, Colon-Otero G, Ahmann G, Braggio E, Albertie M, Ailawadhi S, Fonseca R. Similar prevalence of t(14,18) in African American and Caucasian subjects Cancer Epidemiology Biomarkers & Prevention. 2016 Mar; 25: (3).

358. Fonseca R, Panjabi S, Campioni M, Giannopoulou A, Benedict A, Houisse I, Aggarwal S, Jakubowiak A. Economic evaluation of carfilzomib plus lenalidomide plus dexamethasone (krd) vs lenalidomide plus dexamethasone (rd) in relapsed or refractory multiple myeloma (r/rmm) Haematologica. 2016 Jun; 101: (Suppl 1)526.

359. Avet-Loiseaul H, Fonseca R, SiegeI D, Dimopoulos M, Spicka I, Masszi T, Hajek R, Rosinol L, Garanava-Marinova V, Mihaylavlo G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Tonda M, Obreja M, Moreau P. Efficacy and safety by cytogenetic risk status: phase 3 study (aspire) of carfilzomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma Haematologica. 2016 Jun; 101: (Suppl 1)262-3.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

360. Barrio S, Shanafelt TD, Ojha J, Chaffee KG, Secreto C, Kortum MK, Slager SL, Fonseca R, Kay NE, Braggio E. Genomic characterization of high-count mbl individuals indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome Haematologica. 2016 Jun; 101: (Suppl 1)45.

361. Van Vliet M, Kuiper R, Ubels J, Bosman L, Dumee B, van Beers E, de Best L, Waage A, Zweegman S, Morgan G, Levy J, Auclair D, Fonseca R, Goldschmidt H, Sonneveld P. Robustness of the prognostic value of the sky92 marker versus fish markers across nine multiple myeloma cohorts Haematologica. 2016 Jun; 101: (Suppl 1)520-1.

362. Van Vliet M, Kuiper R, Ubels J, Dumee B, Bosman L, van Beers E, de Best L, Waage A, Zweegman S, Morgan G, Levy J, Auclair D, Fonseca R, Goldschmidt H, van Duin M, Sonneveld P. The sky92 prognostic marker is validated in eight multiple myeloma clinical datasets Haematologica. 2016 Jun; 101: (Suppl 1)83.

363. Jain T, Fonseca R, Chen R, Patel R, Jani P, Gonzalez De La Calle V, Meghji Z, Hoffman JE, Alencar AJ, Kelly KR, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S. Racial Differences in Disease Characteristics: Understanding Multiple Myeloma in Hispanics. Blood.2017 Dec;130:(Suppl 1) Abstract no.864.

364. Kim S, Larkey L, Meeker C, Jo S, Fonseca R, Leis JF, Mikhael JR, Noel P, Palmer J, Slack JL, Sproat LZ, Reeder C, Rosenthal A, Langer S, Khera N. Feasibility and impact of digital stories intervention on psychosocial well-being among patients undergoing hematopoietic cell transplantation: a pilot study. Biology Of Blood And Marrow Transplantation. 2018 Mar; 24(3 Suppl 1):S221

365. Jain T, Sonbol MB, Firwana B, Kolla KR, Almader-Douglas D, Palmer J, Fonseca R. High dose chemotherapy with early autologous stem cell transplantation compared to standard dose chemotherapy or delayed transplantation in patients with newly diagnosed multiple myeloma: a meta-analysis Biology Of Blood And Marrow Transplantation. 2018 Mar; 24(3 Suppl 1):S37. Epub 1900 Jan 01.

366. Fonseca R, Alsina M, Berdeja J, Heitner SB, Morris C, Khurana M, Niesvizky R. An open-label phase 2 study of carfilzomib plus dexamethasone to assess tolerability and adherence in patients with relapsed or refractory multiple myeloma at us community oncology centers Clinical Lymphoma Myeloma & Leukemia. 2018 Sep; 18(Suppl 1):S240-1

367. Cope S, Toor K, Fonseca R, Landgren O, Mateos MV, Weisel K, Jansen JP. Why clinicians are not relying on evidence from indirect comparison studies evaluating comparative efficacy of interventions for relapsed or refractory multiple myeloma: a critical review Clinical Lymphoma Myeloma & Leukemia. 2018 Sep; 18(Suppl 1):S251-2

368. Fonseca R, Jena AB, Peneva D, Clancy Z. Survival gains in multiple myeloma from 2003 to 2014 Journal Of Clinical Oncology. 2018 Oct 20; 36(30 Suppl):98

369. Hagiwara M, Delea T, Panjabi S, Yucel E, Fonseca R. Burden of disease progression in patients with multiple myeloma who have received at least one line of therapy in the US Blood. 2018 Nov 29; 132(Suppl 1):4754

370. Fonseca R, Usmani SZ, Mehra M, Slavcev M, Ukropec J, Lam A, Potluri R. Characterization of frontline treatment patterns and attrition rates according to subsequent lines of therapy in non-transplant patients with newly diagnosed multiple myeloma Blood. 2018 Nov 29; 132(Suppl 1):3291

371. Mountjoy L, Chirackal S, Jain T, Girardo M, Larsen J, Fonseca R. Results of a flow cytometry assay measuring oxidative stress relief as a predictor of immunomodulatory drugs (imids) sensitivity in myeloma Blood. 2018 Nov 29; 132(Suppl 1):4443

372. Haradhvala NJ, Zavidij O, Mouhieddine TH, Sklavenitis-Pistofidis R, Park J, Reidy M, Flaifel A, Ferland B, Manier S, Bustoros M, Huynh D, Capelletti M, Berrios B, Rahmat M, Liu CJ, He MX, Braggio E, Fonseca R, Maruvka Y, Guerriero J, Goldman M, Van Allen E, McCarroll S, Azzi J, Getz G, Ghobrial IM. Single-cell rna sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma Cancer Research. 2019 Jul; 79(13 Suppl):139

373. Cowan A, Higgins A, Fonseca R, Getz G, Borrello I, Rebbeck T, Murray D, Johnson J, Bustoros M, Stewart C, Zavidij O, Adalsteinsson V, Soule P, Hamilton C, Shayegh N, Guimond K, Berrios B, Su N, Oluwadara D, Marinac CR, Ghobrial I. The promise study: a nationwide project for predicting the progression of developing myeloma in a high-risk screened population Clinical Lymphoma Myeloma & Leukemia. 2019 Oct; 19(10 Suppl):E310

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

374. Sidiqi MH, Al Saleh AS, Lee J, Jevremovic D, Fonseca R, Gertz MA, Dispenzieri A, Buadi F, Lacy M, Leung N, Muchtar E, Kyle R, Go R, Hobbs M, Gonsalves W, Kourelis T, Warsame R, Dingli D, Lust J, Hayman S, Kumar S, Rajkumar SV, Kapoor P. Venetoclax for the treatment of multiple myeloma: outcomes outside of clinical trials Clinical Lymphoma Myeloma & Leukemia. 2019 Oct; 19(10 Suppl):E278-9

375. Sidiqi MH, Al Saleh AS, Leung N, Aljama M, Jevremovic D, Gonsalves W, Buadi F, Kourelis T, Warsame R, Muchtar E, Hobbs M, Lacy M, Dingli D, Go R, Hayman S, Rajkumar SV, Kumar S, Dispenzieri A, Fonseca R, Gertz MA, Kapoor P. Venetoclax for the treatment of translocation al amyloidosis Clinical Lymphoma Myeloma & Leukemia. 2019 Oct; 19(10 Suppl):E332

Letters 1. Loprinzi CL, Fonseca R, Jensen MD. Megestrol acetate-induced adrenal suppression. J Clin Oncol. 1996

Feb; 14(2):689. PMID:8636799 DOI: 2. Loprinzi CL, Fonseca R, Jensen MD. Induction of adrenal suppression by megestrol acetate. Ann Intern

Med. 1996 Mar 15; 124(6):613; author reply 614. PMID:8597330 DOI: 3. Liu JJ, Fonseca R, Edmonson JH, Rubin J. Creatine kinase release after hepatic artery embolization in

patients with carcinoid tumors. Cancer Invest. 1998; 16(3):211. PMID:9541636 DOI:

4. Fonseca R, Rajkumar SV, Inwards DJ. Granulomatous vasculitis associated with herpes virus. Mayo Clin Proc. 1998 Apr; 73(4):390-1. PMID:9559047 DOI:10.1016/S0025-6196(11)63710-5

5. Rajkumar SV, Fonseca R, Letendre L. Ineffectiveness of pulmonary irradiation in the treatment of leukemic blast crisis. Leukemia. 1999 Mar; 13(3):490. PMID:10086744 DOI:

6. Fonseca R, Inwards DJ, Habermann TM, Egan KS. Author reply Cancer. 2000 Aug 1; 89 (3):714 PMID:10931480 DOI:10.1002/1097-0142(20000801)89:3<714::aid-cncr36>3.0.co;2-k

7. Fonseca R, Oken MM, Greipp PR, Eastern Cooperative Oncology Group Myeloma Group. The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood. 2001 Aug 15; 98(4):1271-2. PMID:11510469 DOI:

8. Tefferi A, Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood. 2002 Apr 1; 99(7):2627. PMID:11926187 DOI:

9. Winkler JM, Greipp PR, Fonseca R. t(4;14)(p16.3;q32) is strongly associated with a shorter survival in myeloma patients. Br J Haematol. 2003 Jan; 120(1):170-1. PMID:12492597 DOI:

10. Chng WJ, Gualberto A, Fonseca R. IGF-1R is overexpressed in poor-prognostic subtypes of multiple myeloma. Leukemia. 2006 Jan; 20(1):174-6. PMID:16239907 DOI:10.1038/sj.leu.2403997

11. Chng WJ, Price-Troska T, Gonzalez-Paz N, Van Wier S, Jacobus S, Blood E, Henderson K, Oken M, Van Ness B, Greipp P, Rajkumar SV, Fonseca R. Clinical significance of TP53 mutation in myeloma. Leukemia. 2007 Mar; 21(3):582-4. PMID:17215851 DOI:

12. Claudio JO, Zhan F, Zhuang L, Khaja R, Zhu YX, Sivananthan K, Trudel S, Masih-Khan E, Fonseca R, Bergsagel PL, Scherer SW, Shaughnessy J, Stewart AK. Expression and mutation status of candidate kinases in multiple myeloma. Leukemia. 2007 May; 21(5):1124-7. Epub 2007 Mar 8. PMID:17344920 DOI:

13. Stewart AK, Chang H, Trudel S, Anderson K, Richardson P, Alsina M, Reece D, Young S, Sable-Hunt A, Li Z, Keats J, Van Wier S, Ahmann G, Price-Troska T, Giusti K, Bergsagel P, Chesi M, Fonseca R. Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution. Leukemia. 2007 Nov; 21(11):2358-9. Epub 2007 Jun 14. PMID:17568814 DOI:10.1038/sj.leu.2404800

14. Chng WJ, Kuehl WM, Bergsagel PL, Fonseca R. Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature. Leukemia. 2008 Feb; 22(2):459-61. Epub 2007 Sep 06. PMID:17805328 DOI:10.1038/sj.leu.2404934

15. Chng WJ, Jacobus S, Fonseca R. Do beta2 microglobulin levels affect survival of newly diagnosed myeloma patients with translocation t(4;14) or 17p13 deletion treated with conventional chemotherapy? Leukemia. 2008 May; 22(5):1080-1. Epub 2007 Nov 29. PMID:18046451 DOI:10.1038/sj.leu.2405009

16. Paripati H, Stewart AK, Cabou S, Dueck A, Zepeda VJ, Pirooz N, Ehlenbeck C, Reeder C, Slack J, Leis JF, Boesiger J, Torloni AS, Fonseca R, Bergsagel PL. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia. 2008 Jun; 22(6):1282-4. Epub 2008 Jan 24. PMID:18216870 DOI:10.1038/sj.leu.2405100

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

17. Chng WJ, Gonzalez-Paz N, Price-Troska T, Jacobus S, Rajkumar SV, Oken MM, Kyle RA, Henderson KJ, Van Wier S, Greipp P, Van Ness B, Fonseca R. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia. 2008 Dec; 22(12):2280-4. Epub 2008 Jun 05. PMID:18528420 DOI:10.1038/leu.2008.142

18. Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Laumann K, Hentz J, Pirooz NA, Piza JG, Tiedemann R, Mikhael JR, Bergsagel PL, Leis JF, Fonseca R, Stewart AK. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood. 2010 Apr 22; 115(16):3416-7. PMID:20413666 DOI:10.1182/blood-2010-02-271676

19. Fonseca R. How physicians interpret research funding disclosures. N Engl J Med. 2012; 367(24):2358. 20. Reeder CB, Reece DE, Kukreti V, Mikhael JR, Chen C, Trudel S, Laumann K, Vohra H, Fonseca R,

Bergsagel PL, Leis JF, Tiedemann R, Stewart AK. Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma. Br J Haematol. 2014 Nov; 167(4):563-5. Epub 2014 Jun 30. PMID:24974945 DOI:10.1111/bjh.13004

21. Roy V, Stewart AK, Bergsagel PL, Dispenzieri A, Laumann K, Allred J, Lacy MQ, Fonseca R, Reeder CB, Kumar S, Rivera CE, Gertz MA, Buadi FK, Hayman SR, Rajkumar SV. Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation. Blood Cancer J 2015 Mar 20; 5:e294 PMID:25794130 DOI:10.1038/bcj.2015.23

22. Jain T, Dueck AC, Kosiorek HE, Ginos BF, Mayo A, Reeder CB, Chesi M, Mikhael J, Keith Stewart A, Leif Bergsagel P, Bergsagel PL, Fonseca R. Phase II trial of nab-paclitaxel in patients with relapsed or refractory multiple myeloma. Am J Hematol 2016 Dec; 91 (12):E504-E505 Epub 2016 Oct 11 PMID:27581088 DOI:10.1002/ajh.24548

23. Jain T, Narayanasamy H, Mikhael J, Reeder CB, Bergsagel PL, Mayo A, Stewart AK, Mookadam F, Fonseca R. Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma. Blood Cancer J 2017 Dec 13; 7 (12):642 PMID:29234003 DOI:10.1038/s41408-017-0026-7

Miscellaneous 1. Bonfante E, Fonseca R, Romano JG, Schwartz I. Epidemiological trends and statistics for the infectious

diseases in the municipality of Atizapan, State of Mexico. Recpetional thesis, 1991 May. 2. Fonseca R, Greipp PR. Multiple myeloma update: New advances in biology and treatment. Medscape. 2000

Mar 28; 0:0. 3. Fonseca R. Inaugural post for the libertarian doc. The Patient Comes First (Blog). 2013 Dec. 4. Fonseca R. Politics and medicine; ACA and 2013. The Patient Comes First (Blog). 2013 Dec. 5. Fonseca R. The coercive nature of “Against Medical Advice”. The Patient Comes First (Blog). 2013 Dec. 6. Fonseca R. A dispatch to a red state? Non-physicians commentary in the NEJM. The Patient Comes First

(Blog). 2013 Dec. 7. Fonseca R. Medicaid, ED and Oregon; net result is a failur The Patient Comes First (Blog). 2014 Jan. 8. Fonseca R. The Renaissance of Medicine? Respect for Primary Care Docs!. The Patient Comes First

(Blog). 2014 Feb. 9. Fonseca R. Incentives for care: fee versus population. The Patient Comes First (Blog). 2014 Feb. 10. Fonseca R. A single ethos for all doctors? Come on!!!. The Patient Comes First (Blog). 2017 Mar. 11. Fonseca R. To whom is the doctors fiduciary responsibility; the patient? society?. The Patient Comes First

(Blog). 2014 Apr. 12. Fonseca R. Secretary burnout and FCOI disclosures. The Patient Comes First (Blog). 2015 Jan. 13. Fonseca R. Cancer drug costs and “what the market will bear”? What does that mean? The Patient Comes

First (Blog). 2015 Jun. 14. Fonseca R. “Driving with the handbrake on” at ASCO 2015; discussions regarding drug costs. The Patient

Comes First (Blog). 2015 Jun . 15. Fonseca R. IMIDS and “Me too drugs” Innovation versus invention. The Patient Comes First (Blog). 2015

Jul.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

16. Fonseca R. When it comes to drugs Dr. Avorn is opposed to freedom #21stcenturycures The Patient Comes First (Blog). 2015 Jul.

17. Fonseca R. Complementary and alternative medicine and political correctness. The Patient Comes First (Blog). 2015 Aug.

18. Fonseca R. Comments for the proposal by the Institute for Clinical and Economic Review (ICER) to do an evaluation of treatment options for relapse or refractory multiple myeloma. The Patient Comes First (Blog). 2016 Feb.

19. Fonseca R. Imatinib generics, competition and the free market. The Patient Comes First (Blog). 2016 Mar. 20. Fonseca R. Withholding or delaying needed treatments because drugs are “expensive”; a moral trap, and

“anti-ethical” behavior. The Patient Comes First (Blog). 2016 Mar. 21. Fonseca R. Libertarianism and objectivism (in medicine): Intellectual honesty and consistency. The Patient

Comes First (Blog). 2016 Mar. 22. Fonseca R. The perverse incentives of bundled payment, capitation and physician bonuses. The Patient

Comes First (Blog). 2016 Apr. 23. Fonseca R. “QALYfying the value of life”; questions about the ethics of QALYs. The Patient Comes First

(Blog). 2016 Apr. 24. Fonseca R. Getting unapproved medications to patients; venetoclax and the “Right to try.” The Patient

Comes First (Blog). 2016 May. 25. Fonseca R. The tragedy of the many who killed his wife for “financial toxicity” The Patient Comes First

(Blog). 2016 May. 26. Fonseca R. Expert Perspectives on the Management of Multiple Myeloma. OncLive Peer Exchange:

Oncology Specialty Group (video). 2016 Jun. 27. Fonseca R. Association between industry payment and prescription of branded statins; the free lunch

debate. The Patient Comes First (Blog). 2016 Jun. 28. Fonseca R. EHA 2016: New Therapeutic Strategies for the Management of Patients with Relapsed-

Refractory Multiple Myeloma. Elsevier Office of CME/Adademic CME (video). 2016 Jun. 29. Fonseca R. The difference between the high cost of drugs vs. high co-pays; the myeloma example and

IMIDS #MMSM. The Patient Comes First (Blog). 2016 Aug. 30. Fonseca R. A brief story about the Duke of Parma, Medicare and Price controls. The Patient Comes First

(Blog). 2016 Aug. 31. Fonseca R. Who wins by lowering prices for cancer drugs? The Patient Comes First (Blog). 2016 Aug. 32. Fonseca R. Myeloma patient who does not want to bankrupt his family goes to hospice… It happened

again! The Patient Comes First (Blog). 2016 Aug. 33. Fonseca R. Approaches in Newly Diagnosed MM: When and What. Medscape Oncology. (video). 2016

Aug. 34. Fonseca R. Settlements and “off-label” promotion. The Patient Comes First (Blog). 2016 Sep. 35. Fonseca R. Conflict of interest, personal agendas and the myeloma ICER report. The Patient Comes First

(Blog). 2016 Sep. 36. Fonseca R. The fallacy of the blue pill and the red pill. The Patient Comes First (Blog). 2019 Sep. 37. Fonseca R. Gene Expression Profiling in Multiple Myeloma: Basics. Managing Myeloma Practice

Essentials. (video). 2016 Oct. 38. Fonseca R. Gene Expression Profiling in Multiple Myeloma: Implications for Practice. Managing Myeloma

Practice Essentials. (video). 2016 Oct. 39. Fonseca R. Medications; generic vs. commercial names, and chicken meat! The Patient Comes First (Blog).

2016 Oct. 40. Fonseca R. Allow Medicare beneficiaries to receive co-pay assistance directly. The Patient Comes FIrst

(Blog). 2016 Oct. 41. Fonseca R. Medical journal bias in favor of the ACA? – The case of the NEJM. The Patient Comes First

(Blog). 2016 Oct.

Rafael Fonseca, MD

of 91

RE-AIMS 2/8/2021 1:52:28 PM

42. Fonseca R. Limiting co-pay assistance is against medicine’s tradition of benevolence. The Patient Comes First (Blog). 2016 Oct.

43. Fonseca R. Focusing on the Treatment of Patients with Multiple Myeloma. Research to Practice. (video). 2016 Nov.

44. Fonseca R. The patient owns the tissue - period The Patient Comes First (Blog). 2016 Dec. 45. Fonseca R. Do not interfere with copay assistance unless you have a proven alternative solution. The

Patient Comes First (Blog). 2016 Dec. 46. Fonseca R. Changing landscape of multiple myeloma. Medscape/WebMD Video Filming. 2017 Jan 12. 47. Stewart AK, Bergsagel P, Fonseca R, Braggio E. Methods and materials for assessing responsiveness to

lenalidomide, thalidomide, and/or other thalidomide analogs 2017 May 30. (Patent). 48. Fonseca R. Why the COI science is weak or flawed. #weakCOIscience. The Patient Comes First (Blog).

2017 Jun. 49. Fonseca R. It’s all about “sticker shock” – the glasses economists use. The Patient Comes First (Blog).

2017 Jun. 50. Fonseca R. Balanced news reporting? Video in the CBS Money Watch website. Presented without

comment. The Patient Comes First (Blog). 2017 Jun. 51. Fonseca R. Uncertainty, medical paternalism, and Charlie Gard’s fate. The Patient Comes First (Blog).

2017 Jul. 52. Fonseca R. Physicians have more important things to worry about than DTC genetic testing. The Patient

Comes First (Blog). 2017 Aug. 53. Fonseca R. Copay Assistance Programs. The Patient Comes First (Blog). 2017 Oct. 54. Fonseca R. Predictions for future ASH Annual meetings? The Patient Comes FIrst (Blog). 2017 Dec. 55. Fonseca R. Cancer, the cartographers and the pioneers. The Patient Comes First (Blog). 2018 Feb. 56. Fonseca R. The criminal drug prices. The Patient Comes First (Blog). 2018 Feb. 57. Fonseca R, et al. Cost vs. Value and the Price of Innovation in Cancer Care: Oral Anticancer Drugs in

Multiple Myeloma, as a Case Study. The Goldwater Institute. 2018 Mar. 58. Fonseca R. Stop harassing patient support organizations!. The Patient Comes First (Blog). 2018 Apr. 59. Fonseca R. We need you Britain!. The Patient Comes First (Blog). 2018 Apr. 60. Fonseca R. Breakthrough designation by the FDA; is it too risky?. The Patient Comes First (Blog). 2018 Jul. 61. Fonseca R, Tucker J. Are Doctors Bribed by Pharma? An Analysis of Data. The Healthcare Blog (Blog).

2018 Jul. 62. Fonseca R. Cell phones, battery life, and earthquakes. The Patient Comes First (Blog). 2018 Sep. 63. Fonseca R. Ethical implications of Step Therapy (“Fail First”) The Patient Comes First (Blog). 2018 Oct. 64. Fonseca R. Se le castigo por no hincarse. En defensa del Dr. Baselga. The Patient Comes First (Blog).

2018 Oct. 65. Fonseca R. Medicare for all? Effects on medical innovation and the history of renal failure. The Patient

Comes First (Blog). 2018 Nov.

* Indicates that the primary author was a mentee of this author.

Curriculum Vitae and Bibliography Rafael Fonseca, MD

Documents

Transcript of Curriculum Vitae and Bibliography Rafael Fonseca, MD